'We don't need your blood': revealing the opportunities in the complex and surprisingly individualised volatile organic compound profiles of human skin and saliva by Helen J. Martin (7162925)
  
 
 
 
 
 
 
‘WE DON’T NEED YOUR BLOOD’: 
Revealing the Opportunities in the Complex and 
Surprisingly Individualised Volatile Organic 
Compound Profiles of Human Skin and Saliva 
 
 
Helen Jennifer Martin 
 
 
 
A Doctoral Thesis 
 
 
Submitted in partial fulfillment 
 of the requirements for the award of 
 Doctor of Philosophy of  
Loughborough University 
 
 
March 2014 
 
 
 
© Helen Jennifer Martin (2014)
i 
 
 
ACKNOWLEDGEMENTS 
 
First and foremost I would like to acknowledge my supervisor Prof Paul Thomas who over the last five years 
has guided, and at times dragged, me through my PhD with his unique blend of humour, compassion, 
gentle coaxing, bribery and even the odd threat, offering unconditional and limitless support.  
This thesis is a study in collaboration and I would like to thank the entirety of my research group but first 
special mention must go to Matthew Turner, Aditya Malkar and Pareen Patel with whom I collaborated on 
many sampling campaigns and who kept me sane and laughing throughout all night experiments, 4am 
starts and 70 hour weeks and for being the team I could always rely on. It is a rare and lucky person who 
can call her colleagues friends and I would also like to thank the rest of the team for making the most 
challenging few years of my life into the best, to Neil, Caitlyn, Vicky, Rob, Lauren, Cristina, Corrinne, Jim, 
Little Vic, Big Vic, Ran, Shuo, Dorota and Liam: thanks for the memories – I couldn’t have done this without 
you! 
A big thank you to other academic collaborators at Loughborough including; Dr Stephan Bandelow and Dr 
Louisa Edwards for their collaboration and guidance in the psychological stress study and their students 
Toni McKay and Elliot Poole for assisting with the study. To Prof Ronald Maughan and Dr Phillip Watson for 
their guidance and for taking blood samples and allowing us to use their facilities during the physical stress 
study. To Colin Creaser for his support and guidance and for giving me my first taste of academic research 
during my undergraduate degree.  
To my friends and colleagues at Markes International, thanks for all the support during my PhD and the 
advice, encouragement and understanding since I joined the company and have had to write my thesis and 
work full time. Particular thanks go to Martyn Cole for his help with CAD drawings. 
I would like to acknowledge Unilever PLC for financial support of the project and in particular Svetlana, 
Teresa, Ruediger, Rajesh, Viv and Pete for their support and friendship during my secondment.   
The most important thanks must go to my wonderful parents for their continual support and unfaltering 
belief in me – even though, as my dad loves to remind me, I have spent almost 25 years ‘at school’! Also to 
Oliver Bullock for his never-ending patience, love and support and for whisking me away on some amazing 
holidays when it all got too much! 
I am fortunate to have too many good friends to list here, but to everybody else that has been there for me 
throughout the last 5 years – you know who you are and I am eternally grateful for your friendship and 
support.   
  
ii 
 
 
ABSTRACT 
Non-invasive techniques for in-vivo sampling of volatile organic compounds (VOCs) from human skin and 
saliva have been developed and characterised using polydimethyl siloxane (PDMS) as a sorptive material. 
These samplers have been analysed by thermal desorption (TD) in combination with gas chromatography – 
mass spectrometry (GC-MS) and applied to global, untargeted metabolic profiling studies of skin and saliva.  
The utility of an existing PDMS ‘Skin Patch’ for untargeted metabolic profiling studies has been evaluated 
and background artefact levels and sample storage stability shown to be key considerations. Successful 
storage of skin samples for up to 21 days at -80 ºC has been demonstrated.  
Evaluation of published methods reveals that existing methods for saliva sampling do not address the 
physical–chemical attributes of VOCs and evidence is presented for adopting in situ sampling of salivary 
VOCs directly from the oral cavity. In-vitro studies indicated that the vapour pressure of analytes was a 
factor in both the recovery of analytes and the precision of the recovery. The highest recoveries were 
observed for VOCs with the lowest vapour pressures, for example 5-nonanol (vapour pressure (Pv= 14 Pa) 
recoveries were approximately 20 times greater than those observed for octane (Pv = 1726 Pa). Similarly, 
relative standard deviations reduced with vapour pressure, with the % relative standard deviation (RSD) for 
5-nonanol responses observed to be 2.7% when compared to 26% for octane. Evaluation of VOCs 
recovered from in-vivo samples (n = 6) indicated that VOC concentrations in saliva may follow lognormal 
distributions. Comparison of in-situ sampling with passive drool saliva collection revealed up to 105 fold 
concentration enhancement with reduced variability compared to drooled samples.  
Evaluation of data processing workflows highlighted the challenges in automating data handling for the 
complex data sets produced; dynamic background compensation (DBC), deconvolution and retention index 
alignment were required to create a data matrix for multivariate analysis.  
The samplers and workflows have been applied in metabolomic profiling studies on stress. Four potential 
skin VOC markers of psychological stress have been tentatively identified and a principle component 
analysis (PCA) model demonstrated good predictive capability for stressed and un-stressed individuals.  
Potential biomarkers of physiological stress have been tentatively identified in skin and saliva VOC samples 
collected before, during and after exercise. A suite of candidate markers in skin (n = 8) and  saliva (n = 7) 
has been shown to differentiate between individuals in differing stages of relaxation, physical exertion and 
recovery. The complementary datasets produced from the different sample types using the workflows 
developed and described in this thesis has been highlighted and the potential for combining VOC profiles to 
build a person’s ‘volatolome’ discussed.    
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1 INTRODUCTION: THE HIDDEN CODES IN HUMAN SCENT 
 
1.1. VOLATILE ORGANIC COMPOUNDS AS MARKERS OF HUMAN FUNCTION 
 
1.1.1. The role of olfaction in disease detection 
The scents of mammals are complex blends of natural products that can reveal a wealth of 
individual information [1]. The most evocative and nostalgic of all the human senses, smell can 
affect a person’s mood, memory and whole sense of well-being; a house filled with familiar 
comforting aromas such as baking bread and log fires can make us feel instantly at home and 
safe [2] [3]. The sense of smell relies on specialised sensory receptors in the olfactory system 
perceiving volatile compounds and humans are able to distinguish over 10,000 odour molecules 
and apply this information in everyday life, often without realising – testing whether food is fresh 
to eat for example [4].  
The application of the sense of smell to medical diagnosis is likely to have originated with the 
father of modern medicine, Hippocrates, around 400 BC, long before the germ theory of disease 
had developed. Medical practitioners described how they were able to perceive that diseases in 
humans changed the odour of bodily excretions [5]. This understanding of the relationship between 
odours and disease states can be traced through history to ancient Greek apothecaries, who 
employed urine charts linking taste, smell and colour to known medical conditions, and traditional 
Chinese medical practitioners who poured sputum onto hot coals and identified a unique scent 
indicative of tuberculosis [5-7]. 
The link between olfactory perception and disease diagnosis is not limited to our more primitive 
ancestors; diagnosis based on smell remained one of the most reliable methods used in bedside 
medicine for many years. In 1982 Fitzgerald and Tierney, concerned that this skill would be lost in 
translation to future generations of medical practitioners, felt this area to be of such import that 
they documented a list of descriptive aromas for particular human diseases and disorders [5]. An 
excerpt is included in Table 1.1.  
On the battle field in World Wars One and Two physicians had no option but to rely on their sense 
of smell to identify gas gangrene and even today warning signs of liver disease include a fishy 
smell from patients and the ‘fruity’ smelling breath caused by diabetic ketoacidosis is employed in 
emergency rooms for rapid, potentially life saving diagnosis [7].   
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Table 1.1  Early uses of descriptive aromas in diagnosing diseases and metabolic disorders, adapted 
from reference 5. 
Disease / Disorder Body Source Descriptive Aroma 
Anaerobic infection Skin / Sweat Rotten apples 
Cystic fibrosis Infant stool Foul 
Diphtheria Sweat Sweet 
Lung abscess Breath / Sweat / Urine Foul, putrid 
Renal failure Breath Stale urine 
Rubella Sweat Freshly plucked feathers 
Typhoid Skin Brown bread 
Yellow fever Skin Butcher’s shop 
 
Whilst human olfaction has been employed with some success in this field humans, have long 
relied on the far superior canine sense of smell; bloodhounds have reportedly been used in 
tracking humans based on their scent since the sixteenth century! Canine scent plays a 
fundamental role in their existence and this has been exploited by humans in many ways, the 
principle among these being tracking, drug detection, search and rescue and forensic applications 
based on the premise that the individuality of human scent can be distinguished by trained dogs 
[8]. Dutch researchers have shown the scent from the human palm to be the most individualised 
and trained police dogs have been shown to match individuals to their clothing by matching the 
scent from their palms with the pockets on the clothing [9].  
The hypothesis that the ‘smell of cancer’ in humans can be distinguished by dogs was proposed 
as early as 1989 but has recently caught public imagination with a number of articles appearing in 
news items, one notable publication boasted the headline ‘Paging Dr Dog…’ in the Wall Street 
Journal (10.07.2012). Williams and Pembroke first reported the observation of an untrained dog 
aiding in identifying a melanoma, reportedly the dog kept ‘worrying’ a mole on its owners leg and 
ultimately tried to bite it off, this caused the owner to seek medical advice which resulted in 
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diagnosis and treatment for the cancer [10]. Several examples of trained dogs differentiating 
between diseased and healthy controls have been reported with sensitivities from 88-100% and 
specificities from 91-99% for tissues from ovarian tumours and melanoma, exhaled breath for 
lung, breast and colorectal cancers, urine for prostate cancer and faeces for colorectal cancer. For 
more detail on specific studies the reader is referred Buszewski and co-workers review on 
unconventional methods of cancer detection using odour [8].  
There are also a number of anecdotal reports of dogs raising the alarm when their owners become 
hypoglycaemic [7]. The reason behind a dog’s reaction to these disease states is currently 
unknown, yet it is commonly accepted that something in the volatile emanations from these 
individuals is detected by canines and elicits a reaction.  
While it is evident that the canine sense of smell is in many aspects superior to current analytical 
instrumentation in detecting and processing this kind of data, there must be metabolic changes 
associated with the disease states that alter the volatile profile from human sufferers and 
therefore with suitable instrumentation and data processing an objective measure of these 
changes should be a realistic research goal.  
 
1.1.2. The advent of biomarker discovery 
The invention of techniques for separating complex mixtures, in particular gas chromatography 
(GC), during the 1950s and their subsequent coupling with mass spectrometry (MS) provided 
instrumentation to begin to address the challenge of separating and identifying the volatile organic 
compounds (VOCs) responsible for the changes in odour with disease states [5]. The World Health 
Organisation classifies VOCs as those compounds with boiling points within the range 50-100ºC to 
240-260ºC and semi-volatile organic compounds (SVOC) as those compounds with boiling points 
within the range 240-260ºC to 380-400ºC these classifications will be adopted for the purposes of 
this thesis [11]. It is now understood that the changes in odours associated with biological fluids or 
tissues are due in part to metabolic changes within the body and may be indicative of an 
individual’s state of health, such was the birth of metabolomics and metabonomics [12].  
Metabolomics and metabonomics both study the collection of metabolites from a cell or organism, 
known as the metabolome. The distinction between the two terms is tenuous and numerous 
definitions can be found in the literature, one such attempt to differentiate between the two is 
based on the choice of technique stating ‘metabolomic studies typically utilise MS whilst the term 
metabonomics typically describes studies performed with nuclear magnetic resonance (NMR) 
spectroscopy’ [13]. Another review defines metabonomics as aiming to measure the global, 
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dynamic metabolic response of living systems to biological stimuli or genetic manipulation, and 
metabolomics as seeking an analytical description of complex biological samples, aiming to 
characterise and quantify all the small molecules in such a sample [6]. In practice the same 
analytical and data processing procedures are followed in both and the terminology is generally 
used interchangeably. In this thesis all studies of this kind will be referred to as metabolomic 
studies.  
VOCs are released by biological systems and can be considered as a kind of terminal metabolite 
[14] representing the end points of gene expression and cell activity. Thus metabolomics offers a 
holistic approach to exploring the phenotype of an organism [15].  
Early practitioners of metabolomics used paper chromatography to characterise individual 
metabolic patterns in human biological fluids. This pioneering work was soon followed by thin layer 
chromatography (TLC) [15]. The complexity of the challenge was soon recognised and the need for 
enhanced separation, improved sensitivity, and automated analytical and data handling 
procedures led to extensive research resulting in a number of analytical techniques employed in 
metabolomic studies. For the volatile signatures associated with the changes in odour with 
disease state the ‘gold standard’ technique is GC, preferably coupled with MS.  
A number of biological matrices have been employed in metabolomic studies for human 
biomonitoring. Blood directly reflects the internal environment of the body including nutritional, 
metabolic and immune status [16] and is less affected by exogenous contaminants than most other 
biofluids. As a result whole blood, serum and plasma have been employed in biomarker 
prospecting studies [17] [18]. Obtaining blood samples is not easy, patients find it invasive and often 
painful, there is an increased risk of infection due to the inevitable puncture wounds and the 
necessity for stringent storage and pre-treatment procedures makes blood sampling a time 
consuming and expensive method.  
A recent headline in the British press read ‘Half of UK population will get cancer in lifetime’ (BBC 
News 07.06.2013). This highlights the need for effective screening techniques for early diagnosis. 
Currently screening based on imaging methods, such as ultrasound and mammography, are 
employed to select patients suspected of having cancer but ultimately the diagnosis can only be 
made on the basis of tissue biopsy and histopathological examination [8]. Whilst an effective 
method, the drawbacks associated with diagnosis by tissue biopsy are much the same as with 
blood sampling and neither of these present an acceptable solution for widespread routine, in-
field or in-clinic screening of large populations. Widespread in-clinic screening is essential for 
successful early diagnosis, and must be the end-goal of research into early cancer, or indeed any 
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disease, diagnosis. A desirable screening method should be non-invasive, painless, easily 
accessible and inexpensive but, above all, it should be sensitive, reliable and highly selective for 
markers of the disease to facilitate early stage diagnosis of the disease state [8]. 
Identified as early as 400 BC the volatile emanations, or smell, from human beings may contain 
useful information about an individual’s state of health. Once relationships between VOC profiles 
and biological pathways are understood VOC profiles will transcribe complicated bio-information 
[14] and may provide a route to the next generation of non-invasive screening techniques. To this 
end significant research effort has been invested in identifying and developing non-invasive 
sampling techniques for the measurement of human function and applying them to metabolomic 
studies.  
 
1.1.3. Non-invasive sample collection for metabolomics 
The natural starting point for a non-invasive sample is a matrix that is regularly excreted from the 
body; urine and faeces for example. Biomarkers for cholera [19], inflammatory bowel diseases [20] 
and colorectal cancer [21] have been tentatively identified in faecal samples, however these 
samples are more routinely used in monitoring exposure to pesticides or biomonitoring of metals 
than in diagnostic screening [22].  
Urine samples have found application in many areas of bioanalysis including, but not limited to, 
pharmacokinetic studies of administered pharmaceuticals, detecting drugs of abuse, doping in 
sports, and measuring exposure to xenobiotic substances [18] [23]. Due to the ease of collection and 
relative volume of samples urine has also been studied extensively in metabolomics and 
biomarkers have been proposed for chronic obstructive pulmonary disease (COPD) [24] and a 
number of cancers including prostate, bladder, breast, ovarian, cervical and renal [25] [26]. Direct 
analysis of urine is limited by high concentrations of urinary salts so a clean-up stage and 
consideration of pH control is required prior to analysis [22]. The variations in excreted volumes, 
and hence concentrations, also necessitate normalisation as part of the analytical work flow; most 
commonly achieved by the creatinine concentration adjustment method [27]. As with blood 
samples storage conditions are paramount in preserving the integrity of urine and faecal samples 
prior to analysis, typically low temperatures (-80 °C) are required.  
For many people faeces and urine are bound up with taboo and providing such samples can be 
discomfiting and embarrassing for patients, and this may result in problems with patient 
compliance. These approaches cannot necessarily be considered as being completely non-
invasive, the term ‘minimally invasive’ may perhaps be more appropriate.   
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Sputum has been employed with some limited success in metabolomics and biomarkers for 
asthma [28], COPD [29], lung cancer [30] and tuberculosis [7] have been described. Whilst sputum 
may be considered non-invasive, because there is no requirement for tissue damage to collect the 
sample, sputum induction requires salbutamol ingestion followed by inhalation of hypertonic 
saline solution [28]. This combination causes the patient to cough violently so that sputum is 
ejected from the lower airways into the mouth for collection. At best this procedure can be 
described as semi-invasive and, as with blood sampling and tissue biopsy, is relatively expensive 
and requires trained medical personnel to perform the sampling.   
Skin cancer is currently both the most common and the fastest growing cancer in the United 
Kingdom [31]. If melanoma is detected early enough the 5 year survival rate is around 98.2% [32]. 
Unfortunately the majority of cases are not detected in this time window and some of this may be 
attributed to patients’ reluctance to bother their general practitioner (GP) with ‘just a mole’, or to 
the fear of unnecessary biopsy or hospitalisation. The idea that VOC profiles may contain 
signatures from melanoma is not a new one and headspace sampling of excised melanoma, naevi 
and healthy skin has shown volatile markers that differentiate between them [12] [32] and provides 
a proof of principle that diagnosis of malignant melanoma may be possible in-vivo. Other local skin 
conditions have also been explored in conjunction with skin profiles including atopic dermatitis [33], 
chronic wounds [34] and allergens from skin creams [35]. Skin sampling has even been applied to 
studies of systemic diseases; a marked difference in metabolic activity was observed in skin 
fibroblasts from Alzheimer’s sufferers and preliminary studies have shown indications that dermal 
markers may reflect the presence of breast cancer [33]. One study of emanations from human skin 
has shown acetone levels to correlate with circulating blood glucose which may provide the basis 
for a non-invasive monitoring technique for Type 1 diabetes sufferers [36]. 
Studies on volatile emanations from the skin surface have not been limited to diseases and 
disorders, numerous studies characterising body odour [37] [38], mosquito attractants [39] [40], gender 
differences [41], age-specific odours [42], fragrance release [43] and even indicators of seasonal 
changes [44] have all  been studied non-invasively by various collection and analytical techniques. 
The skin sampling techniques that have been described are many and varied and will be covered 
in more detail later in this chapter, at this point it is sufficient to comment that these studies all 
highlight the low concentration of some potentially significant skin emanations so non-invasive 
sampling from human skin requires an enrichment step to harness the full potential indicated by 
these preliminary studies [45]. Volatile profiles from human skin have been shown to be highly 
complex and individualised and early indicators point towards useful, diagnostic information on 
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human function present in such profiles that may prove key in the drive towards non-invasive 
sampling for early diagnosis based on VOCs. 
Human saliva is an easy to collect, low-cost matrix useful for screening large populations without 
the need for trained clinical staff. The pace of research into saliva as a diagnostic medium has 
accelerated in recent years as the non-invasive nature makes it preferable for the patient 
compared to blood, biopsy, urine or faeces [46] and quantitative studies have indicated meaningful 
correlations between blood and saliva concentrations for non-protein bound analytes [47-49]. 
Collection is straightforward and comfortable and saliva sampling and analysis has been used to: 
monitor exposure to hazardous chemicals [50] [51], identify drugs of abuse [52] [53] and study dietary 
factors [54-56]. In metabolomic studies biomarkers for a number of systemic conditions have been 
proposed including renal disease [57], gout [58], cystic fibrosis, diabetes mellitus, kidney dysfunction 
and alcoholic liver sclerosis [59].   
Whilst skin and saliva sampling have demonstrated promise as potential non- invasive sources of 
biologically relevant information the greatest focus in this area in recent years has been on VOCs 
in exhaled breath [60].  
Exhaled air is a mixture of nitrogen, oxygen, carbon dioxide, inert gases, water vapour and trace 
level VOCs [61] and the non-invasive, safe and straightforward nature of the sampling process 
makes breath analysis an attractive tool for clinical screening and metabolomic studies [62].  
Numerous techniques for capturing the VOC profile in exhaled breath have developed in recent 
years but the first quantitative measurement of alveolar breath was developed as early as the 
1930s – the Haldane-Priestly sample tube, and variants, has been used in a number of studies on 
metabolic disorders [63]. Two main approaches have been used for sampling exhaled breath, real-
time analysis which requires a participant to expire directly into the analytical instrument gives the 
advantage of real-time breath by breath measurements. The concentrations of potentially 
significant VOCs in breath can range from ppmv to as low as pptv [63] and so the majority of 
modern breath samplers employ a pre-concentration step either by collecting breath into a 
canister or sampling bag followed by cryofocussing, or by passing breath through an adsorbent 
trap [60].  
Volatile markers for a number of lung diseases have been proposed in exhaled breath samples; 
elevated levels of hydrocarbons have been found in patients with asthma, COPD, obstructive sleep 
apnea, cystic fibrosis and pneumonia [60] while a number of methylated hydrocarbons have been 
proposed as markers of lung, breast, colorectal and prostate cancer [64] [65]. Metabolic disorders 
have also been explored in relation to breath VOC profiles and levels of breath acetone have been 
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shown to correlate with blood glucose levels in diabetic patients [60]. Other, non-clinical, 
applications of breath samples in metabolomic studies have included the variation in VOC profiles 
with diet, environment, exercise and even induced psychological stress [66-68] [62].  
Whilst breath sampling appears to offer many advantages in the drive for non-invasive large-scale 
screening techniques, obtaining a reproducible and representative breath sample is not as simple 
as it may initially seem; exhaled air comprises a mixture of dead space air – approximately 150 
mL from the upper airway where there is no direct gaseous exchange with circulating blood, and 
alveolar, or end-tidal air. Dead space air offers little information about the metabolites circulating 
in blood and is often heavily contaminated with exogenous compounds recently inspired, whereas 
alveolar air, originating in the lower respiratory pathways, is in contact with circulating blood and 
rich in endogenous VOCs. Three modes of breath sampling then present themselves; whole breath 
sampling – a mixture of dead space and alveolar air, dead space air only or alveolar air only. For 
diagnostic screening or metabolomic studies the obvious choice is alveolar only. Unfortunately this 
complicates the sample collection strategy, end-tidal breath is often diluted by dead-space air and 
sophisticated techniques that sample only alveolar air are required. A number of samplers have 
been designed to this end the more sophisticated of which employ a CO2 controlled valve [69] or 
pressure sensor [63] to mark the transition between dead space and alveolar breath. While these 
techniques facilitate high quality, reproducible breath samples the additional complexity and 
training required to obtain the samples reduces the applicability of the sampling to large scale 
routine screening. For remote sampling a number of single-breath sampling methods have been 
employed, however it is difficult to achieve sufficient sensitivity and reproducibility from a single, or 
several, breaths.   
High levels of water vapour in breath samples can cause complications with sampling, polar 
species dissolve in condensation and so may not reach the sample collection vessel and water 
can block adsorption sites in sampling media.  Table 1.2 outlines the principle biological matrices 
for human health and disease monitoring and their main advantages and disadvantages as a 
sample for large scale clinical screening. 
  
9 
 
Table 1.2 Overview of sample matrices for disease diagnosis. 
 
 Blood Tissue 
(Biopsy) 
Faeces Urine Sputum Skin / 
Sweat 
Saliva  
 
Breath 
Invasive Yes Yes Minimally Minimally Semi None None None 
Privacy concerns? None None Yes Yes Some None None None 
Minimum sample size >50mL N/A >50mL >50mL mL N/A / (µL) mL >50mL 
Pretreatment? Yes Yes Yes Yes Yes Some 
methods 
Some methods Some methods 
Self administrable? No No Yes Yes No Yes Yes Some 
Easily Fieldable? No No No Yes No Yes Yes Yes 
Storage requirements -80ºC -80ºC -80ºC -80ºC -80ºC Variable Variable Variable 
Used in routine methods? Yes Yes No Yes Yes No Yes 
DNA only 
Yes  
Suitable for vulnerable 
participants? 
No No No Yes No Yes Yes Yes 
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The potential of biological VOC profiles in moving clinical screening towards simple, safe and 
sensitive non-invasive sampling techniques has reached a proof-of-principle, demonstrated by 
the studies detailed in this section. The challenges in advancing this field of research 
principally lie in the benefits of standardisation. A recent drive for more robust studies in breath 
metabolomics lead to the publication of a workflow for the metabolomic / metabonomic 
investigation of exhaled breath [70] providing a basic dynamic framework upon which a set of 
standardised guidelines for breath VOC analysis in metabolomic studies can be built and 
amended / improved upon in an iterative process.  
The studies in this thesis focus on skin and saliva as non-invasive sample matrices that 
potentially offer complementary information to exhaled breath samples and evaluate the 
potential for standardised sampling and analysis workflows across a number of biological 
compartments.  
 
1.2. RESEARCH AIMS 
This research is based on the following premises: 
 There are discernible differences in the biological volatile organic compound profiles 
emanating from individuals in different metabolic states.  
 Complementary and comparable information can be obtained from volatile profiles 
associated with different biological compartments; therefore less invasive sampling 
techniques may be substituted for the established puncture wound based sampling for 
clinical screening. 
 The workflow for collecting, analysing and processing data from volatile biomarker 
discovery studies for non-invasive VOC samples can be applied to different sample 
types resulting in complementary data sets.  
 
The research aims of this project are to explore non-invasive sampling and analysis of 
biological VOCs from human skin and saliva, evaluate the steps in this multi-disciplinary work 
flow including ethical clearance, sampler design and optimisation, pilot studies and data 
handling and evaluate each process against the current forerunner in non-invasive 
measurement: exhaled breath analysis.  
This introductory chapter will explain the rationale behind the selection of skin and saliva 
samples by introducing the transport membranes and discussing the biological and physical 
chemical aspects that create the associated VOC profiles and review the current status of 
sampling methodologies and metabolomic studies in this field.  
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1.3. THE ANALYSIS OF HUMAN SKIN 
The skin is the largest organ of the human body comprising around 10% of the body mass and 
covering approximately 1.7 m2 of an average adult [71]. The skin can be viewed as a highly 
efficient, self repairing barrier which serves to act as a permeation obstacle preventing ingress 
of exogenous molecules and regulating excretion from the surfaces of the body. This oft-
overlooked, uniquely engineered organ regulates the loss of heat and body water and performs 
vital functions both as a protector and in homeostasis, [10] but is generally considered rather 
simplistically as a barrier to ‘keep the insides in and the outside out’. Continually regenerating 
and metabolically active the skin is functionally the most versatile organ of the human body 
and can in fact be viewed at varying levels of complexity and facilitates selective absorption 
and excretion of nutrients, waste products and even pharmaceuticals [72]; essential yet 
unobtrusive, the human skin is the first line of defence and the end of numerous metabolic 
pathways performing many more functions than a humble blockade against the outside world.   
 
1.3.1. Human skin structure 
The skin consists of four main, physically and functionally distinct, layers which connect to the 
surface by a number of bridging structures an overview of the principal structures may be seen 
in Figure 1.1 [73]. The innermost of these layers, the hypodermis, is composed mainly of fat 
microlobules and fibrous collagen and is also known as the subcutaneous fat layer. A relatively 
thick layer, in the order of millimetres, the hypodermis is found over the majority of the human 
body and connects the outer skin layers to muscle and bone whilst allowing movement and 
offering mechanical protection and insulation. Principle blood vessels and nerves pass through 
the hypodermis to the outer layers of the skin [71].  
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Figure 1.1 A cross section of human skin showing the principle layers, appendages, blood and 
lymph vessels, adapted from reference 74. 
Adjacent to the hypodermis lies the dermis which consists of a network of connective tissue 
and collagen fibrils providing support and elasticity to the skin, two principle layers exist within 
the dermis; the lower reticular dermis comprising thick collagen fibrils and coarse elastic fibres, 
and the upper papillary dermis, a mixture of thin collagen bundles, elastin fibres and ground 
substance [71]. The dermis also houses blood vessels and sections of the lymphatic and 
nervous system. Skin blood vessels are most concentrated in the papillary dermis as the 
superficial plexus; a dense collection of arterioles and venules that run along the dermal-
epidermal junction. Another, less dense, deep plexus of arteries and veins run roughly parallel 
deeper in the reticular dermis with a network of connecting blood vessels between the two [74]. 
Lymphatic system vessels within the skin lie roughly parallel to the blood vessels.  
Several classes of surface appendage originate in the dermis, providing bridging links from 
inner skin layers to the surface: 
Hair follicles cover on average 0.1 % of a human body [73] and are distributed evenly over the 
surface with notable absences on load bearing areas such as the palms of the hands and soles 
of the feet as well as on the lips and genitals [71].  The conical entrance from the skin surface, 
known as the infundibulum, extends up to 500 µm into the skin, deeper than the dermal-
epidermal junction. A hair follicle joins a sebaceous duct which in turn connects to a sebaceous 
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gland, sebaceous glands can also be found without associated hair follicles, most commonly 
on the face. Sebum, a lipophillic skin lubricant, is secreted by the sebaceous glands and fills 
the infundibulum to provide the skin with protection against bacteria, over wetting and heat 
loss [75]. The precise composition of sebum varies between individuals and body site and 
comprises a mixture of triglycerides, fatty acids, wax esters, cholesterol and squalene. The hair 
follicle is heavily vascularised, the bulb at the base is surrounded by interconnected blood 
vessels running parallel to the length of the follicle that connect with the vessels surrounding 
the sebaceous gland [75].  
Eccrine glands are a class of sweat gland present from birth and found over the majority of the 
human body at an average density of 100-200 glands per square centimetre [71], they are 
particularly numerous on the palms of the hands and soles of the feet with a maximum density 
of 700 cm-2, absent on the lips and at a minimum on the back with a density of around 64 cm-2 
[76].  Eccrine sweat is composed of 99% water with the remaining 1% consisting of electrolytes, 
lactic acid, urea, ammonia, amino acids and a number of protein species [71].  The glands are 
based in the lower regions of the dermis and connect to the surface by a duct, approximately 
100 µm in diameter, which coils around the gland before rising through the outer layers to the 
skin surface. The main functions of these glands are thermal regulation, improved grip and to 
sensitise the skin. Secretions are released from the cell as a liquid in response to heat or 
emotional stress and the composition can vary depending on hydration, state of health and 
region of the body. Salts and electrolytes can be re-absorbed through the walls of the duct to 
maintain homeostasis [71].   
Apocrine glands are another type of sweat gland connecting the lower skin layers to the 
surface, apocrine ducts open into the infundibulum in more limited areas of the body such as 
axillae, nipples and mons pubis [75]. The precise function of these glands is unknown, they have 
no role in thermal regulation, and they are thought to be relics of odour producing glands in 
mammals for territory marking and sexual attraction. A milky, viscous fluid is excreted from 
apocrine glands which is rich in proteins, carbohydrates and ammonia, although sterile 
apocrine sweat is odourless, bacterial degradation on the skin surface results in the odour of 
sweat. Apoeccrine glands appear during adolescence and have common features with both 
eccrine and apocrine glands [71].  
The outermost layer of skin is called the epidermis and this consists of both viable and non-
viable cell layers which, for the purposes of this chapter, will be addressed separately. 
Epidermal cells undergo continual migration from the dermal-epidermal junction to the 
uppermost skin layer, the stratum corneum which consists of dead, annucleated, keratinised 
cells [77]. Between the dermal-epidermal junction and the stratum corneum lies the viable 
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epidermis, an avascular environment across which desquamation occurs; enzymes degrade 
viable cell components and nuclei disintegrate before the cells become part of the stratum 
corneum approximately 14 days after beginning the migration [75]. 
The final stages of desquamation see the epidermal keratinocytes formed into flat, closely 
packed corneocytes embedded in a highly organised lipid bilayer matrix; forming the stratum 
corneum. The lipid composition and organisation in the skin differs to other biological 
membranes; phospholipids are largely absent and instead eight uniquely structured ceramides 
together with fatty acids, cholesterol and cholesterol sulphate provide the ampiphillic 
properties for bilayer formation [71]. The stratum corneum acts as the main physiochemical 
barrier against uncontrolled permeation both into and out of the skin and is often represented 
as a ‘bricks and mortar’ like structure [78].  
 
1.3.2. Skin as a transport membrane 
Human skin is more than a barrier; compounds can selectively cross the skin to be excreted in 
eccrine and apocrine sweat, in sebum and by perfusion from underlying blood vessels giving a 
rich and highly individualised mixture of metabolites on the skin surface. The transport 
properties of the skin membrane are exploited in transdermal drug delivery systems such as 
nicotine patches and hormone treatments, this delivery route offers some unique advantages 
in that it is non-invasive and self administrable, improving patient compliance, and avoids first 
pass metabolism by the liver [73].  
The skin as a transport membrane can be viewed at varying levels of complexity, the simplest 
as a single physical barrier, more accurately when the different properties of skin layers are 
considered; a collection of barriers with differing transport properties arranged in series [71]. 
This was recognised as early as 1971 by Scheuplein who commented that percutaneous 
absorption requires absorption into the stratum corneum, and subsequent diffusion through it, 
the viable epidermis, the papillary dermis and into the microcirculation. The reverse is true for 
elimination through the skin. The layers of tissue in the viable epidermis, the dermis and the 
capillary walls are relatively permeable and for the great majority of substances percutaneous 
absorption or elimination is rate-limited by the stratum corneum [79].  
More accurately still when surface appendages, such as hair follicles and sweat glands, are 
taken into account the skin can be considered as a collection of barriers with varied 
physiochemical properties both in series and in parallel. Molecules up to a few hundred 
Daltons in size can cross the skin and their permeation is a multifactoral phenomenon 
dependant on many physical, chemical and biological interactions [78].  
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1.3.2.1. Percutaneous permeation 
The principle barrier to permeation through the skin lies in the 10-20 µm thick non-viable cell 
layer; the stratum corneum, transport across which occurs by passive diffusion [78] [80]. The 
widely accepted ‘bricks and mortar’ structure of the stratum corneum, represented in Figure 
1.2,  offers two pathways for diffusion; the transcellular route requires repeated partitioning of 
a solute molecule into both lipophillic and hydrophilic compartments and studies have 
indicated that this is the minor route of epidermal permeation [73] [79] [80].  
 
 
Figure 1.2  A bricks and mortar representation of the outermost skin layer, the stratum corneum. 
The major routes of transport from circulating blood to the skin surface are shown. 
Adapted from reference 73. 
The second, more widely accepted, diffusion pathway is the tortuous intercellular path that 
winds around the cellular ‘bricks’ through the lipid bilayer ‘mortar’. Hydrophilic compounds, 
soluble in the polar head, groups have been observed to have a near constant permeation 
through the aqueous regions whereas passage of lipophillic compounds transported by 
diffusion through the non-polar tail groups vary considerably with lipophilicity [73]. The transport 
of lipophilic compounds through the ‘tail’ section of the lipid bilayer is highly constrained by 
structural and solubility properties and can be approximated by the octanol/water partition 
coefficients, logP. Log P values between 1 and 3 are considered ideal to facilitate penetration 
through the stratum corneum [73]. The third route, transappendageal transport, will be 
discussed in the next section.  
Molecules in the gas phase undergo Brownian motion which induces an overall diffusional flux 
from areas of high to areas of low concentration in a homogenous medium [80] [81]. For a simple 
inert membrane the steady state flux, Jss (moles cm-2 s-1) is defined by the amount of 
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substance, Qss (moles), passing across a surface of area A (cm2) in a given time period t (s) and 
is related to the concentration difference between the two membrane surfaces,  [ ] (moles cm-
3), the diffusion coefficient of the solute in the membrane, D (cm2 s-1), and the diffusion path 
length or membrane thickness   (cm) [81]: 
     
   
  
 
  [ ]
 
 
Equation 1. 1 
 
 
Skin is not inert and the thermodynamics of adsorption/absorption vary with the type of 
compound and its concentration.  Adsorption / absorption kinetics are determined in part by 
the solution/membrane absorption isotherm [81]. For dilute solutions, such as those likely to be 
found in circulating blood or the lymphatic system, these isotherms are linear and obey Henry’s 
law in which absorption is proportional to concentration with the constant of proportionality the 
partition coefficient between the two phases (P): 
  
[ ] 
[ ] 
 
Equation 1. 2 
 
[ ] , Concentration absorbed in skin (moles cm-3), [ ] ,Circulating concentration in blood/lymph vessels (moles 
cm-3),  , Partition coefficient. 
 
This allows the correlation between concentrations across the membrane to be stated in terms 
of the solute-membrane partition coefficient, P. In skin this partition coefficient is generally 
approximated based on a molecules octanol/water partition coefficient; usually expressed as 
log P [79].  
Permeation across the skin membrane occurs via a solution-diffusion mechanism governed by 
both Fick’s diffusion and Henry’s solubility laws [79] [82] and the rate of permeation, or flux, at a 
steady state, Jss, is related to a solutes partition and diffusion coefficients in skin, the 
circulating concentration and the skin thickness: 
 
     
  [ ] 
 
 
Equation 1. 3 
 
The coefficient of permeability,    (cm s-1) is: 
 
    
  
 
 
Equation 1. 4 
 
For a molecule with a circulating concentration sufficiently low to obey Henry’s law the rate of 
change in concentration at the surface of the skin is proportional to the circulating 
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concentration and inversely proportional to the skin thickness with the constants of 
proportionality being the diffusion coefficient of that molecule in the lipid bilayers of the 
stratum corneum and the partitioning coefficient between the blood/lymph vessels in which 
the molecule is carried to the skin, and the intracellular lipid bilayers of the stratum corneum. 
This model assumes a constant circulating concentration with respect to the time taken for 
permeation to reach a steady state. During skin sampling this process will be driven by a 
continual depletion at the skin surface due to partitioning into the sampler. It is more likely that 
concentrations measured by sampling the skin surface will give rise to time-weighted average 
concentrations with respect to the circulating concentration.  
While diffusion through the stratum corneum usually acts as the rate limiting step in excretion 
via the skin it is also worth mentioning the contribution from the deeper layers [73]; the viable 
epidermis consists of ~40% protein, 40% water with the remainder made of a lipids. Diffusion 
through the viable epidermis can be considered as diffusion through an aqueous medium 
interspersed with regions of higher lipophilcity, the barrier effects of the viable epidermis in 
transport across skin can be incorporated into skin permeation models by treating it as an 
homogenous aqueous layer immediately below the stratum corneum so the total epidermal 
permeability depends on the permeability of the stratum corneum (        and the viable 
epidermis         and can be represented by the epidermal permeability coefficient, kp.Epi [75]  
 
 
      
 
 
      
 
 
    
 
Equation 1. 5 
 
 
Similar to the viable epidermis the dermis can be viewed as gelled water however, there are 
important differences. While the viable epidermis is avascular the dermis is rich in blood and 
lymph vessels which contribute significantly to the transport and distribution of molecules in 
the skin. Vasoconstriction and vasodilatation will significantly alter the clearance and 
absorption rates of compounds through the skin. The treatment of the stratum corneum and 
viable epidermis as barriers in series can be extended to include the dermis as a third barrier 
[73].   
Highly hydrophilic molecules with low log Po/w values, such as volatile fatty acids and alcohols, 
will exhibit low rates of permeation across the stratum corneum. Polar, hydrophilic compounds 
are commonly reported on the skin surface however and other transport routes may contribute 
to their presence [83].  
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1.3.2.2. Transappendageal transport 
The models above present skin as a series of homogenous layers between the circulatory 
system and the skin surface, this is a simplification for  a number of structures create bridges 
from the deeper skin layers to the surface and as such bypass some of the diffusive processes 
described above [73]. As shown in Figure 1.2 transport across the skin can be considered as a 
collection of barriers both in series as described in Section 1.3.2.1 and when 
transappendageal routes are considered, in parallel. 
The hair follicles, eccrine, and apocrine glands act as transport links to the skin surface and the 
composition of their secretions contribute to the chemical cocktail on the skin surface and 
influence the overall permeability [75-80]. 
Apocrine sweat glands open into hair follicle infandibular in more limited areas of the body. 
Secretion takes place as apical budding of cells of the duct and is stimulated in response to 
emotional stimuli such as anxiety, pain or sexual arousal. Apocrine sweat is a milky, viscous 
fluid containing proteins, lipids and steroids. Recent studies into the odour of sweat have found 
a set of apocrine secretion binding proteins that act as carrier proteins for a number of volatile 
odorous molecules [76]. Volatile fatty acids and sulphurous compounds, accredited as the 
primary causes of human body malodour, are carried to the skin surface in apocrine sweat as 
amino acid conjugates where they are subsequently released by bacterial enzymes [84].  
Apoeccrine glands are not as well understood as other sweat glands although they share 
characteristics of both eccrine and apocrine glands. Their function is as yet unknown but they 
are not thought to play a role in thermal regulation. They secrete a watery substance the 
composition of which strongly resembles eccrine sweat but has yet to be fully characterised 
due to the difficulty in differentiating between them and eccrine glands during sweating [84].  
Sebaceous glands also open into, although are not limited to, hair follicles and as such the 
composition of apocrine sweat may in fact be contaminated with sebaceous gland secretions. 
The true function of these glands has yet to be determined. Antioxidant and antibacterial 
effects are chief among the theories for sebaceous gland function as well as the carriage of 
pheromones to the skin surface [85]. These glands secrete sebum, a skin lubricant rich in 
squalene, wax esters, triglycerides and phospholipids. The sebaceous gland, in common with 
apocrine glands, is a holocrine gland which means that its secretions consist of cells from the 
gland itself and it secretes a number of compounds in common with those originating from the 
epidermis, cholesterol for example, but also a number of  compounds unique to sebum on the 
skin surface including squalene and wax esters [85].  
These structures complete the set of transport routes of VOCs from the circulatory and 
lymphatic system to the skin surface. Re-absorption and biotransformations may occur 
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throughout the whole structure and the rate of secretion is dependent on a number of 
physiological and psychological factors that will influence the ultimate composition of 
compounds on the skin surface at any given time. The distribution of these glands is not even 
across the body so it is highly likely that the profile of compounds sampled from the skin 
surface will be dependent upon body site.  
 
1.3.2.3. Metabolism in skin 
The skin is also a metabolically active organ and its structures contain a number of metabolic 
enzymes; results from histochemical tests indicate that the majority of skin enzymes are 
concentrated in the epidermis, hair follicles and sebaceous glands [86] [87]. Oxidation, reduction, 
hydrolysis, methylation and glucuronidation reactions have been reported to occur in skin. 
Concentrations of metabolic enzymes in skin tend to be low in relation to the liver however and 
these tend to have specific activities at less than 10% of those found in the liver [86]. In contrast 
esterase enzymes reportedly have high activity within the skin, topically applied benzoyl 
peroxide is completely hydrolysed to benzoic acid by human skin [71], indeed this property of 
human skin has been advantageously employed in transdermal drug delivery applications 
allowing the drug to be applied in a lipophillic form to cross the epidermis. Subsequent 
enzymatic activity within the skin converts it to a more hydrophilic compound to cross the 
dermis and enter the circulation [87].  
Distribution of enzymes both within the layers of human skin and across the body is not well 
understood at this time. It has however been observed that topically applied drugs in ex-vivo 
skin from some areas will be completely metabolised, whereas the same drugs applied to skin 
from other body sites will be unaffected [87]. This provides further evidence for the variability in 
the profile of compounds likely to be observed across the skin of the human body.  
Another form of metabolism that must be considered when discussing the chemical profile of 
human skin is one that occurs outside of the body; human skin supports microscopic flora and 
fauna which also metabolise compounds on the skin surface, whether endogenous or 
exogenous in origin. This facet of skin metabolism is most well-documented in the field of body 
odour research [84]. It has long been understood that, while sterile apocrine sweat is odourless, 
bacterial metabolism releases volatile odorous compounds from carriers creating ‘body odour’. 
Significant effort has been expended on understanding in this field and the bacteria 
responsible for metabolising known precursors to produce the principle causal molecules of 
malodour have been extensively reviewed, as have their distributions across the body surface 
[84]. The learning and observations derived from these body odour studies inform research and 
analytical studies that involve sampling from the surface of the human skin. Any compound 
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recovered from a skin sample may have been transported there as a conjugate with another 
molecule before being released during bacterial metabolism; yet one more pathway for 
transport across the skin.  
 
1.3.3. Human skin analysis: current sampling techniques and key considerations 
Early studies of the volatile constituents associated with human skin collected liquid sweat or 
used solvent extraction to obtain samples for analysis [99] [100]. More recently, headspace or 
direct contact sampling of the skin with a sorptive material have been described [88] [110] [111]. A 
number of continuous, on-line sampling and analysis techniques have also been applied [89] [90] 
[91] [92].  
1.3.3.1. On-line sampling methods 
The majority of sampling methods for collecting volatiles from human skin rely on liquid 
extraction or solvent or thermal desorption of the sampling medium, the resultant sample is 
then typically transferred to a gas chromatograph for subsequent separation and detection of 
volatile signatures [111]. Such approaches generate extensive VOC profiles that are rich in 
information, and are potentially useful for global profiling and non-targeted biomarker 
discovery. However, such analytical workflows are time consuming, and analysis times may not 
be applicable for clinical screening applications.  
“Ambient” mass spectrometry approaches, where samples are introduced directly to an 
external ionisation source, have been applied to human skin to provide rapid and sensitive 
analyses. Mass spectral “fingerprints” obtained in-vivo directly from the skin surface with 
desorption electrospray ionisation (DESI) [89], secondary electrospray ionisation (SESI) [90] [91] 
and extractive electrospray ionisation (EESI) [92] are exciting and promising developments in 
this field that have yet to be applied to pilot metabolomic studies.  
Enclosing a participants arm inside a Tedlar bag then directing the collected air for analysis by 
selected ion flow tube mass spectrometry (SIFT-MS) has provided real-time information for 
acetone emanating from skin as a potential indicator of blood glucose levels, further work may 
lead to techniques for monitoring type 1 diabetes [93].  
Proton transfer reaction mass spectrometry (PTR-MS), in which gaseous samples are 
introduced by flowing synthetic air over the surface which is then directed to the a reaction 
region, has been applied to monitoring of UV-lipid peroxidation products of skin [94]. 
All these methods enable fast, selective and sensitive analysis of the area of a participant’s 
skin presented to the instrument providing a near-real time, on-line analytical technique.  
These approaches are all non-invasive however these instruments are difficult to deploy for 
larger scale clinical studies: 
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 they are expensive and require skilled operators; 
 they are difficult to sterilise and compliance with local biosecurity rules is often 
difficult; 
 ambient ionisation techniques require the application of high voltages, presenting 
further challenges for clinical safety which clinicians may find off-putting; 
 
Whilst offering a distinct time advantage, on-line analysis techniques require the participant to 
present the skin to be studied to the instrument, which is not always practical. Consider, for 
example, the practicalities of sampling and analysing skin from a large number of participants’ 
over a short period. The difficulty increases if the study encompasses a large geographic 
region, or remote locations for which it would not be feasible to bring each participant to the 
instrument or move large instrumentation to such areas.    
The current design of such sensitive analytical instrumentation is likely to prohibit their 
application at patients’ bed-sides or in widespread metabolomic or screening studies until 
smaller units that require fewer resources have been developed. 
Some efforts have been made to mimic canine olfaction by utilising electronic noses for 
monitoring volatile emissions from human skin, e-noses respond to volatile compounds using a 
sensor array and can be handheld instruments. One such study has employed an e-nose and 
demonstrated 87% accuracy in discriminating between patients with decompensated and 
compensated heart failure [95].  
Near real-time monitoring of skin emissions has recently been achieved using ion mobility 
spectrometry (IMS) coupled with a short multi-capillary column in which the headspace from 
the skin surface was continually directed through a sampling loop the flow from which was then 
switched automatically to inject into the instrument with a sampling rate of 5 minutes [96]. 
Whilst IMS offers the advantages of being rapid, simple and sensitive the variation in 
instrumental configurations and the current lack of standardised substance libraries means 
that the identification of unknown compounds is difficult and the complex matrices expected 
from these kinds of samples may prove challenging in moving this technique forward without 
parallel GC-MS analysis. 
 
1.3.3.2. Sweat collection methods 
A common approach to sampling VOCs from the skin surface has been to collect sweat 
samples and a number of methods have been tested to this end.  
Several simple sweat sampling techniques apply a form of cotton or gauze pad to collect 
samples, commonly from the axillae, usually with an exercise intervention or in a temperature 
controlled chamber to induce sweating. These pads can then be solvent extracted for liquid 
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injection into the analytical system or the headspace sampled onto an intermediate sorbent 
material such as a solid phase micro-extraction fiber (SPME) [88] or a tube packed with sorbent 
materials, typically porous polymers such as Tenax or Porapak Q [83].  
These methods are likely to extract some compounds that are not volatile at naturally occurring 
body temperatures and the potential for transfer losses is increased with the two step analysis 
process from the sample pad to extraction solvent or secondary sorbent, and then recovery 
from these into the analytical instrument. One such study found common sterilisation 
techniques such as autoclave to not produce ‘analytically clean’ gauze pads even though they 
are considered biologically sterile [97].  
Several methods for collecting sweat by encapsulating a limb or the entire body have been 
reported [98] [99]. The ‘arm-bag method’ is rather self explanatory. In this study sweat is collected 
in a polythene bag attached to the participants arm [99]. Whole body sweat collection has been 
attempted to remove variability between body sites and give a measure of the total electrolyte 
loss during exercise. In one study subjects were required to wash with distilled water and use 
an exercise bike inside a polythene bag for a set time period [98]. After exercise the subject 
washed again with distilled water whilst still inside the bag and the contents analysed by ion 
chromatography. This method was designed to ensure that no extraneous contaminants were 
sampled and therefore any results could only be a result of the individual’s physiological state. 
Encapsulation of the whole body is designed to reduce variability between body sites however a 
great deal of information is lost by removing this variable. The experimental design of washing 
then protecting the skin from the environment so that only physiological factors are monitored 
may have application to other skin sampling techniques. The whole body sweat collection 
method claims to have an advantage over studies in which only one body area is sampled, for 
example the arm-bag method described previously as enclosing a limb causes water-logging 
inside the vessel used which results in sweat remaining on the skin, prevented from 
evaporating naturally by the surrounding air becoming saturated with water.  
Many other methods have been employed to induce sweating in order to collect a sufficient 
sample volume [82]. Although these may be effective in increasing the rate of sample collection, 
they may serve to simply dilute an already low concentration sample and the biological and 
metabolic relevance of the collected sample must be called in to question. For a metabolomic 
or clinical application, sampling should cause minimal disruption to the participant’s metabolic 
state and the high variability in sweat production, both inter and intra individual severely limits 
this sample type for this application.  
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1.3.3.3. Solvent extraction methods 
Skin emanations have been sampled by directly washing the skin with organic solvents; one 
such method involves a glass funnel pressed against the skin surface to hold the solvent on 
the skin surface. The solvent and extracted compounds are then recovered using a Pasteur 
pipette and either analysed directly or pre-concentrated by drying on a rotary evaporator [100].  
Several concerns with this approach as a solution to non-invasive sampling of biological VOCs 
immediately present themselves; the application of organic solvents to a participant’s skin 
must be considered invasive and is highly likely to cause irritation. This technique is likely to 
extract a number of high molecular weight compounds along with the volatile of interest. By 
nature this technique will dilute the sample limiting the sensitivity and pre-concentration by 
drying is likely to cause major losses of the most volatile compounds extracted – something the 
authors observed when comparing to headspace samples from the same experiment [100]. 
Squalene monohydroperoxide (SQ-OOH), a product of sunlight-induced oxidative stress on the 
skin lipid squalene, has been sampled by wiping acetone-wet cotton pads across the skin 
surface. The sampled cotton pads are then solvent extracted, again diluting the collected 
sample, and analysed [101]. 
In summary solvent extraction techniques are inherently invasive, produce dilute samples, 
introduce contamination into the protocol, perturb the underlying metabolism that is being 
studied and require extensive sample work-up before analysis.  This sampling approach has no 
place in non-invasive screening techniques.   
 
1.3.3.4. Headspace sampling methods 
Early headspace sampling methods relied on cotton pads, or even articles of clothing such as 
socks, to collect VOCs from the skin surfaces. These samples would then be sealed into a 
container, sometimes purged with clean carrier gas, and an adsorbent material was then 
exposed to the headspace. Analytes were then recovered by solvent or thermal desorption.  
The same drawbacks are true for this sampling mode as with sampling sweat using absorbent 
pads. Many of the more recent studies into volatile emanations from human skin have used 
techniques sampling ‘skin gas’, or the headspace, directly above the skin surface; these offer a 
significant advantage in that only those compounds that are volatile at body temperature will 
reach the sampling medium.  
For these headspace sampling protocols a headspace must first be created over the area of 
skin to be sampled and this has generally been achieved using a glass vial, funnel, petri-dish or 
even by inserting an entire arm into a jar or Tedlar bag. An adsorbent material is then exposed 
to the headspace after a certain equilibration time for sampling to commence. 
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One such sampler was designed to monitor medically significant VOCs such as acetone and 
acetaldehyde emitted from human skin and was based on passive flux sampling originally 
developed for material emissions applications [102]. A stainless steel petri-dish placed on the 
skin surface and sealed with a polytetrafluoroethylene (PTFE) o-ring created a headspace. Skin 
gas emanations moved through the open face of the sampler towards a trapping filter. In this 
case the trapping filter was activated with the derivatising agent 2,4-Dinitrophenylhydrazine 
(DNPH) which converts the carbonyl groups associated with aldehydes and ketones to 
hydrazone derivatives for analysis by high performance liquid chromatography (HPLC) [102].  
One non-contact skin sampling method chose to enclose their volunteer’s entire bodies, 
excepting the head, inside aluminised plastic bags which were then purged with filtered air 
onto sorbent tubes containing Porapak Q to trap the volatile emanations for subsequent 
solvent desorption and GC analysis [103]. Other sampling systems have used specialised bags to 
create a sealed headspace around limbs or appendages from which the headspace can be 
directed onto a ‘cold trapping’ device [104], or a sorbent material exposed directly into the 
enclosed bag for collection and preconcentration of volatile species [83]. Sampling in this 
manner has some key drawbacks; enclosing the body or a limb in an airtight bag prevents 
natural ventilation of the skin surface and hence will affect the physical chemical processes 
governing release into the headspace. Over-time the vapour around the skin is likely to become 
saturated with water, restricting the release of compounds both into the skin gas and onto the 
skin surface itself. This water vapour will condense on the inside surfaces of the sampling bag 
and can significantly effect recovery of a number compound types – a problem more commonly 
reported in exhaled breath analysis. A study into the feasibility of Tedlar bags for breath 
sampling demonstrated losses of a number of polar species including acetone, methanol, 
acetaldehyde and isoprene and some heavier compounds such as styrene [105].  
Many successful non-contact skin sampling techniques have combined sampling and pre-
concentration steps by exposing a sorptive material to a headspace created by a vial, petri dish 
or jar held against the skin surface; many of these have employed solid phase microextraction 
(SPME) fibres for sampling and enrichment. SPME offers the advantages of simple sensitive 
sampling and direct, solvent free analyte recovery by thermal desorption into a GC injector for 
analysis. SPME has been employed in profiling volatile emissions from the skin of the forearm 
[44], back [100], hand [44] and foot [106] predominantly in studies on malodour and principally 
polydimethylsiloxane (PDMS) – based fibres have been employed.  
Whilst SPME is a widely used technique in this area application is limited by sensitivity due to 
the small volume of phase available, in response to this other samplers based on the same 
solid sorptive extraction mechanism utilising thin films of PDMS as the absorbent have been 
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introduced for headspace sampling [43] [107]. These sampling approaches offer much improved 
efficiency and sensitivity compared to SPME as they have a much higher surface area / 
extraction phase volume ratio, the physical chemical modelling of this will be explained in more 
detail in the following chapter [107].  
These methods offer simple, non-invasive methodologies for sampling from human skin. The 
main difficulty in applying this kind of sampler to more widespread studies lies in creating the 
headspace – finding vials or jars to cover a representative portion of individuals of different 
sizes is likely to be challenging and with sampling times up to several hours ideally a sampler 
should not prohibit movement of the participant.  
Recently, in response to this challenge, a new method for obtaining a headspace skin sample 
based on a thin film of PDMS has been developed; the PDMS is sandwiched between two 
layers of thin, flexible stainless steel mesh [45]. The bottom mesh prevents the sampler from 
coming into direct contact with the skin and the top to hold the sampler in place, now with this 
small, unobstrusive sampler the participant is free to move without being restricted by the 
sampling device. This technique was demonstrated to be reproducible for the compounds 
studied and showed potential for quantitative methods in future studies. One issue not 
addressed by the authors for this sampler is the inertness of the stainless steel meshes used 
to separate the membrane from the skin surface, a number of known malodour compounds 
have been reported to be labile and inert coated flow paths are necessary for the successful 
collection and thermal desorption of such compounds [108] [109]. 
 
1.3.3.5. Direct contact sampling methods 
Perhaps the most straightforward of all techniques currently applied to skin analysis recovers 
analytes from skin by direct contact with a sampling medium. This has evolved beyond the use 
of fabrics and gauzes to solid sorptive materials. The sorptive material in contact with the skin 
surface absorbs or adsorbs a portion of the lipid layer, utilising the natural pre-concentration of 
VOCs in this layer, which contains a representative mixture of VOCs from the surface and 
provides additional storage stability [110]. Once samples have been collected, no further 
treatment is generally required for these samplers; they can simply be thermally desorbed in a 
heated GC injector or dedicated thermal desorption unit for analysis by GC.  
A major problem associated with sampling human emanations is how to manage the large 
amount of aqueous eccrine perspiration that contains little metabolically relevant information; 
loading of water onto capillary columns most commonly employed in GC can damage the 
stationary phase, causing losses in sensitivity and peak shape, shifting retention times and 
poor reproducibility [39].  This was recognised by Bernier et al who studied mosquito attractants 
26 
 
in human VOC profiles using glass beads which are able to collect and concentrate non-
aqueous emanations while minimising the collection of aqueous perspiration [39] [40]. The glass 
beads can then be placed directly into the injection port of a GC and thermally desorbed for 
analysis. A simple, easy and elegant sampling device this technique is limited in sensitivity by 
the relatively low affinity of the sampling phase [45] as the low concentration skin volatile 
emissions require an enrichment step before analysis .  
To overcome this several sampling methods based on sorptive materials typically employed in 
GC column stationary phases have been developed for direct contact sampling of volatiles from 
human skin. As described for headspace sampling the most popular absorbent used in this 
field is PDMS. This safe, inert and flexible polymer can be formed into a number of 
configurations to be compatible with direct sampling of human skin.  
SPME fibres have been stroked across the skin surface to sample feet and given results 
comparable to more classical headspace SPME sampling. This method is also limited in 
sensitivity by the low phase volumes and surface area / volume ratio [95].  
Combining the high surface area of the glass beads and the higher affinity sorptive phase a 
PDMS coated stir-bar was developed for direct contact sampling of a pre-defined area of skin. A 
bespoke holder allowed the stir bar to be rolled across the skin surface and semi-quantitiative 
analysis has been achieved by embedding the stir bar with internal standards prior to sampling 
[41] [110]. This method of sampling VOCs from human skin has shown significant promise as a 
simple, non-invasive sampler. The main drawbacks with this sampler are difficulties associated 
with transfer handling reported due to the cylindrical geometry [45] and the need for continual 
rolling which means that realistically only one sample could be taken at any one time, unless 
several clinicians or researchers were available to sample every individual. Should participants 
be required to self administer the number of potential sampling locations is limited to where 
the participant can reach and how long someone can realistically be expected to reproducibly 
roll the sampler across their skin.  
The principle geometry used in direct contact sampling from human skin with PDMS has been 
a thin film that conforms to the contours of the body giving a comfortable, simple, secure 
sampler with the desired high surface area to phase volume ratio for maximum extraction 
efficiency [41] [45] [110] [111]. A sorptive tape extractor (STE) has been employed to monitor 
perfume release from human skin [41] and the non-invasive identification of biomarkers from 
chronic wounds has been achieved using a thin film of PDMS known as the ‘Skin Patch’ [34] 
both of which simply require a PDMS film to be affixed to the skin surface for a defined time 
period. Skin Patches or STEs can be transferred directly to empty tubes compatible with 
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commercially available thermal desorption instrumentation for storage and subsequent 
analysis.  
Direct contact samplers such as those described here are directly compatible with 
commercially available analytical systems and these PDMS based sampling approaches, 
headspace or direct contact, have generally been analysed by a two-stage desorption process 
in which volatiles released from the bulk sorbent in hundreds of millilitres of carrier gas are re-
focussed, either by cryofocussing or cold trapping, to provide a second pre-concentration stage 
before GC analysis providing significant enhancements in sensitivity.  
Direct contact skin sampling is non-invasive, pain-free, simple, self-administrable, portable and 
clean making it highly suitable for in-field or in-clinic sampling. Studies on the analytical utility 
of the Skin Patch have demonstrated it to be reproducible, with %RSDs from a minimum of 7% 
in-vitro to a maximum of 32% in-vivo of trace level endogenous VOCs, robust and sensitive [111]. 
It is possible to take multiple samples simultaneously, whether to study different emanation 
sites or to obtain duplicate samples, and the small sample footprint and ease of storage and 
transport make the Skin Patch approach highly suitable to wide spread non-invasive sampling 
for clinical or metabolomic applications.  
To date direct contact skin sampling has been applied to a number of ad hoc studies exploring 
VOC profiles for monitoring perfume release [43], studying mosquito attractants [39] [40], 
examining fingerprints in human body odour, gender specific emanations [41], tracking the 
release of known metabolites [45] and identifying biomarkers of chronic wounds [34]. This thesis 
will further explore the potential for the Skin Patch sampler when applied to pilot metabolomic 
studies. 
 
1.3.4. Skin sampling summary and key considerations 
Previous research reports have shown the skin VOC profile to be highly variable and 
individualised with the potential to contain metabolically significant information about an 
individual. The identities of compounds sampled from the skin have varied significantly 
between studies and much of this variation can be attributed to the sampling techniques, as 
described previously. It is also apparent that the mechanical properties and distributions of 
glands and hair follicles will also have a significant effect on the class of compound recovered 
from a given sampling site. This was demonstrated well in a SPME based study investigating 
VOC profiles from the back and forearm of a group of participants; who noted 9 VOCs found 
only on the back as well as a higher level of exogenous compounds from personal care 
products [100]. These results correlate with another recent study sampling the upper back, 
forearm and thigh which also showed the upper back to yield the richest VOC profile, a fact that 
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the authors attribute to the high sebaceous gland density on the back when compared to the 
other sites [45].  
In-vivo metabolic fingerprinting of human skin using extractive electrospray sampling has 
shown distinct fingerprints associated with the abdomen, foot and forehead of an individual; 
glucose was detected on the forehead but no other investigated body sites, whilst the foot 
sample gave a much less rich fingerprint leading the authors to propose that ‘hard’ foot skin 
allows less excretion of metabolites across it than softer skin on other body sites [92]. While 
these studies do not offer any particular direction for choice of sampling site they highlight the 
importance of carefully considering sampling site for skin studies and may explain the 
difference in identified compounds between studies. 
Studies on age profiling with skin VOCs have found a higher prevalence of exogeneous 
compounds hexyl salicylate and α-hexyl cinnamaldehyde in younger subjects (<39 years) and 
attribute this to a more frequent use of personal care products in younger people while 
dimethylsulphone, benzothiazole and nonanal were proposed as ‘biomarkers of increased 
age’[100]. Interestingly another study investigating the effect of age on VOC profiles identified 2-
nonenal as the ‘odour of old age’ in a cohort of Japanese men [42]. The discrepancy between 
these two studies could be attributed to different sampling techniques, different sampling sites 
or perhaps a cultural phenomeneon due to the different climate and diet between the two 
cohorts [42] [100].  
The different studies described here were chosen to illustrate the potential confounding factors 
associated with sampling the skin surface and highlight that the choice of sampling site, 
sampling technique, environment, diet and personal care product usage of the participants 
must have an effect on the data acquired.  
Skin pre-treatment has been another highly variable factor between studies in the literature. In 
the days or hours prior to sampling, participants have been given specific instructions relating 
to diet, e.g no spicy food or garlic [83], personal care, e.g use of only unfragranced products and 
no deodorants or antiperspirants [9] [97], and exercise, in an attempt to restrict the confounding 
factors arising from exogenous compounds.  
Immediately prior to sampling a number of protocols require a washing step to remove 
exogenous contaminants and sample only those emanating during the sampling period, 
typically clean water or soaps have been used for this purpose [88] [100] [111]. It is apparent that, 
whilst skin sampling offers an attractive simple non-invasive biological VOC sampling solution, 
careful consideration of participant cohorts, sampling site and pre-treatment techniques or 
restrictions must be undertaken, or at least appreciated, for a successful study.  
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1.4. THE ANALYSIS OF HUMAN SALIVA 
In general healthy adults produce 500-1500 cm3 of saliva per day at an approximate rate of 
0.5 cm3 min-1 [112]. A most valuable bio-fluid, saliva is critical to the preservation and 
maintenance of oral health in lubrication and protection, buffering and clearance, maintaining 
tooth integrity, antibacterial activity and taste and digestion [113].  Human saliva is a highly 
variable and individualised biological fluid comprised of the secretions from a number of 
salivary glands, gingival crevicular fluid, bacteria and their metabolites, epithelial cells and food 
debris [113].  
 
Figure 1.3 Location of the major salivary glands in the human oral cavity. Reproduced from 
reference 114 
  
Figure 1.3 shows a cross section of the human oral cavity with the three major salivary glands 
labelled; paired parotid glands located opposite the maxillary first molars and the 
submandibular and sublingual glands, both located on the floor of the mouth, under the 
tongue. The major glands contribute the largest volume to whole saliva yet the composition will 
also be affected by secretions from minor salivary glands located on the lower lip, tongue, 
palate, cheeks and pharynx as well as gingival crevicular fluid, bacteria and their metabolites, 
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epithelial cells and food debris. The salivary glands consist of three cell types, acinar cells are 
the site of the 1st secretion and it is here that the type of secretion is determined. The secretion 
from each type of salivary gland varies and is determined by the ratio of serous to mucous 
glandular cells. Serous cells are located in the parotid and submandibular glands as well as 
those of the palate and the lingual glands, these secrete a watery fluid devoid of mucus, 
whereas mucus cells secrete a rich viscous solution and are found in the submandibular and 
sublingual glands as well as the lips and palate.  
The second type of glandular cells are the duct system cells which can be further classified into 
three sections; intercalated duct system cells are the first in the duct network and connect 
secretions from the acinar cells to the rest of the gland, striated cells are the next in the 
network and it is here that reabsorption of sodium occurs for electrolyte regulation before the 
fluid reaches the final set of duct system cells; the excretory cells.  
The final type of salivary gland cells are myoepithelial cells. These are elongated cell structures 
wrapped around acinar cells. On stimulation by neural processes the myoepithelial cells 
contract to constrict the acinar cells and secrete the fluid accumulated within. 
VOCs in saliva may also be derived from serum, blood, skin lipids and microorganisms. The 
composition of whole saliva varies with circadian rhythm as well as a number of physiological 
and pathological conditions including: external stimuli such as taste and smell, metabolic 
influences associated with age, menstrual cycle, physical exercise, emotional state and drugs 
[113].  Quantitative analysis of saliva specimens has indicated meaningful correlations between 
circulating un-bound plasmatic and salivary levels of analytes [22] [59] [115]. This combined with 
the ready availability and non-invasive nature of the saliva sample make it a highly attractive 
alternative to blood and urine for screening human subjects [47].  
 
1.4.1. Transport mechanisms: From circulating blood to saliva 
While a large number of compounds in saliva are produced in the salivary glands the most 
biologically relevant information is likely to be found in the portion that passes directly from 
circulating blood vessels. The physical chemistry governing these processes is analogous to 
that described for transport across skin in Section 1.3 and an overview will be included here. 
1.4.1.1. Passive diffusion 
The capillaries surrounding salivary glands are relatively porous for many small molecules and 
passive diffusion is the most common route for migration of volatile compounds from blood to 
saliva [116]. To pass from serum to saliva by diffusion a molecule must cross the capillary wall, 
interstitial space and the membranes and cyctoplasm of the cell types in the saliva gland.  The 
ease with which a compound can passively diffuse from blood to saliva depends on its size and 
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polarity; lipophillic and neutral molecules pass from blood to saliva more efficiently than 
hydrophilic and ionised molecules as cell membranes are composed of phospholipids. Any 
compounds circulating as bound complexes are too large to cross into saliva by this route [113] 
[116].  
1.4.1.2. Ultrafiltration 
An extracellular mechanism ultrafiltration involves relatively small compounds filtering through 
the gaps between acinus and ductal cells to cross from blood vessels to saliva. Only 
compounds less than 1900 Da can cross in this way and their salivary concentrations are 300-
3000 times lower than plasma [116].  
1.4.1.3. Other minor mechanisms 
Other mechanisms for transport into saliva from blood include active transport through the 
secretory cells of the glands and transudation from crevicular fluid or directly from the oral 
mucosa. Figure 1.4 shows a schematic representation of the modes of transport between 
blood and saliva. 
 
Figure 1.4 Schematic representation of the transport of biomolecules from blood capillaries into 
saliva. Adapted from reference 116. 
 
1.4.2. The analysis of human saliva: Current sampling techniques and key 
considerations 
Many protocols have been proposed for the collection of saliva samples. Bespoke methods 
have been described to collect the specific excretions from individual salivary glands which 
allow comparison between gland secretions. Such approaches require high-levels of specialist 
training to enable reliable sampling. The most common approach, as it is practical and 
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straightforward to achieve compliance with the sampling protocol, is to collect whole saliva. 
Even so, this approach requires carefully framed and rigorously conducted protocols to ensure 
consistency between samples and subjects [47]. 
Salivation can be induced using mastication or citric acid, known as a stimulated method. 
Alternatively participants may be asked to spit into a vial or sit quietly while saliva drains off 
their lower lip into a collection vessel, a technique known as passive drool, such approaches 
are termed unstimulated methods [117]. Introduction of citric acid to stimulate saliva lowers the 
pH and will alter the transport properties of some analytes, testosterone for example, and so 
the most commonly used method for collection of stimulated saliva uses the Salivette [117]. The 
Salivette is a cotton roll that the participant chews until it is saturated, after which the sample 
is recovered by centrifugation. The use of cotton wool introduces artefacts into the analysis and 
has been reported to enhance or reduce the results of immunoassays [117].  
A study comparing bacterial levels in unstimulated samples obtained from spitting and passive 
drool reported 14-fold more bacteria in specimens obtained from spitting than those obtained 
by passive drool [117]. Bacterial action within a saliva sample is a vital factor operating from the 
moment sampling starts, hence the passive drool approach is commonly adopted to minimise 
such effects [118]. 
Standardisation of all saliva collection methods is a significant challenge and poor compliance 
with varied interpretations of sampling protocols has been reported [119]. It appears to be 
accepted that obtaining representative and reproducible whole saliva samples is a non-trivial 
task. Once collected, sample handling and storage procedures are also important with bacteria 
in the sample continuing to metabolise compounds and degrade the samples’ integrity. Many 
salivary constituents have a short biological half-life, and rapidly degrade after sample 
collection. Further, the more volatile components are likely to be lost to the headspace or 
adsorbed/absorbed onto surfaces during collection and storage.  
Storage procedures that specify freezing or refrigeration of saliva samples to stabilise them 
and inhibit bacterial action seek to address temperature instability and bacterial degradation 
on storage. One review of the salivary specimen as a new tool for investigation recommends 
aliquoting immediately on collection followed by storage at 4ºC, -20ºC or -80ºC depending on 
the proposed storage time [117]. Other sample stabilisation steps include inhibition of enzyme or 
bacterial activity by snap freezing, or addition of inhibitors, denaturing agents or sodium azide 
for example [49] [117]. Such measures are time consuming, increase the number of steps in the 
analytical pathway, are susceptible to human error, while ensuring significant ventilation of the 
sample’s headspace with subsequent loss of volatiles [47]. The resultant sampled material may 
well not be truly representative of the salivary composition at the moment of sampling [117]. The 
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challenges associated with reproducible collection and storage of saliva samples as well as the 
many and varied pre-treatment techniques necessary for a range of analysis techniques have 
been more extensively reviewed elsewhere [49] [56] [59] [113] [117] [120-122]. 
Many of these challenges have been addressed by adopting solid phase microextraction 
(SPME), for SPME offers simplicity, speed, reliability, and flexibility. Time-consuming pre-
concentration is reproducibly achieved during sampling, and SPME integrates easily with GC 
instrumentation. Although SPME offers many improvements over established saliva sampling 
techniques for volatile components the challenges associated with standardisation of 
collection, stabilisation and storage of drooled saliva still exist [47]. 
 
1.5. CONCLUSIONS 
This review has detailed the historical and anecdotal evidence for volatile emanations from 
humans containing biologically relevant information about an individual’s state of health. 
Evidence for early identification of markers for systemic diseases in volatile profiles has been 
reviewed and the potential to harness these biological VOCs in new non-invasive, simple, 
fieldable sample techniques been explored.  
Skin and saliva VOC profiles have been identified as biological compartments that lend 
themselves well to both non-invasive and large scale, portable sampling that may provide 
complementary information to the more established exhaled breath sample.  
A review of the current sampling techniques for capturing VOC profiles from human skin has 
highlighted direct contact sampling with a sorptive material to offer advantages for simple, self-
administrable, sensitive and robust sample collection. A number of key considerations for 
employing this kind of sample have been discussed including careful selection of sampling site, 
minimising confounding factors and exogenous contaminants and participant preparation. The 
PDMS based Skin Patch characterised by Riazanskaia et. al. has been selected to best fulfil 
the sampler requirements and will be evaluated for pilot metabolomic skin sampling in studies 
in this thesis.  
The difficulties associated with collecting a representative saliva sample, briefly comprising 
techniques for inducing salivation, the relative increase in collected bacteria when saliva is 
collected by spitting versus drooling and the potential losses of volatile compounds during 
sampling have been reviewed and highlighted the number of potential confounding factors that 
require rigorous control in something apparently so simple as collecting an individual’s saliva. 
When sample handling and storage techniques are also examined it becomes apparent that a 
wide range of factors can affect the VOC profile ultimately obtained from a saliva sample and 
the most volatile compounds are likely to be affected to a greater degree. This thesis will 
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extend the PDMS based sampling of the Skin Patch to saliva sampling and explore new 
avenues for collecting a more reliable saliva VOC sample.  
 
1.6. THESIS 
The underlying thesis of this work is that there is diagnostic information in volatile emanations 
from individuals in differing states of health and well-being that may be captured and exploited 
in developing the next generation of non-invasive clinical screening techniques.  
The information contained in samples from different biological compartments may be 
comparable and will be complementary so different sample types may be applicable to 
different situations; these sample types can be incorporated into one workflow for sampling, 
analysis and data handling to produce complementary data and bring a level of rigor to 
metabolomic studies of volatile profiles, ultimately moving clinical diagnosis away from 
puncture wounds towards non-invasive methods.  
 
1.7. RESEARCH OBJECTIVES 
To test the central thesis a series of studies were designed around the following research 
objectives: 
 Characterise and develop PDMS-based non-invasive sampling techniques for human 
skin and saliva. 
 Critically evaluate and optimise existing workflows for pilot volatile metabolomic studies 
for the application to skin and saliva samples. 
 Evaluate the performance of the samplers and workflows in pilot metabolomic studies 
with healthy young adults subject to a stress intervention. 
For successful application of novel samplers to untargeted global metabolite profiling it is first 
necessary to appreciate the contribution of each step in a large multi-disciplinary work flow and 
the impact they may have on the study design. Chapter 2 describes the key elements that must 
be evaluated and optimised prior to designing a metabolomic study and discusses the relevant 
theory and key parameters.  
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2 AN INTRODUCTION TO VOC SAMPLING: A MULTIDISCIPLINARY 
COMBINATION OF ETHICS, IN-VIVO SAMPLING TECHNIQUES, 
ADVANCED INSTRUMENTATION AND ADVANCED DATA 
PROCESSING 
2.1. INTRODUCTION 
Global metabolite profiling of complex in-vivo samples requires a multi-disciplinary workflow 
that starts with ethical clearance for studies with human volunteers, encompasses the design 
of novel sampling techniques and the optimisation of analytical methods and ends with a 
rigorous adherence to data handling protocols. Currently such workflows are dynamic 
processes, with each study providing invaluable experience and insight. Objective evaluation of 
this must lead to modification of the work flow in an iterative process with each study 
enhancing the next.  
This Chapter discusses the key elements that must be considered before undertaking a pilot 
metabolomic study and include critical factors in designing a non-invasive VOC sampling 
method, an overview of analytical instrumentation for the recovery, separation and detection of 
VOCs and finally the techniques available to handle and characterise complex data sets.  This 
Chapter presents a working knowledge of the theories and a discussion of the most relevant 
principles for each stage of the analytical workflow, more in-depth theoretical explanations 
have been extensively reviewed elsewhere [123-127] and as such do not form part of this thesis. 
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2.2. ABSORPTIVE SAMPLING FOR IN-VIVO STUDIES 
Polydimethylsiloxane (PDMS), Figure 2.1, a non-toxic, highly hydrophobic polymer was chosen 
for the sampling material for these studies and its application as an extraction medium in 
numerous geometric forms for liquid or gaseous samples has been reviewed for a wide range 
of sampling challenges [128]. Perhaps the first notable application of PDMS in analytical 
chemistry was as a stationary phase in gas-liquid chromatography [129] and since then its 
capabilities for sample enrichment have led to its use as a sampling medium for organic 
compounds from air, water, soil and biological matrices [130-133]. Unlike adsorptive sampling 
usually applied to these matrix types in which compounds are trapped by adsorption onto the 
sorbent surface, analytes partition into the bulk phase of the PDMS.   
 
Figure 2.1 The structure of polydimethylsiloxane (PDMS). 
The retention properties of PDMS are not influenced by the presence of high levels of water or 
other analytes as each solute has its own partitioning equilibrium into the PDMS, so its 
retention capabilities are largely independent of sample matrix [128].  
PDMS is a non-toxic hydrophobic polymer which can be formed into a required shape or 
thickness in a simple and reproducible manner which lends it the versatility to be applied to a 
number of sampling challenges. The first exploration of PDMS as an enrichment phase for 
organic sampling used open tubular trapping (OTT). In this technique a layer of PDMS is coated 
onto a capillary wall, much like a gas chromatography column, and a liquid or gas sample is 
drawn through the tube. OTT found limited application as the sample capacity was limited by 
the thickness of the coating, so metres of tubing are required to give adequate limits of 
detection. In a similar fashion, larger tubes packed with PDMS particles have been successful 
for gas sampling; the sample gas passes through the tube and the analytes partition into the 
phase. This approach is hampered by the rapid breakthrough of the most volatile species [134].  
Solid phase microextraction (SPME) often employs a PDMS phase coated on the outside of a 
needle; this needle is either placed directly into a sample or into the headspace above it, again 
this technique is somewhat limited by the volume of PDMS on the needle. Stir bar sorptive 
extraction (SBSE) and solid phase extraction (SPE) employ a layer of PDMS coated on the 
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outside of a magnetic stir bar or titanium support which is then immersed in the sample. This 
approach provides the enrichment factor of the PDMS tubes with a relatively large PDMS 
volume whilst maintaining the simplicity of SPME [134]. The use of thin films of PDMS, 
unsupported by needle or stir bar, has also been successful in this form of sampling and 
approaches such as thin film micro-extraction, sorptive tape extraction and the ‘Skin Patch’ 
have shown application in direct contact sampling with solid matrices  [43] [34] [111] [135].  
In adopting PDMS as a sampling medium there are three key processes to consider: 
 absorption into (partitioning); 
 diffusion through; 
 and evaporation from the membrane (permeability). 
 
If there is a difference in chemical potential of a species between two phases in contact there 
will be a net movement of that species in the direction to bring the system to equilibrium. For 
PDMS this is usually described by solubility and partitioning coefficients and is based on the 
assumption that partitioning coefficients between PDMS and sample matrix (KPDMS/S) are 
approximately proportional to the standard partitioning coefficients between 1-octanol and 
water used for biological systems (KO/W) [134], summarised in Equation 2.1.  
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Equation 2. 1 
 
Where   represents the concentration of analyte in the PDMS or sample matrix and m the 
mass in the same,   represents the volume of the PDMS or sample matrix and the ratio of the 
two can be described as the phase ratio  . 
  
  
     
 
Equation 2. 2 
 
 
 
Entering    into Equation 2.1 then rearranging in terms of extraction efficiency we can now see 
that the mass of analyte extracted into the PDMS is proportional to the partition coefficient and 
inversely proportional to the phase ratio. 
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Equation 2. 3 
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The physical factors governing extraction efficiency of an analyte into PDMS are the phase-ratio 
and the partition coefficient. For in-vivo sampling common approaches to increasing KO/W such 
as raising the temperature, or pH control will not generally be possible, therefore when 
designing an in-vivo PDMS based sampler it is important to consider the phase ratio,  .  
Absorption is an equilibrium process, when PDMS is exposed to a sample matrix the 
concentration in the polymer will initially rise rapidly in a linear fashion described as the kinetic 
region. A plot of time versus analyte concentration in PDMS (CPDMS) would ultimately reach a 
plateau once the system is at equilibrium, at this point the extraction into the PDMS will equal 
the elimination from it [128]. At sampling time  ,       will be dependent on the concentration in 
the sample matrix,   , and the uptake and elimination constants    and    respectively.  
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Equation 2. 4 
 
Partitioning into a PDMS sampler depends on the phase ratio, the analyte’s partition coefficient 
and the sampling time. For in-vivo sampling of biological systems only   and   are available 
parameters for optimisation and while increasing the thickness of a PDMS membrane in direct 
contact with a surface will decrease   greater extraction efficiency in a given procedure is more 
likely to be achieved by increasing the surface area in contact with the sample, in other words 
increasing the analyte flux into the membrane [131]. 
When sampling from a solid surface using a PDMS membrane the PDMS is not submerged in 
the sample, only one side is in contact, in these cases it is important to consider factors other 
than partitioning into the phase when selecting sampler parameters. In cases such as these 
there exists a concentration gradient across the membrane from the sample surface to the air 
on the non-sampling side of the PDMS. Sampling in this situation will begin following the 
partitioning mechanism already described then continue with diffusion across the membrane, 
along a concentration gradient from the inner surface to the outer and ultimately elimination 
from the other side. Such processes are utilised in techniques such as membrane inlet mass 
spectrometry as a method for selectively eliminating matrix interferences [136-138]. 
Under steady state conditions the flow rate of a given solute,      (moles s-1), across a 
membrane of area A (cm2) and thickness   (cm) can be described in terms of the difference in 
concentration between the membrane surfaces,    (moles cm-3) and the diffusion, D (cm2 s-1), 
and partition, P, coefficients of the solute in the membrane: 
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Equation 2. 5 
 
For a given solute D and P are constant and only   , A and   may be manipulated to control 
    . For in-vivo sampling    is typically unknown and uncontrolled so analyte losses due to 
permeation across the PDMS membrane can be minimised by controlling the membrane 
thickness and surface area: 
 
     
 
 
 
 
Increasing A will increase the amount of solute partitioning into the PDMS at a given time, so 
increasing      , whilst increasing   will decrease      and reduce the loss of VOCs from the outer 
PDMS surface in a given time. 
Figure 2.2 shows a simplified schematic describing absorption of one compound from the skin 
surface, onto the inner surface of the PDMS, diffusion through the membrane, absorption onto 
the outer surface of the PDMS and elimination into the diffusion layer of air above it. This 
system would ultimately reach equilibrium and the rate at which equilibrium is achieved will be 
compound specific and determined by the partition diffusion coefficients for the analyte.  
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Figure 2.2 Simplified schematic diagram representing the partitioning and permeation processes governing absorptive sampling from the skin surface: 
A: Initially there is a concentration gradient from the skin to the inner PDMS surface causing a net movement of VOCs governed by the 
partition coefficient KS/PDMS. B: concentration gradient through the PDMS membrane from the inner to outer surface, diffusion occurs 
across the membrane with diffusion coefficient D. C: concentration gradient from the outer PDMS surface to the boundary layer of air above 
it, VOCs are eliminated from the PDMS with partitioning coefficient KPDMS/Air. D: Assuming a constant skin surface concentration these 
processes will reach equilibrium and a steady state CPDMS achieved: D. KS/PDMS, D and KPDMS/Air are compound dependant so the rate 
at which a steady state CPDMS is realised will vary with compound; a key consideration when optimising sampling protocols. 
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When sampling the skin surface using a PDMS membrane analyte uptake will be governed by 
partitioning into the PDMS, for which we can manipulate the phase ratio and sampling time and 
the permeability across the membrane, which can be limited by the path length and the sampling 
time. Optimal sampler conditions are likely to be based on a compromise between these factors.  
pH and temperature are also factors that will contribute to the rate at which VOCs are absorbed 
and eliminated by the PDMS samplers. These factors are less practical to control for in-field in-vivo 
sampling and initial work will focus only on sampling time and the sampler dimensions.  
These studies utilise a combination of SPE and thin film PDMS based sampling approaches for the 
recovery of VOCs from human skin and saliva. Specific sampler characteristics will be discussed in 
Sections 3.1 and 3.2.  
 
2.3. EXTRACTION OF VOCs FROM PDMS SAMPLERS 
There are two main techniques applied to recovering analytes from PDMS for analysis; solvent or 
thermal desorption. In brief solvent desorption (SD) involves extracting the PDMS with a suitable 
liquid solvent for injection into the analytical system whilst thermal desorption (TD) employs heat 
and a flow of inert carrier gas to transport desorbed volatiles to the analytical system.  
The advantages of thermal over solvent desorption are reviewed in detail by Woolfenden in ‘Gas 
Chromatography’ and will be discussed in brief here [125]. Thermal desorption is a pre-
concentration technique in which analytes from hundreds of litres of a vapour sample undergo two 
stages of focussing before transfer to the analytical column in ~100 µl of carrier gas, giving 
concentration enhancements up to 1 million fold. Conversely solvent extraction typically involves 
extraction of analytes into millilitres of solvent of which microlitres are then introduced into the 
analytical system. Thus solvent extraction acts to dilute the sample whereas thermal desorption 
acts as a concentrator.  
The introduction of organic solvents into the analytical procedure brings sources of contamination; 
whilst it is common to find carrier gas cylinders with sub ppm level impurities in routine 
laboratories achieving the same level of purity in solvents is difficult and expensive. Once such 
solvents are opened within the laboratory they begin diffusively sampling laboratory air whilst 
evaporating into it to contaminate other solvents and it is difficult to maintain the level of solvent 
purity originally purchased. 
The key consideration for direct desorption applications such as extraction of VOCs from PDMS 
samplers is that thermal desorption enables transfer of 100 % of recovered compounds to the 
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analytical system, whereas solvent desorption invariably allows transfer of only a portion of the 
resultant solution.  
Whilst thermal desorption can be fully automated requiring no sample preparation steps, solvent 
desorption is more labour intensive, with greater potential for introducing operator error and 
exposes individuals to hazardous solvents, such as CS2, which is commonly employed for such 
extractions. Thermal desorption is a dynamic  extraction process and methods typically achieve 
greater than 95% recovery whereas many solvent desorption techniques employ a static extraction 
which limits recovery to approximately 75% [125].   
With numerous analytical methods favouring the use of mass spectrometric detectors many 
extraction solvents can cause interferences such as baseline disturbances, signal quenching, 
overloading or masking peaks of interest. Thermal desorption on the other hand is inherently 
solvent free and artefacts exhibited by common sorbents tend to be in the order of nanograms, 
giving discreet peaks rather than overloading chromatographic systems as is often seen with 
solvent injections. Artefacts exhibited from the thermal desorption of PDMS are well characterised 
and not endogenous to humans so are unlikely to cause interferences in these studies. 
A review of the above led to thermal desorption being chosen for analyte recovery in these studies, 
the PDMS Skin Patch or SPE-td cartridge was placed inside empty thermal desorption tubes for 
introduction to a Unity 2TM thermal desorber (Markes International, Llantrisant, UK). 
 
2.3.1. Principles of thermal desorption 
In its simplest form thermal desorption is an extension of gas-solid chromatography, a material or 
sorbent is heated in a flow of inert carrier gas and the desorbed VOCs are swept onto a gas 
chromatography column for subsequent separation and detection. As with gas chromatography 
key parameters are carrier flow rate, desorption temperature and desorption time.  
Standard sorbent tubes contain hundreds of milligrams of sorbent and direct desorption 
applications, such as thermal desorption of PDMS, achieve exhaustive extraction via a dynamic 
equilibrium process. As such either of these techniques typically require tens of millilitres of carrier 
gas for complete desorption of the sorbent material [139]. Gas volumes of this magnitude are not 
compatible with standard gas chromatography columns and result in poor analyte focussing at the 
column head giving broad peaks, poor resolution and compromised signal to noise ratios.  
A 2-stage desorption process during which analytes released from the sorbent tube onto an 
electrically cooled secondary focussing trap overcomes this limitation. Typically a ‘cold trap’ 
consists of a narrow bore quartz tube (2 mm id) packed with a 60 mm long sorbent bed held at a 
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low temperature (-30 - +20 ºC). Desorbed analytes from the sorbent tube are focussed on the cold 
trap which is then heated rapidly, at up to 100ºC s-1, transferring analytes to the GC column in a 
narrow band of vapour, typically 100 to 200 µl, yielding improved sensitivity and peak shape 
compared to single stage desorption [139].  
Selection of sorbents for the cold trap is influenced by a number of factors. Principally for sampling 
using sorbent tubes it is advisable to choose a sorbent of the same or greater “strength” than 
those in the sample tube. For direct desorption of a PDMS membrane the choice is less limited 
and becomes a balance between several key factors including strength, hydrophobicity, inertness, 
artefact levels and thermal stability [125]. It is important to select a sorbent that not only 
quantitatively retains compounds of interest but that also releases them efficiently, so it is not 
recommended to simply use the strongest sorbent available. For profiling studies such as those 
explored in this thesis it is common to encounter a wide volatility range and the properties of more 
than one adsorbent may be required.  
Thermal desorption is achieved using a ‘backflush’ mode to desorb the cold trap (Figure 2.3) 
which means that the VOCs enter the cold trap in a flow of gas which is then reversed to desorb 
them into the analytical system. This allows two or more adsorbent beds to be packed into the 
cold trap in series, extending the volatility range of VOCs that may be included in the analytical 
work-up of the sample. The desorbed VOCs enter the cold trap encountering the weakest 
adsorbent first where the less volatile compounds are retained, the more volatile compounds 
breakthrough the weak adsorbent bed into the stronger adsorbent where they are retained. If 
desorption of the cold trap adsorbent used a forward flow approach the VOCs would have to pass 
through the entire cold trap to reach the analytical system. With a multi-bed adsorbent trap this 
would require the least volatile and most active compounds to elute through a highly retentive 
strong adsorbent bed. This would require a large volume of gas and negate the benefits of using 
two stage desorption. The ability to backflush the cold trap allows the sample gas to leave the cold 
trap in the same direction as it entered [139] with the additional benefit that the desorption gas 
supply is protected from overly contaminated samples. 
The system used in these studies, Unity 2 thermal desorption unit (Markes International, 
Llantrisant UK), performs an automatic leak test to ensure sample integrity before heating, a 
failure of the leak test will halt sample analysis. Figure 2.3 summarises the subsequent thermal 
desorption process described above and performed automatically by this system.  
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Figure 2.3 A depiction of the stages of operation during thermal desorption  of a PDMS Skin Patch held 
inside an empty stainless steel tube. 
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A two-bed cold trap containing Tenax TA, an inert, hydrophobic polymeric sorbent backed up with 
Carbograph 1TD a stronger, hydrophobic graphitised carbon black sorbent was specified for 
quantitative retention of compounds with boiling points in the range 30 – 500 ºC whilst being 
virtually unaffected by high water content [140].  
Successful application of thermal desorption to recover VOCs from PDMS samplers requires 
quantitative, and complete transfer of analytes from the sampler to the cold trap and the 
subsequent analytical systems. Key method parameters include the sample desorption 
temperature, flow rate of desorption carrier gas (desorb flow) and the time allowed for extraction. 
To ensure retention of the extracted analytes on the cold trap it is important to consider the 
breakthrough volumes of the most volatile compounds on the sorbents in the cold trap, at the 
temperature of the cold trap during sample desorption (cold trap low temperature).  
Breakthrough is the term used to describe a situation in which an analyte is no longer 
quantitatively retained on a sorbent, the breakthrough volume is the volume of carrier or sample 
gas that can pass through the sorbent bed before breakthrough is achieved. There are extensive 
lists of published breakthrough volumes for a wide range of analytes on a wide range of sorbents; 
it is advisable to use these as a guideline when first designing a new analytical method. For 
profiling studies such as those undertaken on skin and saliva in this thesis where the sample 
compositions are unknown a literature search reveals acetic acid and acetone to be among the 
most volatile compounds recovered from skin and saliva using a PDMS based sampler [96] [100] [142]. 
These compounds have a breakthrough volume on a 60 mm long 200 mg bed of  Tenax at 20 °C 
of 550 and 500 mL respectively [142].   When optimising the desorption of the PDMS sampler to 
ensure quantitative recovery of the sampled VOC it is also important to ensure that the most 
volatile compounds do not breakthrough the cold trap; method development and optimisation is 
likely to be a compromise between these two factors and is discussed further in Section 3.4.1.  
 
2.4. SEPARATION OF VOLATILE MIXTURES 
Gas chromatography (GC) is the gold standard technique for separating complex mixtures of VOCs 
and of the various iterations capillary GC is by far the most widely used today. Capillary GC passes 
a gas phase mixture through an open tubular column coated with an absorbing liquid polymer film, 
known as a stationary phase. The gas phase analytes are carried in a flow of inert carrier gas, 
known as the mobile phase, and separation of the volatile analytes is achieved through 
partitioning between these two phases.  
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2.4.1. Principles of gas chromatography 
A solute passing through a GC column interacts with the stationary phase so that at a certain point 
the solute’s net velocity is less than that of the mobile phase; the solute is retained on the 
stationary phase. Different solutes will distribute differently between the two phases and so will 
migrate through the column at different velocities, eluting and being detected at different times, 
these are known as retention times. This provides the basis of gas chromatographic separation 
and careful control of key parameters will govern the separation of compounds of interest [125].  
Analysis of complex VOC mixtures by GC presents a significant challenge in selecting and 
optimising method parameters. The wide volatility range of unknown analytes means that there is 
unlikely to be one perfect method and compromises will be necessary.  
The principle factor governing retention and separation of analytes by GC is the column itself; key 
column parameters include selection of the optimum stationary phase, length, film thickness and 
internal diameter. Selection of a stationary phase can be a difficult task for a profiling study from 
which a wide range of functionalities and volatilities are expected, key considerations include 
polarity, selectivity and bleed [143]. While it is advisable to select a stationary phase with similar 
characteristics to the analytes, it will always be difficult to match a column to volatile fatty acids 
and long chain hydrocarbons that are to be expected with skin samples. As a result of the wode 
range of compounds expected from skin samples in this study a general purpose 5% phenyl 95% 
dimethyl polysilxoane stationary phase was chosen which exhibits low polarity, low bleed and has 
a high temperature limit [143]. 
Other column parameters affecting separation include internal diameter (i.d), length and film 
thickness. A larger internal diameter (i.d) column will allow a higher column flow, this can be 
advantageous when analysing less volatile more ‘sticky’ compounds and is particularly important 
when coupled with thermal desorption operating in splitless mode where the cold trap desorption 
flow is equal to the column flow and it is desirable to have as high a column flow as possible for 
efficient desorption. Column efficiency, however, is inversely proportional to internal diameter so 
where separation is poor a smaller i.d column can improve resolution. Smaller i.d columns also 
have a more limited capacity so the choice of column diameter is a balance between desired flow 
rates, separation by the stationary phase and the expected column loading [125] [143].  
A longer GC column will offer improved efficiency with the payoff of longer analysis times and 
higher levels of column bleed. For complex samples with a high number of solutes a long column 
can be advantageous. A thicker film column, that is to say a higher volume of stationary phase, will 
offer increased retention at a given temperature than a thinner film; this can usefully be applied to 
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improving retention of the most volatile compounds in a mixture, conversely thinner films may be 
employed to allow highly retained compounds to elute faster [143]. 
For these studies a 60 m long column with a film thickness of 0.25 μm and an internal diameter of 
0.25 mm was chosen for profiling unknowns over wide volatility range, representing a compromise 
between retention of the most volatile and timely elution of the least volatile compounds, loading 
capacity and separation efficiency.  
 Other factors affecting GC separation include temperature and mobile phase flow rate. Simply put 
higher temperatures and higher flow rates reduce analysis time and separation so selection of 
these factors is a balance between achieving sufficient separation within a practical analysis time. 
Slower heating rates again yield improved separation, indeed many GC methods use a constant 
temperature (isothermal) for maximum separation. For complex mixtures over a wide volatility 
range the time necessary for an isothermal method would be prohibitive so a temperature 
programmed method must be employed in which the column temperature is increased across the 
chromatographic run to speed up elution of the less volatile compounds. Selection of flow rates 
and temperature programmes will be discussed in more detail in Section 3.4.2.   
 
2.5. DETECTORS FOR GAS CHROMATOGRAPHY 
Gas chromatography has a distinct advantage over many other common separation techniques in 
that it can be coupled to a wide range of detectors. These fall neatly into two categories; selective 
detectors which detect only specific classes of compounds based on a molecular or physical 
property for example an NPD detector which responds to nitrogen or phosphorous, or universal 
detectors which are able to detect all (or most) compounds eluting from the GC. For profiling 
studies in which a wide range of unknown compounds are of interest the choice is simple; the only 
option is a universal detector. Examples of universal detectors include the flame ionisation 
detector (FID), a mass sensitive detector which gives a univariate response based on the mass of 
carbon detected, the thermal conductivity detector (TCD), another univariate detector which 
responds to anything with a different thermal conductivity from the carrier gas and the mass 
spectrometer (MS), a mass sensitive, multivariate detector which not only responds to almost any 
compound but also gives structural information making the mass spectrometer the detector of 
choice for profiling of unknown mixtures [139].  
First coupled to GC by McLafferty and Gohlke in the 1950’s, mass spectrometry enjoys a rich 
heritage dating back to J.J.Thompson’s experiments on the characterisation of electrons during 
which he determined their mass to charge ratio and went on to develop the first mass 
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spectrometer in 1912. Since then there have been numerous and wide – ranging advances in this 
technique to allow the introduction of gas, liquid or solid samples at vacuum or ambient pressure 
with many different mass analysers with varying properties available to suit an array of 
applications. Extensive literature resources are available detailing and describing every aspect of 
mass spectrometry in detail [126], the descriptions in this section will therefore be limited only to 
those techniques employed in this work.  
 
2.5.1. Principles of mass spectrometry 
Mass spectrometry is a technique in which gas phase ions are formed and separated in space or 
time and detected according to their mass-to-charge ratio, conventionally denoted as m/z. 
Schematically, a mass spectrometer consists of a sample introduction system – in this case the 
GC – an ionisation source, a mass analyser and a detector (Figure 2.4).  
 
Figure 2.4 Simplified schematic diagram of a mass spectrometer 
 
2.5.1.1. Electron ionisation 
When coupled to a gas chromatograph the analytes arrive at the mass spectrometer as separated 
peaks of gaseous molecules and the first stage is to ionise them. Electron ionisation, first devised 
by Dempster in 1918, accelerates electrons generated by a hot rhenium filament towards an 
anode (trap) perpendicular to the flow of sample gas, these electrons collide with neutral analyte 
molecules, electronic excitations occur and, where there is sufficient energy, an electron can be 
expelled [144]. Figure  2.5 shows a schematic of an EI source. 
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M + e-  M
+ + 2e-              Scheme 2.1 
 
 Where M is the neutral analyte molecule and e- an electron. This technique is commonly applied 
to organic compounds and is a high energy technique which produces not only ionised parent 
molecules but often also breaks them apart into fragments. A curve of number of ions formed 
against electron energy (the kinetic energy supplied to the electrons) gives a wide maximum at 70 
electron volts (eV) for organic molecules and is the standard value used for electron ionisation 
mass spectrometry with gas chromatography. The energy transferred to the molecule during 
ionisation often exceeds the ionisation energy and so the radical cation formed is likely to undergo 
extensive fragmentation to form either a radical (R●) and an ion with an even number of electrons 
(EE), or a neutral molecule (N) and a new radical cation with an odd number of electrons (OE) [126]: 
 
Scheme 2. 2 
 
 
 
 
These primary product ions can undergo several further fragmentations and the resultant ions are 
collimated into the mass analyser by a repeller electrode and electrostatic focussing lenses where 
they are separated based on their mass-to-charge ratio and detected in proportion to their 
abundance, producing the mass spectrum of a molecule.  
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Figure 2.5       Schematic diagram of an electron ionisation source; (A) filament, (B) trap electrode, (C) 
repeller, (D) electron beam, (E) sample entry on the z-axis, (F) extraction and focussing 
lenses. The electron beam is directed in the x-plane from the filament towards the trap 
where analyte molecules are ionised (M+) and directed towards and focused into the mass 
analyser by the repeller and lenses respectively. 
 
2.5.1.2. Quadrupole mass analyser 
The mass analyser region of the mass spectrometer separates ions according to their m/z ratio. 
Ions generated in the ionisation source are accelerated into the analyser chamber by applying 
potential to a series of electrostatic lenses that focus and direct the ion beam. There are a number 
of mass analysers available that can be divided into two categories, those that allow simultaneous 
transmission of all ions and those that scan a selected m/z range. Scanning mass analysers 
transmit ions with a selected m/z value; a range of m/z values may be selected and transmitted 
sequentially within each scan [126]. 
In these studies a scanning mass analyser known as a linear quadrupole was employed. A linear 
quadrupole utilises oscillating electrical fields in which ions have either a stable, or an unstable, 
trajectory depending on their m/z ratio. Wolfgang Paul showed that in a linear quadrupole these 
fields could be manipulated to allow selective transmission of an ion with a specific m/z ratio from 
one end of the quadrupole to the other and hence be detected. Ions of other m/z ratios would 
have an unstable trajectory under these conditions and be lost before reaching the detector [145]. A 
schematic of a linear quadrupole is shown in Figure 2.6. 
M+
Mass Analyser
A B
C
D E
F
51 
 
 
Figure  2.6       Schematic representation of a linear quadrupole. Ions enter the source slit (A) and are 
directed into the quadrupole, ions of a specific m/z ratio will have a stable trajectory and 
reach the detector (blue trace) via the exit slit (C) all other m/z values will be unstable and 
the ions will discharge themselves on one of the rods (B) (red trace).  
The quadrupole itself comprises four rods which are electrically connected in opposing pairs, 
superimposed RF and DC voltages are applied to the rods. A positive ion entering the space 
between the rods will be drawn towards a negative rod; if the potential on the rod switches polarity 
before the ion has discharged itself it will change direction. In this way a quadrupole acts as a true 
mass filter and m/z values are detected on a mass selected stability basis [126].  
2.5.1.3. Detectors 
Several types of detector are used in mass spectrometry to convert the separated ions into an 
electric current that is proportional to their abundance; ultimately presented to the analyst as a 
mass spectrum. In these studies an electron multiplier was employed. This converts incident 
positive or negative ions into electrons which are amplified by subsequent collisions in a cascade 
effect; producing a current [126]. 
Key considerations 
While mass spectrometry offers many advantages when profiling unknowns there are some key 
parameters that need to be considered for its successful application to complex matrices. For 
metabolomic studies mass spectrometers are generally operated in either one of two modes; 
scanning or selected ion monitoring. If the study is targeting a series of compounds with known 
common fragment ions the mass spectrometer can be programmed to monitor only select m/z 
values this allows the analyser to switch rapidly between a small number of masses, significantly 
improving signal – to – noise ratios.  
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For completely unknown samples, or those where a wide range of compounds are likely to be of 
interest, operating the mass spectrometer in scanning mode will yield the most information. When 
scanning, complete spectra are rapidly measured between an upper and a lower m/z value 
defined by the user and the time allowed for each m/z value, known as the scan time, is a key 
factor affecting both the sensitivity of the detection and the accuracy of the obtained spectra. 
Suppose a chromatographic peak was to have a width of 10 s, it stands to reason that at least one 
complete spectrum (i.e. signals from every m/z value in the defined range) must be obtained every 
5 seconds to ensure that a complete spectrum lies entirely within the peak. If the defined mass 
range was m/z 35-350 that means that 300 m/z values must be selected during those 5 seconds 
and so a scan time of 0.017 s per atomic mass unit (amu) can be used. Increasing the scan time 
increases the amount of time allowed for ions of a particular m/z value to reach the detector, thus 
increasing the number of ions detected and so the sensitivity. This comes with a sacrifice, longer 
scan times must mean that there will be fewer scans across a chromatographic peak, reducing the 
fidelity of the chromatographic peak and heterogeneity of the mass-spectrum. This poses a 
particular problem for complex samples where chromatographic peaks are unlikely to be fully 
resolved and deconvolution algorithms (Section 2.6.3) will be required to separate and assign the 
correct ions to the correct contributing spectrum – the higher the number of scans across a peak 
the more spectral information is present, leading to more accurate deconvolution. A balance 
between these two factors will be required in profiling studies to provide sufficient sensitivity whilst 
maintaining sufficient spectral information for deconvolution and confident identification of co-
eluting unknown compounds.         
 
2.6. DATA PREPARATION 
The output from a GC-MS system operating in scanning mode as detailed in Section 2.5 is typically 
a total ion current (TIC) chromatogram. The x-axis of a chromatogram represents retention time (tR) 
and the y-axis signal intensity, represented as absolute intensity or relative to the most intense 
signal. A TIC represents the summed intensity across the m/z range on the y-axis with retention 
time on the x-axis.  
Figure 2.7 shows an example TIC chromatogram of a skin VOC sample, immediately obvious is the 
complexity and the wide dynamic range of detected compounds. Data such as this, with typically 
300 to 600 resolved and unresolved peaks and intensities spanning several orders of magnitude 
presents a significant data processing challenge in profiling studies where every peak, no matter 
how large or small, may be significant.  
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Figure 2.7       An example total ion current chromatogram (TIC) of the VOC profile from a skin patch 
analysed by TD – GC - MS. 
The data handling workflow developed here, summarized in Figure 2.8, is based on that published 
by Guallar et. al. for metabolomic profiling of exhaled breath [70] and has been adapted to 
accommodate for the added complexity associated with skin profiles.  
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Figure 2.8        A schematic representation of the work flow used to process data from VOC samples. Visual 
inspection of the data confirms its validity before background interferences are removed by 
dynamic background compensation and deconvolution provides mass spectral lists. 
Alignment by retention index compensates for any drift in chromatography and each new 
compound is assigned a unique identifier based on its retention index and deconvolved 
spectral list and catalogued. After removal of exogenous compounds the data is 
incorporated into a matrix for multivariate analysis. This workflow was adapated from that 
devised by Guallar et al reference 70. 
 
2.6.1. Visual inspection 
The first step in data processing is the visual inspection of raw data using the instrument’s data 
handling software, in this case Waters MassLynx (V4.1 SCN 779). Whilst regular quality control 
standards and system blanks verify the performance of the instrument, visual inspection of each 
chromatogram enables any instrument failures, chromatographic interferences or confounding 
factors to be rapidly identified and assessed before proceeding with more automated data 
processing steps. Monitoring known column bleed ions such as m/z 207 for polysiloxane columns 
can give a good indication of instrument response between runs. Spikes due to high water loading 
or ion suppression due to overloading of volatile analytes towards the beginning of a 
chromatogram can also be observed by a simple visual inspection of the chromatography which 
may confound automated deconvolution and integration techniques employed further down the 
workflow.  
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2.6.2. Dynamic background compensation 
Once a data file has been passed by visual inspection can then be imported into TargetView 
(ALMSCO International, Llantrisant, UK) for dynamic background compensation (DBC) and mass 
spectral deconvolution. 
DBC algorithms distinguish between ions that contribute to chromatographic peaks and those that 
can be attributed to noise, suppressing ions from column bleed, oil hills and air/water ingress 
leaving spectra of much enhanced purity. Signal – to – noise ratios are greatly enhanced for low 
level compounds after DBC, particularly in a matrix with a wide concentration range [146].  Figure 
2.9 shows enhancement from DBC.  
 
Figure 2.9       Improvement in spectral quality of the mass spectrum of plasticizer dibutyl phthalate, an 
artifact from the skin patch, by  dynamic background compensation. Bottom: The tailing 
from the preceding chromatographic peak(inset) introduces noise into the mass spectrum 
without DBC. Top: The influence of the tail from the preceding peak is reduced (inset) and a 
purer mass spectrum is achieved after DBC. The NIST forward matched for dibutyl phthalate 
before and after DBC are 589 and 849 respectively.  
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Important parameters to consider when using DBC algorithms are peak width and noise counts. 
The noise counts value is an absolute value below which spectral peaks are attributed to noise. 
More importantly for skin and saliva samples it may be that different peak width values give 
optimal peak shapes for different classes of compound. Figure 2.10 shows an extracted ion 
chromatogram for octanoic acid and octanal on a DB-5 column (used throughout this research). 
The shape of the octanoic acid peak is due to its higher polarity relative to the column stationary 
phase and is an unfortunate consequence of using one column for a wide range of analytes. This 
is an important reminder that optimisation of automated data handling techniques is equally as 
important as optimisation of instrumental parameters. This will be discussed in more detail in 
Section 3.5.1.  
 
 
 
Figure 2.10     Extracted ion chromatograms for octanal (m/z 56, left) and octanoic acid (m/z 60, right) 
showing the different peak shapes obtained from VOC profiles using the methods applied in 
this thesis. Chromatographi peak shape is a key consideration in the development of 
automated data processing methods. 
2.6.3. Mass spectral deconvolution 
Ideally all compounds eluting from the GC column would be baseline separated, that is to say that 
there is no overlap at all between the peaks. For complex samples such as skin and saliva profiles 
complete separation of every compound is highly unlikely and would be likely to require 
prohibitively long analysis times or extra instrumentation such as two – dimensional 
chromatography systems which bring a significant financial and operational burden. To alleviate 
this, spectra from co-eluting compounds can be separated and attributed to the individual 
components by a process known as deconvolution. Deconvolution algorithms process the mass 
spectral data for each scan and assign the ions to the appropriate contributing compound, 
generating a deconvolved spectrum of only the ions originating from that compound, giving more 
accurate mass spectra for use as a target against which other samples can be compared or for 
searching against mass spectral databases [146]. 
0
50000
100000
150000
200000
250000
300000
350000
400000
6.5 6.7 6.9 7.1 7.3 7.5 7.7 7.9 8.1 8.3 8.5
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
23.5 23.7 23.9 24.1 24.3 24.5 24.7 24.9 25.1 25.3 25.5
57 
 
Figure 2.11 shows a representation of mass spectral deconvolution and the resulting 
‘deconvolved spectral list’ for the co-eluting compounds. 
 
 
Figure 2.11      A schematic representation of mass spectral deconvolution showing; top left, 3 components 
contributing to one chromatographic peak and top right, the resultant composite mass 
spectrum. Deconvolved mass spectra and spectral lists for each component are shown at 
the bottom. 
As with DBC the input peak width parameter in TargetView can have a significant effect on the 
resultant deconvolved spectrum and careful optimisation of this parameter is essential to achieve 
accurate spectra.  
 
2.6.4. Chromatographic alignment by retention index 
Many metabolomic studies require long term stability of analytical instrumentation to enable 
studies to be performed over an extended time period without the complication of long term 
sample storage. Deterioration of column stationary phases due to high levels of water and organic 
acids in biological samples can cause retention times to drift and present a significant problem for 
these kinds of applications [70]. For many studies employing mass spectrometric detection and 
monitoring a small number of target compounds this does not present too much of a difficulty, 
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simply matching the target mass spectrum to a library or widening selected ion monitoring 
windows may be enough to accommodate for this slippage of retention time. Metabolomic 
profiling studies however typically screen hundreds of unknown compounds in every 
chromatogram, many of which have common ions in their mass spectra; to confidently assign a 
chromatographic peak to the same compound between the first and last samples matching of 
more than one criteria is required. Many proposals favour the use of an internal standard against 
which the relative retention time of each component in the mixture is calculated [147]. One 
considerable disadvantage, however, is that as the retention gap between the analytes and the 
standard is increased a reduction in accuracy is likely to occur.  
The most widely accepted solution to chromatographic alignment is based on a system developed 
by Kováts in 1958. He showed a homologous series of n-paraffin standards eluting in isothermal 
conditions to have retention times increasing exponentially with the number of carbons in the 
chain, giving a ‘ladder’ of standards over the entire chromatographic run. Kováts based his 
retention index system on the retention time of an analyte relative to the standards eluting either 
side of it, demonstrated in Figure 2.12  [147]. 
 
Figure 2.12     Example TIC for a Kováts retention index ladder ladder, C8 – C10 show a homologous 
standard series used to create the retention index ladder. The target compound’s retention 
index will be calculated based on the standards eluting either side of it; C9 and C10. 
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By definition the retention index value of the n-paraffin standards is the carbon number multiplied 
by 100 for any given stationary phase at any given temperature. The target compound identified in 
Figure 2.12 would be given a retention index relative to the C9 and C10 paraffins using the Kováts 
Equation: 
 
  
             [  (
           
             
)] 
Equation 2. 6 
I = Isothermal retention index at temperature (T) on a specified stationary phase (st.ph) 
ts = Adjusted retention time of target compound. 
tz = Adjusted retention time of n – paraffin with a carbon number of z. 
t(z+1) = Adjusted retention time of n-paraffin with a carbon number of z + 1. 
 
Any analytical system using the same stationary phase and the same isothermal temperature 
programme should give comparable values when the Kováts retention index is applied for any 
compound [147] [148], allowing not only alignment within one study but comparison with other 
studies, other instruments and even published data. To this end Kováts indices for many 
compounds at various temperatures on various stationary phases have been reported over the 
years [149]. 
The Kováts retention index has been described as the most significant contribution to GC since 
the discovery of the technique by James and Martin in 1952. Limitations of the method become 
apparent when temperature programmes are applied to the chromatographic method [148]. Fifty 
years after its conception the Kováts retention index system is still widely applicable to isothermal 
and some temperature programmed gas chromatography experiments. The limitations of Kováts 
indices for temperature programmed methods are discussed in detail elsewhere [148] [150], however  
provided the system is applied to a fixed chromatographic method using the same stationary 
phase and method parameters Kováts indices provide an excellent solution to chromatographic 
alignment within a study. 
The application of a retention indexing system based on that of Kováts will be discussed in Section 
3.5.3. Following mass spectral deconvolution and retention indexing VOCs from skin and saliva 
samples can be assigned a unique identifier based on retention index values and the most intense 
ions from their deconvolved mass spectra.  
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2.7. MULTIVARIATE ANALYSIS 
Multivariate analysis is the application of multivariate statistics, in which more than one statistical 
variable is simultaneously observed, thus avoiding the loss of any information and generating 
stable models for predicting underlying trends in latent variables. As GC-MS is capable of 
generating large data sets and VOC profiles have been demonstrated to be highly complex with 
hundreds of components in every sample the ability to process and monitor changes across the 
entire profile is essential when prospecting for markers.  
For multivariate analysis data are arranged into a matrix with each sample being denoted an 
observation and each individual compound (classified by the unique identifier described in Section 
2.6) denoted a variable, the matrix structure is shown in Figure 2.13. The matrix is then populated 
with a response value for each variable in each observation, for GC-MS metabolomics this is 
usually the area of the chromatographic peak.  
 
Figure 2.13     Multivariate analysis matrix for the analysis of VOS samples consisting of k variables 
(columns) and N observations (rows). X represents the response (chromatographic peak 
area) for each variable in each observation.  
There are many multivariate statistical models available for investigating variance within a data 
set, two of the most commonly used method in metabolomics studies are principle component 
anlaysis and partial least squares discriminant anlaysis.  
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2.7.1. Principle component analysis 
Principle component analysis (PCA) is a technique for reducing the dimensionality of a data set 
whilst maintaining the maximum amount of variation possible [151]. Data is transformed into a new 
set of uncorrelated variables known as principle components (PC) by linear combination of the 
original variables in such a way that the initial PC accounts for the most variance in the set, the 
subsequent PCs are calculated successively.  
A detailed description of the mathematical basis of PCA can be found elsewhere [152-153], a brief 
description is included here. A geometric space is constructed with k dimensions, k represents the 
number of variables so each variable has its own dimension, and each observation is then 
represented as a point in ‘k dimensional space’. Principle components are constructed by 
transforming the axis of the original plot so that the new vectors lie along the direction of 
maximum variance. The projection of the second principle component is orthogonal to the first in 
the direction of the next highest variance and so on. 
 
Figure 2.14     Visualisation of principle component analysis (PCA) of a 3-dimensional data set. The left 
hand plot shows an example of the first two principle components (PC1 & 2) being projected 
onto a 3-variable data set (K1-3). PC1 explains the highest amount of variance, PC 2 the next 
highest. The right hand plot shows the data re-plotted on axes according to PC1 and PC2, a 
scores plot. The distance of each observation along the PC1 and PC2 axes is called a score 
and is calculated based on their distance from the origin of the original k-dimensional 
space.  
Once the principle components have been calculated the data is re-plotted against new axes 
based on the new principle components, this is called a scores plot and can be generated for any 
two PCs from the data set. The scores for each observation are calculated as the distance of the 
PC1
PC2
K3
K2
K1
PC1
PC2
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point (observation) from the origin after projecting the data onto the new principle component and 
are represented by the position of the observation on the scores plot, Figure 2.14.  
The amount of variance in a data set explained by a principle component is known as the 
eigenvalue and the number of principle components to be calculated is decided by the analyst, the 
percentage of variance explained by each principle component decreases for each successive 
component so any real differences between classes are most likely to be observed in the earlier 
principle components [154].  
In metabolomic studies PCA is principally employed to determine differences between classes [153], 
diseased or healthy for example, and observations tend to be plotted in terms of class to enable a 
complex data set to be represented in such a way as to observe difference with the naked eye.  
 
2.7.2. Partial least squares discriminant analysis 
While PCA is an unsupervised method, that is to say no metadata is input into the model, PLS-DA 
applies a training set of data, where the class information is known, to fit the remaining unknowns 
to the correct class, i.e. it is a supervised method.  
PLS-DA models use prior knowledge to find the maximum separation between the defined classes 
by computing a linear discriminant function, Y, as a combination of the original variables K1.....N. 
Validation of such models is often performed as part of model generation in programmes such as 
SIMCA-P where a ‘leave one out’ validation method is employed [155]. In this method the data is 
divided into a training set, comprising 70% of observations, and a test set, the remaining 30%. The 
model, Y, is then computed based on the training set and the test set used to determine the 
accuracy of classification this is an iterative process that continues until each observation has 
been included in the test set, or ‘left out’, once and the model has determined the optimum result.  
“Perturbation of a biological system causes myriad changes, only some are directly related to the 
cause” [155].The use of supervised statistical models such as these can be controversial as it can 
be seen as forcing the model to fit the data and it is important when using them to remember that 
statistical significance does not always relate to biological significance and it is important to 
remember to relate findings to the original raw data after such complex processing.  
As demonstrated by Turner et al a combination of multivariate models can often provide the 
optimum balance between the discrimating power of supervised models and the confidence 
associated with unsupervised [62]. For highly complex matrices such as human skin, saliva and 
breath there are likely to be a high number of factors causing variation within a data set other than 
the one under study. For example it is difficult to recruit a set of volunteer participants for a panel 
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study that all have the same body mass index, diet, age and gender and these factors will all 
contribute to the variance within the data set. Applying supervised approaches such as PLS-DA the 
analyst is able to ask the model to find any variables that may cause variation due to a known 
intervention or disease under study, the variables predicted by such a model can then be 
extracted and used in an unsupervised model such as PCA. In that way variation due to 
extraneous factors can be screened out and unsupervised PCA then used to determine whether 
these variables do correlate to variation between the classes under study. The utility of this 
approach in pilot metabolomic studies will be demonstrated in subsequent Chapters.  
 
2.8. CONCLUSIONS 
Consideration of the complexity of the challenges associated with designing and implementing 
non-invasive diagnostic sampling and analysis techniques emphasises the need for careful 
optimisation and control of a wide range of factors. For example the thickness of sampling phase 
and sampling time, through to the balance between good chromatographic separation and 
analysis time and high sensitivity with accurate mass spectra ultimately leading to data handling 
techniques such as background compensation, deconvolution and statistical modelling. All have 
the potential to introduce bias to a study and so confound the research. 
The exploration and optimisation of these factors for global metabolomic profiling of human skin 
and saliva (Chapter 3) is likely to involve a series of considered compromises in an attempt to gain 
the most representative snapshot of the metabolic profile of an individual at a moment in time in a 
simple, robust, reproducible and most importantly non-invasive, safe and comfortable manner.  
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3 THE DEVELOPMENT OF A GLOBAL VOC PROFILING WORKFLOW: 
CHARACTERISATION AND OPTIMISATION OF SAMPLERS AND 
ANALYTICAL METHODOLOGY 
The previous Chapter discussed the overall workflow for a metabolomic study and outlined key 
factors and parameters that must be considered for each stage. In this Chapter the 
characterisation of non-invasive VOC samplers is presented alongside optimisation of instrumental 
methods and data processing strategies for global VOC metabolite profiling of human skin and 
saliva.  
 
3.1. ETHICS AND PARTICIPANT PREPARATION 
 
3.1.1. Application for ethical approval 
The studies were conducted in accordance with the ethical principles of Good Clinical Practice and 
the Declaration of Helsinki. Approval from the Ethical Advisory Committee of Loughborough 
University was obtained for the generic sampling protocols for VOC sampling from skin and saliva 
(reference number G10-P7 and G10-P23) and for each specific study.  
At the outset a protocol outlining the details of the study was prepared to include a brief rationale, 
a hypothesis and description of prospective participants including inclusion and exclusion criteria. 
The protocol then described the preparation and sterilisation of the sampling device, the mode of 
sampling and any potential risks, the protocols in place for transport, storage and destruction of 
human biological samples and finally the storage, protection and distribution of data relating to 
human participants. Once complete the protocol was appended to a generic protocol approval 
form for human biological investigations and submitted to the ethical advisory committee along 
with example participant information sheets, consent forms and health screen questionnaires. An 
example ethical approval application bundle is included in Appendix 1.  
The ethical advisory committee reviewed each protocol and any questions or requested 
amendments were passed back to the researchers to be addressed. The researchers then 
responded in writing to the Chairman of the committee. The applications submitted for studies in 
this thesis required only minor points of clarification so the Chairman was able to approve these 
without convening the full committee and ethical approval was obtained within ca. 90 days before 
which no participant recruitment could commence.   
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Volunteer participants were recruited from Loughborough University Staff and Students and 
consisted of healthy adults aged 18-35. Participants were given a brief description regarding the 
nature, purpose and possible risks of the study together with the participant information sheet and 
were encouraged to ask questions before an enforced 24 hour cooling-off period, only after which 
could they decide whether to participate in the study at which point they gave written informed 
consent. A chaperone of the same gender as the participant was present during sample collection 
and access was restricted to only those researchers and participants involved in the sampling 
process.  
 
3.1.2. Participant preparation 
To limit the potential confounding factors associated with sampling from humans, participants 
were requested not to eat, drink anything other than unflavoured water, brush their teeth or use 
any personal care products on the morning of any study visit. As a result of the fasting requirement 
all study visits were scheduled to commence before 11 am. In the 24 hours prior to the study visit 
participants were also requested to refrain from drinking alcohol or exercising. Any other more 
study specific requirements will be discussed in the relevant Chapter. 
 
3.2. SAMPLING OF VOLATILE ORGANIC COMPOUNDS FROM HUMAN SKIN: THE 
SKIN PATCH 
In Chapters 1 and 2 the use of a polydimethylsiloxane (PDMS) membrane to sample VOCs from 
the skin surface was discussed; based on the work of Riazanskaia et. al, this method is known as 
the Skin Patch [111].  The Skin Patch, shown in Figure 3.1, is a PDMS coupon 5 mm x 15 mm x 
0.45 mm that conforms to the contours of the human body, held in place by a cotton-wool pad, to 
absorb VOCs from the skin lipid layer. Detailed characterisation studies of the Skin Patch have 
been described elsewhere, and are supported by in-vivo applications such as profiling chronic 
wounds and bacterial contamination of meat [34] [111] [156}. This work focuses on the factors relating 
to the application of the Skin Patch to metabolomic studies of VOC profiles of human skin. 
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Figure 3.1       Left: PDMS Skin Patch being applied to a participants forehead, and right: Skin Patch being 
transferred to an empty stainless steel thermal desorption tube for storage and analysis. 
 
In-vitro and in-vivo reproducibility studies [111] with the Skin Patch, by Riazanskaia et. al, showed 
recovery and precision to correlate with volatility; higher molecular weight, higher boiling point 
compounds exhibited higher recoveries and lower relative standard deviation in both in-vitro and 
in-vivo data. This was attributed to more volatile species being more sensitive to small variations in 
sampling procedures (faster permeation, diffusion and desorption kinetics), yet the authors were 
able to conclude that the Skin Patch offers a robust, predictable and reliable method for sampling 
VOCs from human skin [111].  It was also observed that the amount of VOCs recovered by the Skin 
Patch increased with reducing volatility. Even so, compounds across the volatility range exhibited a 
linear response with regression coefficients in the range 0.95 to 0.998 for sampled mass versus 
response. The conclusion was that the amount of VOCs recovered from a Skin Patch sample 
reliably reflects changes in the concentration of analytes on the skin. The data presented by 
Riazanskaia, and the independent follow up studies [34] [156], demonstrated the utility of the Skin 
Patch approach for sampling VOCs from skin and this approach was adopted for this research. The 
remainder of this section describes the Skin Patch sampling and analysis protocols and their 
optimisation for global profiling studies.  
 
3.2.1. Sampling time 
Riazanskaia and co-workers investigated the effect of in-vivo sampling time on the recovery of 5 
randomly selected compounds across the human skin VOC profile. The collection of most 
compounds appeared to rapidly increase in a non-linear fashion over 5 to 12 min of sampling [111]. 
After this there was a general trend of recovery increasing linearly with sampling time. The 
exception to this was the most volatile compound studied, trimethylcarbazole, which rapidly 
accumulated for the first 5 min of sampling, and any further extension of sampling time resulted in 
a reduction of the recovery of the compound. This molecule was extracted from the skin, and then 
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lost to the surroundings, faster than it was being excreted, and the conclusion was that sampling 
time should be chosen to match the properties of the compounds of interest; higher volatility 
species are likely to require significantly shorter sampling times than the lower volatility 
counterparts [111]. 
The observations in the studies characterising the Skin Patch all link analyte recovery to volatility 
and highlight the challenges associated with applying one sampling method to a global profiling 
approach. Guided by the data presented by Riazanskaia et. al., and evidence from unpublished 
research a sampling time of 30 min was chosen; giving a compromise between increased 
sensitivity for all but the most volatile, and retention of the lightest compounds.  
 
3.2.2. Conditioning 
The published methodology for preparing Skin Patches prior to analysis was tested and found to 
be insufficient for the current studies. ‘Blank’ profiles obtained after following the recommended 
wash with 5 % aqueous Decon 90 solution and 15 hr conditioning  under vacuum at 180 ºC 
contained levels of VOCs up to 50 ng per compound per Skin Patch, whilst some of these were 
siloxane compounds from the PDMS the majority  were polar species such as acids and alcohols. 
The methodology was improved by an additional step in which the Skin Patches were subject to a 
methanol wash in an ultrasonic bath which was performed in triplicate with clean methanol in 
each repeat. This reduced the levels of non-siloxane VOCs in blanks to below detectable levels; 
less than 10 pg per Skin Patch, calculated as n-decane equivalents.  
The VOC contamination from the cotton-wool pads used to hold the Skin Patch against the skin 
surface was assessed by sampling a cotton-wool pad with a Skin Patch for 30 min. The resultant 
chromatogram was found to contain many more VOCs than anticipated and so a conditioning 
procedure was also developed for these in which cotton pads were conditioned under vacuum at 
70 ºC for 4 hr individually wrapped in aluminium foil. The cotton pads were then stored and 
transported in the tin foil wrapping until use, an example blank chromatogram from a cotton pad 
pre- and post-conditioning is shown in Figure 3.2. 
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Figure 3.2        TIC of samples taken from a cotton pad used to hold the skin patches on the skin surface. 
The top trace shows the chromatogram from an unconditioned cotton pad and inverted is 
the chromatogram from a cotton pad that has been conditioned under vacuum at 70 ºC for 
4 hr. The red dashed line shows marks the response in M counts to 1 ng in n-decane 
equivalents.   
It is important to note that although conditioned Skin Patches gave reproducible qualitative 
profiles, the levels of siloxane artefacts observed in blanks was variable, and so while it was 
possible to exploit the retention time of these compounds within the resultant chromatograms 
(see Section 3.5.3.), it was not possible to use them as internal standards. 
 
3.2.3. Storage 
The published methodology for the Skin Patch reported significant variations in levels of recovered 
VOCs from samples stored longer than 24 hr at 4ºC. The increases observed could not be 
accounted for by any variations in instrument performance, and were attributed to bacterial 
activity. Bacteria transferred to the Skin Patch from the lipid layer were thought to be able to 
survive during storage at 4ºC and continue to metabolise on the Skin Patch.  
The analysis time of a Skin Patch is in the order of 70 min and in order to use this methodology in 
larger scale metabolomic studies it is essential that samples can be stabilised for transport from 
the field or clinic and storage until analysis. With large numbers of samples the time to analysis 
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could be several days to some weeks. Three options were considered for extending  storage time: 
reducing the storage temperature;  sterilisation of the Skin Patch post-sampling with ultra-violet 
light; or thermal desorption and re-trapping of VOCs onto more stable sorbent systems thereby 
sterilising the sample with high temperatures. The simplest and least expensive of these was to 
use lower storage temperatures and storage at -20ºC and -80ºC was studied as a design pilot for 
the metabolomic studies. A central composite design was used to determine storage times for 
investigation as 1 (24), 4 (96), 11(264), 18 (432) and 21 (504) days (hours). Five replicate 
samples were taken for each storage time. In order to simultaneously collect sufficient samples for 
5 replicates at each time point a large area of homogenous skin was required. 30 samples were 
taken from the upper back of each participant for each storage temperature. 6 sampling locations 
were defined on the participants back and the samples taken from each were randomised to 
ensure that no bias occurred and each storage time contained samples from randomised areas of 
the back. 
VOCs were selected at random from within defined 10 min periods of the chromatography to 
provide a representative volatility range and analysis of variance (ANOVA) performed on integrated 
peaks areas with the null hypothesis that storage conditions have no effect on the VOC profile. 
After 4 days storage at -20ºC one compound caused the null hypothesis to be rejected, this was 6-
methyl-5-hept-2-one which has previously been noted to increase up to 300% on storage at 4ºC 
[111]. After 11 days storage at -20ºC other VOCs were also exhibiting increased responses causing 
the null hypothesis to be rejected and at this point the -20ºC storage study was halted and this 
storage condition was deemed insufficient for the storage of skin VOC samples. It is interesting to 
note that while several increased upon storage, none of the compounds monitored showed a 
significant decrease upon storage that would be expected to accompany an increase elsewhere in 
the profile, indicating that these compounds may be the product of bacterial metabolism of 
compounds too heavy to be recovered from the Skin Patch and analysed by the method employed 
here. After 21 days storage at -80ºC none of the monitored compounds showed any statistically 
significant change and this was considered an adequate storage condition for skin VOC samples in 
these pilot metabolomic studies. Figure 3.3 shows the effect of storage duration on 6-methyl-5-
hepten-2-one from Skin Patch samples stored at -20ºC and -80ºC.  
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Figure 3.3       The effect of storage on 6-methyl-5-hepten-2-one in human skin VOC profiles. Each data 
point represents the average peak area and the positive and negative error bars the 
maximum and minimum area obtained for each point respectively. The black trace shows 
data for -20ºC storage and the red -80ºC. The increase in 6-methyl-5-hept-2-one levels after 
96 hours (4 days) is evident when stored at -20ºC while at -80ºC there is no statistically 
significant change over 504 hours storage. 
It is worth noting that the first attempt at this storage-study was unsuccessful because the seals 
on the caps of the thermal desorption tubes failed. This was judged to be the result of differences 
in the thermal expansivity of material used (stainless steel tubes, PTFE ferrules and brass caps), 
causing the caps to become loose. In this study the sample tubes were placed at low temperature 
for 30 min and the caps then re-tightened before long-term storage of samples. 
The loss of sample integrity at -20ºC after 11 days suggests that cooling may be insufficient to halt 
sample degradation for long term storage and other strategies might need to be evaluated for 
longer term storage of skin samples for larger scale studies, or a larger extended sample storage 
study undertaken. 
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3.2.4. Summary of non-invasive skin sampling 
This research used a simple, robust, easily portable, non-invasive sampling methodology to collect 
VOC profiles from human skin. A review of published methods has shown VOC profiles obtained 
using the Skin Patch to be reproducible and representative of concentrations at the skin surface 
[111]. 
The importance of sampling time has been discussed and 30 min was selected to give the 
optimum global profile recovery across the wide volatility range expected from human skin 
samples.  
Enhancements in the quality control of blank samplers ensured conditioning protocols for both the 
Skin Patch and the cotton-wool pad covering consistently produced blank VOC profiles with 
contaminant levels sufficiently low to allow the method to be applied to the global profiling of 
unknown samples.  
Finally investigations into longer term storage solutions confirmed that maintaining sample 
integrity with storage is a critical factor in the design of metabolomic studies. VOC skin profiles 
were found to be stable for up to 21 days when stored at -80ºC. The ability to confidently store 
skin VOC samples for 21 days is an important finding for transferring this methodology to larger 
scale studies.  
The size and shape of the Skin Patch lend it the versatility to be applied to all but the most 
delicate structures of the skin surface and careful consideration of sampling site was, and will be, 
necessary when designing studies. The sampling sites chosen in this thesis were study specific 
and will be discussed in detail in the relevant sections. The protocols described in this section for 
preparing, sampling and storing skin VOC profiles from human participants were used for global 
VOC profiling in pilot metabolomic studies to assess the utility of skin sampling alongside existing 
non-invasive protocols.  
 
3.3. SAMPLING VOCs FROM HUMAN SALIVA 
In line with skin VOC sampling methodologies a polydimethylsiloxane (PDMS) based sampling 
approach was employed for saliva sampling, this strategy for selectively sampling VOCs from 
human saliva has been successfully applied in the form of solid phase microextraction (SPME) and 
stir bar sorptive extraction (SBSE) of expressed saliva samples [50] [133] [157].   
The difficulties associated with collecting a representative saliva sample, briefly comprising 
techniques for inducing salivation, the relative increase in collected bacteria when saliva is 
collected by spitting versus drooling and the potential losses of VOCs during sampling were 
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reviewed Section 1.4 and highlighted the potential confounding factors that must be controlled, 
despite the apparently simple act of collecting an individual’s saliva. When sample handling and 
storage techniques are also examined it becomes apparent that a wide range of factors affect the 
VOC profile ultimately obtained from a saliva sample, and that the recovery and analysis of many 
VOCs may be determined as much by the analytical methodology as by metabolism of the 
individual [47].  
In this study PDMS samplers were applied to in-vivo sampling of human saliva directly from the 
mouth, removing the pre-treatment, collection and handling complications associated with 
collecting expressed saliva.  
 
3.3.1. Designing a saliva sampler 
Initially sampling directly from the oral cavity was achieved using a PDMS Skin Patch secured 
using lockable haemostats with blunt ends, the participant was able to place the PDMS patch 
either under the tongue or inside the cheek whilst holding the handles of the haemostats outside 
the mouth. While this approach was effective participants found both the corners of the coupon 
and the hemostats to be uncomfortable and difficult to bear for more than a minute or so. While it 
would be possible to modify the shape, size and thickness of the PDMS coupon to improve 
comfort and maintain sampling efficiency, the safety and comfort of the participant must be the 
highest priority in designing an in-vivo sampler. The design of a reproducible, inert and safe 
method for placing and controlling the position of the PDMS coupon in the mouth presented a 
significant challenge and several configurations were attempted including several cage type 
approaches, wire leashes and extending the length of the coupon to act as a handle. None of 
these approaches fulfilled all the stated requirements and the configuration of the PDMS sampler 
itself was addressed. 
Other PDMS sampling configurations were reviewed including SPME, SBSE and SPE-td. A saliva 
sampler was designed in collaboration with Unilever PLC and machined by Peter Carroll of 
Unilever. The saliva sampler consisted of a solid phase extraction (SPE) cartridge (Cat no: C-
SPTD5-6MM Markes International Ltd), a hollow titanium rod coated with PDMS, which was 
mounted onto a bespoke holder for sampling. Figure 3.4 shows a computer-aided design (CAD) 
drawing of the component parts and the assembled sampler, this has been reproduced from the 
original drawing with Peter’s permission, the original may be found in Appendix 2. Table 3.1 
summarises the design parameters for the sampler. Sampling was effected by placing the PDMS 
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portion of the sampler into the oral cavity, underneath the tongue, in an analogous manner to an 
oral thermometer, as shown in Figure 3.5.  
 
Table 3.1  Summary of the design parameters for the saliva sampler  
Parameter Dimension 
Cartridge   
Support Hollow Titanium Rod 
Sorbent Polydimethylsiloxane (PDMS)   
Length 6  mm 
PDMS Film Thickness 500 µm 
Holder   
Material Stainless Steel (grade SST-316) 
Total Length 101.19  mm 
Handle Diameter 5.93  mm 
Cartridge Mount Diameter 1.25  mm 
Cartridge Mount Head Diameter 3.96  mm 
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Figure 3.4        Computer aided design (CAD) drawing of the saliva sampler and component parts, all dimensions are in mm unless otherwise stated. 
Panel 1: Drawing of the sampler head and spindle, 2: drawing of the sampler handle into which the head is screwed, 3: the SPE-TD 
cartridge, a hollow titanium cylinder coated with PDMS. Panel 4 shows an exploded diagram of the 3 sampler components, the spindle of 
part 1 passes through the hollow centre of the SPE-TD cartridge and screws into the handle (part 2). The  assembled sampler is shown in 
panel 4, the SPE-TD cartridge is secured between the sampler head and handle and may be safely and comfortably placed into the oral 
cavity to effect sampling.  
1
2
3
4
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Prior to use the cartridges were placed into empty thermal desorption tubes and conditioned with 
50 cm3 min-1 of inert carrier gas at 190 ºC for 60 min. Once conditioned, the samplers were 
thermally desorbed and analysed to ensure that they were free from unacceptable levels of VOC 
contamination; Figure 3.6 shows an example blank chromatogram compared with a saliva VOC 
profile. Immediately prior to sampling the saliva sampler was assembled, with care taken not to 
contaminate the solid-phase extraction cartridges by handling with stainless steel tweezers. The 
sampling procedure commenced with the participant drinking 50 cm3 of water to refresh their 
mouth, 1 min later the participant placed the saliva sampler into the sublingual region of the 
mouth where they could use the handle to stabilise and reposition the saliva sampler if needed, 
Figure 3.5. At the end of sampling the participant removed the saliva sampler by drawing it 
through their closed lips to remove any excess liquid from the surface. The researcher immediately 
unscrewed the spindle and placed the solid-phase extraction cartridge into a clean, empty glass 
thermal desorption tube that was then sealed and stored in an airtight container at 4 ºC until 
analysis.  
 
Figure 3.5 Photographs of the saliva sampler. Clockwise from top left. A titanium cylinder coated with 
polydimethylsiloxane is held in place by two springs inside a glass thermal desorption tube. 
Once conditioned the cylinder was removed and placed onto the threaded stainless steel 
spindle that was then screwed into the holder, (Right). The assembled sampler could then 
be placed comfortably into the mouth of a participant where a VOC sample was collected in-
vivo (Bottom left). 
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Figure 3.6        Top: an example TIC chromatogram of a VOC saliva profile obtained from in-vivo sampling with the SPE cartridge sampler. Bottom: 
the corresponding response from a sampler blank. Traces are magnified 5 fold with a 3Mcounts cut off for the blank and 10 for the 
saliva trace, the saliva trace is offset at 3.5Mcounts.  
0
2
4
6
8
10
0 20 40 60 80 100 120 140
0
1
2
3
0 20 40 60 80 100 120 140
10
8
6
4
2
2 4 6 8 100 120 140
tR / min
In
te
n
s
it
y
 /
 M
c
o
u
n
ts
5 x magnification
5 x magnification
77 
 
3.3.2. Saliva sampler characterization 
The suitability of the saliva sampler for global profiling was assessed in a series of 
characterisation experiments to determine key sampling considerations and produce analytical 
figures of merit [47]. 
3.3.2.1. Reproducibility 
The reproducibility of the technique was assessed both in-vitro and in-vivo.  
In-vitro reproducibility was determined using an aqueous 1 ppm (v/v) standard of five probe 
compounds, octane, heptanal, methyl hexanoate, nonanol and 2-decanone representing 
classes of compound previously observed in human saliva [157] and spanning a representative 
range of chemical functionality. 1.8 cm3 of this standard solution was aliquoted into a 2 cm3 
headspace vial, this minimised the headspace in the vial and allowed liquid displacement 
during sampling with the SPE cartridge. The SPE cartridge was mounted on the spindle from 
the holder (Figure 3.5) and placed into the vial which was sealed and left to stand in a 
thermostatically controlled oven at 37 ºC for 5 min at the end of which the SPE cartridge was 
removed, wiped with a lint free wipe to remove excess water, and placed immediately into a 
thermal desorption tube for analysis. Five replicate samples were acquired following this 
procedure and the results are summarised in Table 3.2 and Figure 3.7. 
 
Table 3.2 Assessment of the reproducibility of the saliva sampler, in-vitro. 
 Compound  M.Wt. Pv TB Q tr A RSD 
1 Octane 114.14 1726 399 43 7.3 20 26 
2  Heptanal 114.10 378 426 70 10.1 108 23 
3  Methyl hexanoate 130.10 50 423 74 10.8 272 1.3 
4  5-Nonanol  144.15 14 468 69 16.1 397 2.7 
5  2-Decanone 156.15 33 484 58 19.4 260 5.5 
 
Note.   M.Wt, relative molecular mass; Pv, Vapour pressure /Pa  at 25 °C (taken from 
Chemspider, www.chemspider.com); TB, Boiling point / K; Q,  Quantitation ion  (m/z);    
tr ,retention time / min;  A, chromatographic peak area; and,  RSD, relative 
standard deviation (%). 
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Figure 3.7       TIC chromatograms from in-vitro sampling with the saliva sampler. Six replicate 1.8 ml 
samples of an aqueous 1ppm standard  of octane (1), heptanal (2), methyl – hexanoate 
(3), 5-nonanol (4) and 2-decanone (5) are shown. Also labeled are artefacts from the 
PDMS sampling medium (A-D). 
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The underlying processes controlling the recovery of the probe molecules into the PDMS phase 
include absorption, followed by diffusion and permeation as described in Section 2.2, and 
these will be a function of concentration, volatility, hydrophobicity and functionality/polarity. 
The most important predictive molecular characteristic appears to be vapour pressure.  As the 
vapour pressure increases so does the relative standard deviation (RSD). The amount of 
material recovered is also inversely correlated to the vapour pressure with the size of the 
chromatographic response increasing logarithmically with reducing vapour pressure, see Figure 
3.8. Such trends indicate that the most volatile compounds are highly susceptible to small 
variations in sampling procedures, most rapidly lost from the experiment and recovered with 
the lowest efficiency, a similar observation has been noted previously [111].  
  
Figure 3.8       A plot of relative standard deviation (RSD) and recovery against vapour pressure for data 
from in-vitro reproducibility studies.  Examination of the recovery data (circles) and 
reproducibility data (diamonds) in Table 3.2 reveals how vapour pressure predicts the 
recovery and reproducibility of VOC.  These two plots show how RSD increases, and 
recovery reduces, with analyte vapour pressure. These data are plotted relative to those 
of octane to enable both trends to be viewed easily on the same graph.  
Data for octane (Table 3.2), Pv: 1726 Pa at 25°C, A: 20, and RSD: 26%. 
In-vivo reproducibility was assessed by taking six samples from the sub-lingual region of the 
mouth of a female participant using the procedure described above with a sampling-time of 5 
min.  The participant was allowed to rest for 1 min between each sample. The complexity of 
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VOC profiles obtained from human saliva is illustrated in Figure 3.6 which shows intensities 
ranging across two to three orders of magnitude and approximately 100 resolved and many 
more unresolved chromatographic peaks.  
In common with data where the variance is significant, means have low values and negative 
responses are not possible the VOC profiles from saliva sampled in-vivo appear to be log-
normally distributed. Indeed such log-normal distributions are often observed in biological 
systems; cell division of bacteria, latent periods of infectious diseases, permeability and solute 
mobility in plant cuticles for example [127] as well as antibody concentration in human blood 
sera[127] [158]. Eight randomised peaks selected from the study were assessed for normal and 
log normal distributions using the Anderson-Darling test and the cumulative distribution 
function appeared to fit a log-normal distribution better than a normal one.  The “S”-shaped 
curves, linear probability plots, and symmetric distribution expected in normally distributed 
data were not observed. Figure 3.9 provides an example of this behaviour.  
The Anderson-Darling test is a goodness of fit test based on the cumulative frequency function. 
It provides a measure of how well the data follow a particular distribution, the smaller the AD 
value the better the fit. The probability of obtaining these results when the distribution of the 
data is true is quantified as a p value. When comparing distributions to determine the best fit it 
is useful to compare both AD and p values; the distribution with the smaller AD and larger p 
values best fits the data. Table 3.3 gives example AD and p values for compounds from in-vivo 
saliva samples.  
 
Table 3.3    Example AD and p values providing evidence for log-normal distributions in human saliva 
 Normal Distribution Lognormal Distribution 
tR / min AD p AD p 
5.2 0.336 0.364 0.169 0.882 
18.3 0.930 0.007 0.417 0.214 
20.3 0.336 0.364 0.213 0.733 
32.7 0.311 0.428 0.158 0.904 
38.9 1.081 <0.005 0.300 0.459 
40.0 0.740 0.025 0.256 0.570 
43.6 0.422 0.207 0.169 0.884 
45.4 0.740 0.025 0.256 0.570 
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Figure 3.9        Example of evidence for log-normal distributions of VOC concentrations in human saliva. 
Cumulative frequency curves, for a benzoic acid ester, tR = 46.3 min in Table 3.3, 
showing normal (A) and log-normal (B) distributions, histograms for normal (C) and log-
normal (D) distributions and probability plots for normal (E) and log-normal (F) 
distributions suggest that VOC levels in the saliva of the participant studied better fit a 
log-normal than a normal distribution.  
For the in-vivo reproducibility data six compounds were selected at random across the 
chromatogram and, where possible, identified from NIST mass-spectral matches as; propanoic 
acid, an unassigned entity, 2-phenoxy ethanol, n-hexyl salicylate, benzoic acid ester-1, and 
finally another benzoic acid ester-2.  For these probe compounds the hypothesis of normality 
was rejected and a log-normal distribution was adopted on the basis that no significant 
departure from a log-normal distribution was observed for any them, such observations lead to 
the inference that the levels of VOCs in human saliva may better follow a log-normal than a 
normal distribution. A summary of the in-vivo reproducibility is given in Table 3.4. 
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Table 3.4  Assessment of the reproducibility of the saliva sampler, in-vivo. 
 Assignment  Q tR ln A  RSD 
1 Propanoic Acid 74  5.2 7.62  18.2  
2  Unassigned 106  18.3 5.77  15.7  
3  2-phenoxy Ethanol  94  20.3 4.94  6.4  
4  n-Hexyl Salicylate  120  32.7 6.68  9.9  
5  Benzoic acid ester -1 123  43.6 10.29  8.8  
6 Benzoic acid ester-2 123  45.4 10.27  9.4  
Note.  Q, Quantitation ion  (m/z); tR ,retention time / min; A, average chromatographic peak 
area; and, RSD, relative standard deviation (%). 
The data from in-vitro and in-vivo studies are consistent with a methodology that performs in a 
predictable and reliable way. Importantly these observations highlight the priority of sample 
management in the analytical work flow, especially for the most volatile components within 
saliva samples, with recovery and reproducibility strongly influenced by the volatility (expressed 
as vapour pressure) of the prospective analyte. 
3.3.2.2. In-vivo sampling time 
Ten chromatographic peaks selected at random retention times across the profile were used to 
assess the effect of sampling time on analyte recovery in-vivo. The compounds were assigned 
identities based on NIST mass spectral database searches, and these tentative assignments 
have not been confirmed with standards. This discussion will focus on the observed sampling 
time dependencies of four example compounds, one from each of the retention time quartiles. 
Figure 3.10 shows a histogram presenting the chromatographic peaks for ethanoic acid, 6-
methyl-5-hepten-2-one, heptadecane and, an unidentified alkylbenzoate. 
Ethanoic acid was accumulated rapidly over the first 5 min of sampling. After this the rate 
slowed reaching a maximum between 5 and 10 min. A further increase in sampling time 
resulted in a reduced response. 6-methyl-5-hepten-2-one showed a similar trend of an 
accumulation to a maximum value followed by a reduction in recovery; in this case the 
maximum recovery was achieved with a sampling time of ca. 15 min. The less volatile 
heptadecane and the unidentified alkylbenzoate, present at significantly lower levels, were 
accumulated with a gradual increase in abundance over 10 min before tending to equilibrate 
with the sampler.  
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Figure 3.10  A histogram showing the effect of sampling time on the recovery of ethanoic acid (A, tR 
5.9min), 6-methyl-5-hepyen-2-one (B, tR 25.1min), heptadecane at 10 x magnification 
(C, tR 73.8min), and an unidentified alkylbenzoate at 100 x magnification (D, tR 
112.6min). The deconvolved peaks for these VOCs are shown against different sampling 
time. 
The underlying physical chemistry and metabolic/catabolic processes governing these 
behaviours are likely to involve a combination of partitioning of VOCs from the saliva into the 
PDMS phase of the sampler cartridge, the continual release of metabolites/catabolites into the 
saliva and the kinetics of permeation and diffusion of the compounds into and out of the PDMS 
phase. Initially, VOCs in the saliva may be viewed as partitioning into the PDMS driven by 
concentration gradients, and more volatile species are likely to penetrate further and 
accumulate more rapidly in the sampling medium (PDMS). The kinetics of less volatile and 
perhaps lower concentration, compounds will be reflected in a slower accumulation. However, 
the partition coefficients for compounds of this nature are higher and so as sampling 
progresses the PDMS sampling phase moves closer to equilibrium with the surrounding saliva 
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and competitive adsorption / absorption processes would result in the displacement of the 
more volatile components, equation 3.1 is helpful in visualizing such a phenomenon [47]. 
 [ ]     
  [ ]      
      [ ]         ∑  [ ]      
 
Equation 3. 1 
 
The equilibrium concentration of an analyte in the PDMS sampling phase ([ ]      may be 
expressed in terms of its partition coefficient between saliva and PDMS (  ), the concentration 
of the analyte in saliva ([ ]        and the sum of the products of the concentrations and 
equilibrium constants of the competing co-absorbed species (∑  [ ]         
The reduced recovery for the more volatile compounds with increased sampling time is likely to 
be due not only to competitive adsorption / absorption but to a combination of factors. 
Principle among which will be depletion of the surrounding saliva; absorption is an equilibrium 
process and initially the concentration gradient from the saliva into the PDMS is large, the 
more volatile species will accumulate rapidly, if subsequent release of such compounds into 
the saliva proceeds at a slower rate there will come a point at which the concentration gradient 
reverses and higher levels of the more volatile compounds are now in the PDMS. Continued 
sampling after this point will result in losses of these compounds from the sampler as the 
system shifts to re-establish equilibrium [47]. 
Figure 3.10 shows that selection of one sampling time for such a range of compounds that 
may be expected in a human saliva sample is not a trivial task. Optimal conditions for sampling 
will depend on the analyte under study and the composition of the matrix at a given point in 
time. The challenge for profiling VOCs in saliva is to develop a method that provides an 
accurate representation of as many compounds within the target range of the profile as 
possible. Conversely this also highlights the inherent selectivity of such techniques and the 
opportunity to ‘tune’ sampling methodologies for targeted analysis.  
It is difficult to draw a conclusion as to the optimum sampling time from this study, the nature 
of the sampling does not permit simultaneous sampling and as such the in-vivo concentration 
may have changed from one sample to another, even with randomisation and careful 
experimental design.  
Figure 3.10 indicates that 10 min appears to be an acceptable operational compromise for a 
sampling time, whilst still maintaining participant comfort, and this was the sampling time used 
for the rest of this study.  
85 
 
3.3.2.3. Comparison with expressed saliva 
To provide a comparison of saliva profiles obtained from the SPE cartridge placed directly into 
the oral cavity (in-situ sampling) and from expressed whole saliva, a 10 participant (5 male, 5 
female) double cross-over design was adopted. Each participant provided samples during two 
separate study visits where they gave in-situ and passive drool samples [47]. The study design is 
summarised in Table 3.5. 1.8 cm3 of whole saliva was transferred to a 2 cm3 headspace vial 
immediately after sampling and extracted using SPE cartridges as described for in-vitro 
sampling in Section 3.3.2.1. Both sample types were extracted for 10 min.  
  
Table 3.5  Summary of the double-crossover sampling campaign adopted for the comparison of 
saliva samples collected in-situ with expressed saliva samples. 
Sample order(x-y) F-02 M-03 M-04 M-05 M-06 F-01 F-07 F-08 M-10 F-09 
1-1 I-S#01 I-S#03 P-D#01 I-S#09 I-S#13 P-D#15 P-D#17 P-D#19 P-D#23 I-S#25 
1-2 P-D#02 P-D#04 I-S#08 P-D#10 P-D#14 I-S#16 I-S#18 I-S#20 I-S#24 P-D#26 
2-1 P-D#05 P-D#11 I-S#33 P-D#21 P-D#39 1-S#37 I-S#31 I-S#27 I-S#35 P-D#29 
2-2 I-S#06 I-S#12 P-D#34 I-S#22 I-S#40 P-D#38 P-D#32 P-D#28 P-D#36 I-S#30 
Note:  Sample order: x-y where x: visit number and y: sample number. The participant code 
designates gender (M/F) and their study identifier number.  Each sample is designated 
as I-S: in-situ or P-D passive drool followed by the position in campaign sequence #. The 
order of the participants reading left to right designates the order of their recruitment to 
this study.  
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Figure 3.11  A comparison of the VOC profiles obtained from saliva samples from one participant. 
The bottom trace shows the profile achieved by in-situ sampling with a bespoke PDMS 
sampler. Offset at 30 M Counts is a profile from an expressed sample collected by 
‘passive drool’. The top trace shows the log of the relative responses for all the peaks 
with an intensity greater than 1% of the maximum.  
Figure 3.11 shows that the chromatograms obtained from the two sampling techniques were 
fundamentally different, while there are many qualitative similarities, with 70% of components 
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present in both cases, the differences in intensity were marked. Somewhat surprisingly this 
was especially the case at higher retention times. Six compounds were selected to represent 
the volatility range across the profile and where possible tentatively identified from NIST mass 
spectral matches, Figure 3.12 shows box-whisker plots for these compounds with each 
sampling protocol.  
 
Figure 3.12 Box whisker plots showing the differences in saliva VOC profiles obtained by in-situ 
sampling and passive drool sampling in a double crossover study with 5 male and 5 
female participants. 6 compounds were selected across the retention time range; 
acetone (tR = 4.56 min), propanoic acid (tR = 7.75 min), benzaldehyde (tR = 22.83 min), 
indole (tR = 48.16 min), n-hexadecanoic acid (tR = 83.77 min) and an unidentified 
benzoic acid ester (tR = 104.0 min). Peak areas have been normalized so that the mean 
of the in-situ samples is equal to 1 to allow all compounds to be presented on the same 
scale. At each retention time the white boxes show normalized peak areas for in-situ 
samples, the grey the same for passively drooled sampled. The higher recoveries and 
lower variability from the in-situ sampling is particularly evident at the extremes of the 
profile.   
The two most volatile compounds, acetone (tR = 4.56 min) and propanoic acid (tR = 7.75 min), 
exhibit higher recoveries and lower variability when sampled in-situ compared to expressed 
saliva. The middle of the volatility range appears to be less affected with no notable difference 
in recovery or variability for benzaldehyde (tR = 22.83 min) and indole (tR = 48.16 min) between 
the two sampling techniques. The marked reduction in recovery for the higher molecular weight 
compounds is highlighted in Figure 3.12 with n-hexadecanoic acid (tR = 83.77 min) and an 
unidentified benzoic acid ester (tR = 104.0 min) exhibiting significantly lower recoveries when 
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sampled from expressed whole saliva.  Higher recoveries of the least volatiles compounds from 
the in-situ sampler may be the result of contact between the PDMS and the surface 
membranes of the mouth or losses due to bacterial degradation in expressed saliva samples. 
Whilst every care was taken in this study to ensure rapid transfer of saliva from the collection 
vessel to the sampling vial for subsequent extraction (the time from the end of the saliva 
collection time to the start of SPE sampling was less than 5 min in all cases) it can take up to 
10 min for some participants to produce 3 cm3 of drooled saliva and headspace losses and 
bacterial degradation may be reasonably anticipated with passively drooled samples. 
 
3.3.3. Summary of non-invasive, in-situ saliva sampling 
This sampling technique was well tolerated by volunteers, simple, fast, reproducible and easy 
to administer and requires no specialist handling or storage techniques, making it more 
applicable to large scale field based sampling campaigns than collecting whole saliva.   
An important element of this work was to develop a robust analytical workflow for saliva 
sampling that was compatible with other non-invasive, in-vivo VOC sampling and analysis 
methods, in particular breath and skin. In adopting this methodology care needs to be taken to 
ensure sampling times are carefully controlled and where possible matched to the volatility of 
analytes under study, this has been previously noted for in-vivo sampling of skin and for global 
profiling must represent a compromise between the most and least volatile analytes as well as 
constraints imposed by the study conditions and comfort of the participants. These 
observations highlight the inherent enhancements in sensitivity and selectivity that may be 
achieved by careful optimisation of these techniques for subsequent targeted studies and 
conversely serves as a reminder of the ease with which bias can be inadvertently introduced if 
this factor is not carefully managed. 
Long term storage stability of these samples has not been addressed in this work principally as 
a result of a shortage of SPE cartridges preventing sufficient data points to provide statistically 
significant data. Short term storage of up to 24 hours at 4 ºC was verified with a series of 5 
paired SPE cartridges sampled simultaneously, one of which was analysed immediately and 
the other stored for 24 hours. Qualitative assessments of the data showed the same profiles to 
be achieved for both samples with peak intensities normalised as a percentage of the most 
intense peak in the chromatogram, all tested peaks were within +/- 5% within sample pairs.  
The tentative observation of log-normal distributions is potentially important and may have 
wider ramifications with other in-vivo measurement techniques. Characterising the inherent 
variability in saliva VOC profiles is not the focus of this thesis and the next logical step would be 
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to incorporate a follow up study with this as the main focus as part of a wider investigation into 
homeostasis in human saliva.  
Comparison of in-situ sampling with expressed saliva has revealed that in-situ sampling 
provides more analytical information with lower intrinsic variability and indicates significant 
analytical utility for this form of in-situ sampling. Sufficient sensitivity and precision has been 
demonstrated to enable this sampling methodology to be included alongside existing breath 
and skin analysis techniques in VOC profiling and biomarker prospecting studies.  
Subsequent studies in this thesis will apply the protocols established in this section for 
preparing, sampling and storing saliva VOC profiles from human participants to global profiling 
in pilot metabolomic studies to assess the utility of this form of saliva sampling alongside skin 
and other non-invasive sampling methodologies. 
 
3.4. INSTRUMENTAL PARAMETERS 
3.4.1. Thermal desorption 
Thermal desorption of VOCs from PDMS samplers was achieved by two-stage thermal 
desorption,  Markes International Unity 2, employing a Tenax TA / Carbograph 1TD cold trap for 
refocusing.  
Direct desorption of PDMS samplers to obtain a representative profile of the absorbed VOCs 
from human skin or saliva must be an exhaustive process, that is to say it must achieve 
complete extraction of VOCs from the PDMS. Heating the PDMS in a flow of inert carrier gas 
sets up a dynamic equilibrium in which volatile analytes desorbed from the PDMS are instantly 
removed from its headspace. This effectively provides a constant headspace concentration of 
zero, maintaining the maximum concentration gradient from the PDMS into the carrier gas. 
A desorption temperature of 180 ºC was chosen as the optimum balance between efficient 
desorption and minimum bleed from the PDMS phase and the desorption time was evaluated 
between 2 and 20 min for both desorption efficiency and breakthrough of the most volatile 
compounds from the cold trap. To ensure that exhaustive extraction had been achieved PDMS 
samplers were ‘redesorbed’ to asses carryover Figure 3.13 shows an example skin VOC profile 
and the same Skin Patch analysed under the same conditions in the subsequent analytical run. 
Desorption efficiency at each desorption time was quantified by the % carryover of a set of 
randomly selected peaks across the profile and extraction was deemed exhaustive when less 
than 1% carryover was observed. For the Skin Patch 10 min desorption was required for 
quantitative extraction, whereas for the SPE cartridge 5 min was sufficient.  
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Figure 3.13 An example total ion current chromatogram (TIC) from TD-GC-MS analysis of a PDMS 
skin patch sample (bottom). Offset at 105 M Counts is a subsequent re-desorption of 
the same skin patch. Less than 1% carryover is exhibited for any compound not 
originating from the PDMS membrane itself. The formation of these PDMS derived 
compounds will be discussed in more detail in Section 3.5.3. 
 
To ensure quantitative retention of the most volatile compounds on the cold trap the responses 
of acetone and acetic acid were monitored at each desorption time, if a reduction in response 
was observed with an increase in desorption time the breakthrough volume of that compound 
had been exceeded and the desorption time would need to be reduced. Due to the 
hydrophobic nature of both PDMS and the sorbents in the cold trap the cold trap could be held 
at sub – ambient temperatures without large volumes of water being retained and as a result 
no breakthrough was observed for either acetone or acetic acid with desorption times up to 15 
min. 
A summary of optimised thermal desorption method parameters employed in these studies is 
included in Table 3.6. 
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Table 3.6 A summary of the thermal desorption parameters used in the analysis of skin and saliva 
VOC samples.  
Parameter Skin Patch SPE Cartridge Unit 
Prepurge    
Flow 30 30 cm
3 
min
-1
 
Time 1 1 min 
Primary Desorption    
Flow 50 50 cm
3
 min
-1
 
Temperature 180 180 ºC 
Time 10 5 min 
Split Flow 0 (Splitless) 0 (Splitless) cm
3 
min
-1
 
Cold Trap    
Low temperature -10 -10 ºC 
Secondary Desorption    
Flow 2 2 cm
3 
min
-1
 
Temperature 300 300 ºC 
Time 5 5 min 
Split Flow 0 (Splitless) 0 (Splitless) cm
3 
min
-1
 
Heating Rate ~100 (max) ~100 (max) ºC s
-1
 
Flow path temperature 180 180 ºC 
 
 
3.4.2. Gas chromatography – mass spectrometry 
A HP 5890 gas chromatograph fitted with a 60 m long, 0.25 mm internal diameter, 0.25 µm 
film thickness DB-5 MS column operating in constant pressure mode was employed in these 
studies. To achieve a column flow of 2 cm3 min-1 during the initial stages of the temperature 
programme, thus ensuring a 2 cm3 min-1 cold trap desorption flow, the system was operated 
with a column head pressure of 29 psi.  
Separation of VOCs was achieved using a temperature programmed GC method and each 
method was study specific, these are outlined in Table 3.7. 
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Mass spectrometric detection was achieved using a Fisons Trio 1000 quadrupole mass 
spectrometer, operating in scanning mode, with an electron ionisation source, operating in 
positive ionisation mode. Conditions are summarised in Table 3.7.  
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Table 3.7  A summary of the  gas chromatography and mass spectrometry parameters used in the 
analysis of skin and saliva VOC samples. 
Parameter Level Unit 
GC Programme 1 
Initial Column Temperature 30 ºC 
Initial Hold Time 0 min 
Initial Heating Rate 2 ºC min
-1
 
Final Column Temperature 300 ºC 
Final Hold Time 8 min 
GC Programme 2 
Initial Column Temperature 40 ºC 
Initial Hold Time 0 min 
Initial Heating Rate 3.3 ºC min
-1
 
2
ry
 Column Temp 90 ºC 
2
ry
 Hold Time 0 min 
2
ry
 Heating Rate 2.5 ºC min
-1
 
3
ry
 Column Temp 140 ºC 
3
ry
 Hold Time 0 min 
3
ry
 Heating Rate 10 ºC min
-1
 
Final Column Temp 300 ºC 
Final Hold Time 8 min 
GC Programme 3 
Initial Column Temperature 40 ºC 
Initial Hold Time 0 min 
Initial Heating Rate 5 ºC min
-1
 
Final Column Temperature 300 ºC 
Final Hold Time 8 min 
Mass Spectrometer Conditions 
Scan Range 40 - 445 m/z 
Scan Time 0.45 s 
Interscan Delay 0.05 s 
Electron Energy 70 eV 
Source Temperature 200 ºC 
Interface Temperature 300 ºC 
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3.5. DATA PROCESSING 
VOC profiles from human skin and saliva are complex containing hundreds of resolved and 
unresolved compounds, with responses ranging over several orders of magnitude. This 
presents a significant challenge for establishing simple and robust automated data processing 
work flows. This section discusses the key factors associated with handling large complex data 
sets and describes the strategy adopted in these studies alongside the optimisation of critical 
parameters for each step in the workflow. 
 
3.5.1. Dynamic background compensation (DBC) 
In these studies DBC and mass spectral deconvolution were achieved using TargetView 
(ALMSCO International, Llantrisant, UK) as described in Section 2.6.2. Important parameters to 
consider when using DBC algorithms are the peak width and noise counts settings, the noise 
counts value is an absolute value below which spectral peaks are attributed to noise. More 
importantly for skin and saliva samples it may be that different peak width values give optimal 
peak shapes for different classes of compound. Figure 3.14 shows an extracted ion 
chromatogram for octanoic acid and octanal on a DB-5 column; used in this study. The shape 
of the octanoic acid peak is due to its higher polarity relative to the column stationary phase 
and is an unfortunate compromise when using one column for a wide range of analytes.  
 
Figure 3.14 A demonstration of the effect of automated data processing parameters on typical skin 
VOC compounds. The different peak shapes in the extracted ion chromoatograms for 
octanal (m/z 56, left) and octanoic acid (m/z 60, right) are shown in the raw data 
(bottom trace). The middle trace shows dynamic background compensated data with a 
peak width setting of 10 seconds and the top a peak width of 30 seconds. The 
truncation of the octanoic acid peak with the 10 second peak width setting is evident.   
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Figure 3.14 shows octanoic acid and octanal before any processing and after DBC with a peak 
width of 10 seconds and 30 seconds, the truncation of the acid peak is evident with the 
smaller window and is an important reminder that optimisation of automated data handling 
techniques is equally as important as optimisation of instrumental parameters.  
 
3.5.2. Mass spectral deconvolution 
As with DBC the input peak width parameter in TargetView can have a significant effect on the 
resultant deconvolved spectrum and careful optimisation of this parameter is essential to 
achieve accurate spectra. Using a series of test compounds identified in a series of skin 
samples and previously reported in literature to be present in VOC profiles recovered from 
human skin [41] [83] [96] the effect of peak width on the accuracy of deconvolved spectra was 
tested using the NIST forward spectral match as a measurement of accuracy. Samples were 
chosen so that a representative concentration range of each compound was assessed and 
Table 3.8 summarises the variability in peak widths observed across the 10 data files. 
 
Table 3.8 A summary of the variation in baseline chromatographic peak widths between classes of 
compound in 10 skin VOC samples.  
 Peak  width  / s 
  AA B D-L 1-D I H n-HA S 
1 33 15 4 9 6 5 48 33 
35 2 35 10 6 7 7 5 60 
3 26 8 9 13 6 6 90 24 
4 25 12 5 12 8 5 51 27 
5 20 13 10 8 5 3 102 31 
6 41 18 12 9 7 4 98 35 
7 38 20 13 10 6 5 100 38 
8 27 15 5 11 4 7 75 20 
9 34 6 6 13 8 6 63 22 
10 30 10 7 10 7 5 72 21 
Mean 30.9 12.7 7.7 10.2 6.6 4.8 75.9 28.6 
Stdev 6.5 4.4 3.1 2.0 1.3 1.1 20.5 6.6 
%RSD 20.9 34.6 40.6 20.0 19.2 22.9 27.0 23.1 
Key:  AA, Acetic Acid; B, Benzaldehyde; D-L, D-Limonene; 1-D, 1-Decanol; I, Indole; H, 
Hexadecane; n-HA, n-Hexadecanoic Acid; S, Squalene. 
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Figure 3.15 The effect of peak width on the accuracy of mass spectral deconvolution in skin VOC 
samples. The average forward mass spectral match generated by NIST for each of the 8 
compounds and 10 samples summarised in Table 3.8 plotted against the peak width 
used for deconvolution shows two general trends. The dashed lines represent 
compounds with average peak widths >25 s and the solid lines those <25 s, the 
optimum peak width for each group is highlighted with grey shading. 
 
The difference in peak widths and the large concentration range of compounds reported to be 
recovered from human skin pose serious difficulties for automated deconvolution. The results 
from interrogating the data with different peak width values indicate that, for the majority of 
compounds, increasing the peak width window has no marked effect on accuracy of 
deconvolution until a peak width of 16 s, these are represented with solid lines in Figure 3.15, 
and this observation appears to hold for all compounds exhibiting Gaussian peak shapes. The 
broader peaks however appear to be greatly affected by utilising too small a peak width, with 
key ions being removed from the deconvolved spectrum or classified as ‘uncertain’.  
In metabolomic studies it is simply not feasible for an analyst to optimise deconvolution 
settings for every peak in every chromatogram. To allow a degree of automation a compromise 
was employed in these studies by which peaks exhibiting Gaussian distribution were 
deconvolved with a peak width of 12 s, those that were not Gaussian in nature were found to 
be predominantly volatile fatty acids and primary amines and for these a peak width of 30 s 
was employed to obtain a deconvolved spectral list. Whilst this method still requires a 
significant degree of manual intervention it allows creation of accurately deconvolved spectral 
lists for inclusion into a database, these lists will ultimately provide quantitation and 
qualification ions for integrating raw data.  
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3.5.3. Chromatographic alignment 
In these studies a homologous n-alkane standard series was used to generate a primary 
retention index ladder. By definition each n-alkane has a retention index equal to its carbon 
number multiplied by 100.  
Table 3.9 A list of the standards used to create a primary retention index for chromatographic 
alignment of skin and saliva VOCs. This table lists each standard with an example 
retention time and the assigned retention index value.  
Standard tR / min RI 
Octane 7.43 800 
Nonane 10.15 900 
Decane 13.3 1000 
Undecane 16.55 1100 
Dodecane 19.7 1200 
Tetradecane 25.57 1400 
Heptadecane 33.22 1700 
Eicosane 39.64 2000 
 
This standard solution was analysed as a quality control standard every 6 samples and 
assessed for any reductions in response, changes to the shape of the overall profile – i.e. loss 
of the lighter or heavier compounds, and any significant shifts in retention time.  
Retention indexing is usually achieved by the addition of internal standards to a liquid sample. 
Rather than add a series of internal standards to PDMS samplers, not a trivial task, and then 
validate such a method, the ubiquitous series of siloxane compounds stripped from the PDMS 
sampling medium during thermal desorption was employed as internal markers. A secondary 
retention index ladder was thus created using these siloxane compounds, example TICs for 
primary and secondary retention index ladders are shown in Figure 3.16.  
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Figure 3.16 Bottom: Primary retention index ladder of n-alkane standards. Top: An example blank 
skin patch, S1-S6 are siloxane compounds used to create a secondary retention index 
ladder. The secondary retention index ladder, calculated based on the primary ladder, is 
used as an internal standard series for chromatographic alignment of skin / saliva VOCs.  
Figure 3.17 shows the mechanism of thermal degradation of the PDMS phase to form one of 
the siloxanes forming the secondary retention index ladder, S1. The final compound eluting in 
both skin and saliva samples was found to be the skin lipid squalene, as this was present in all 
samples squalene was used as the final retention time marker for retention index alignment, 
Table 3.10 lists the internal retention index markers. 
 
 
Figure 3.17 Mechanism showing the thermal degradation of a polydimethyl siloxane (PDMS) 
membrane and its subsequent electron ionisation and fragmentation to give m/z 207, a 
commonly observed siloxane from PDMS samplers  and gas chromatography column 
stationary phases. Siloxanes such as this are used in these studies as internal retention 
time markers. This mechanism has been reproduced from reference 128. 
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A secondary retention index ladder was calculated from the primary index of n-alkane 
standards to assign retention indices to these ubiquitous siloxanes, this calibration was plotted 
for each sample. The retention index value for a specific VOC within a sample was then 
obtained by interpolating the respective retention time to the linear regression generated from 
a plot of retention time versus secondary retention index of the ubiquitous siloxanes as shown 
in Figure 3.18.  
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Table 3.10 The five ubiquitous siloxanes and skin lipid squalene used as internal retention indexing markers in skin and saliva VOC profiles. Each marker 
is defined by retention time (GC parameters 3), retention index, mass spectrum and structure. 
Name 
RI, tr / min, mass spectrum 
Hexamethylcyclotrisiloxane (S1) 
796, 7.9, 207_208_149_209_191 
 
Octamethylcyclotetrasiloxane (S2) 
987, 13.1, 281_282_283_207_133 
 
Dodecamethylcyclohexasiloxane (S3) 
1361, 23.4, 73_429_341_430_147 
 
 
Hexadecamethylcyclooctasiloxane (S4) 
1988, 40.6, 355_73_221_147_356 
 
Eicosamethylcyclodecasiloxane (S5) 
2149, 45.1, 73_281_147_503_221 
 
Squalene (S6) 
2491, 55.4, 69_81_41_95_68 
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Figure 3.18 Example retention time to secondary retention index calibration based on the six 
compounds in Table 3.10. This calibration curve was plotted for each VOC sample to 
convert retention time to retention index thus aligning all samples chromatographically.  
 
3.5.4. Generation of a VOC matrix and multivariate analysis 
The penultimate step in the data processing workflow was incorporation of the compound 
information into a matrix for multivariate analysis (MVA). The variables for a matrix were given 
unique identifiers based on their calculated secondary retention index values (RI) and the 5 
most intense peaks from deconvolved mass spectra taking the form RI_Base Peak_Fragment 
1_Fragment 2..... and so on. Each separate sample became an observation thus creating the 
template for the matrix as detailed in Section 2.7. Exogenous compounds were removed from 
the matrix if they were found to be present in sampler blanks, typically 200 to 300 VOCs were 
found in a skin sample after deconvolution and exogenous removal.    
The matrix was then populated with peak areas calculated as the area under the curve for the 
extracted ion chromatogram of the designated quantitation ion for each variable. In the 
majority of cases this was the base peak but where this did not offer sufficient selectivity a 
different ion was chosen for quantitation. Integration was performed on raw data using 
MassLynx (Waters, Manchester, UK). If the peak area for a compound was below the 
detectable level a value of zero was entered into the matrix.  
Once populated the VOC matrix was imported to SIMCA-P v.12 (Umetrics, Umea, Sweden) for 
multivariate analysis. To give equivalent weighting to all the components in the matrix pareto-
scaling was applied. This divides the peak area of each individual component in the matrix by 
the square root of the standard deviation of the peak areas for that variable set [159-160] and 
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compensates for the large range in response between variables and assign equal significance 
to every variable, independent of relative magnitude.  
In Section 2.7 the combination of supervised and unsupervised statistical models was 
described. Initially, partial least squares discriminant analysis was applied to the matrix in 
which the observations had been divided into classes. An S-plot was generated from this which 
graphically represents all of the variables in the matrix distributed through the S-plot co-
ordinates according to the probability that they contribute to the separation between the 
classes. The variables identified from the S-plot as those with the highest probability of 
contributing to the variance between classes were then copied to a new matrix which was 
analysed using unsupervised principle component analysis (PCA). If separation between the 
classes was observed in the unsupervised model from these variables they were listed as 
candidate markers and more detailed inspection of the data was then undertaken to test this 
finding.  
Candidate markers from MVA were identified on two criteria: a satisfactory match between the 
denconvolved mass spectrum, generated by TargetView, and the respective entry in the NIST 
MS library (NIST 11) and, a satisfactory match between the estimated Kováts retention index 
value obtained from NIST and the calculated retention index value based on a series of 
hydrocarbon standards as described in Section 3.5.3. 
A spectral match was deemed satisfactory if forward and reverse match factors gave values 
greater than or equal to 750. A retention index match was deemed satisfactory if the observed 
retention index value was within 50 retention index units (RIU) of the published estimate. 
Where possible these tentative identifications were confirmed with pure standards.  
 
3.6. CONCLUSIONS 
It is evident that applying non-invasive sampling protocols to complex matrices for global VOC 
profiling in metabolomic studies is not straightforward. Suppressing bias within the sampling, 
analysis and data handling techniques presents a significant challenge. The research 
described in this Chapter sought to characterise and optimise the key parameters for sampler 
design and sampling methodology, recovery of sampled VOCs by thermal desorption, 
separation and detection and data preparation and processing. The result is a work flow for 
global profiling of VOCs from human skin and saliva. 
Whilst this work flow requires a significant level of manual intervention from the analyst it 
presents the first real step towards a robust and valid protocol which encompasses all stages 
from sampling through to statistical modelling for these complex and challenging samples. 
Continual evaluation, enhancement and validation of this work flow will be a dynamic and on-
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going task over the course of many studies and research cycles; the subsequent Chapters 
present its first application to pilot metabolomic studies and provide a critical evaluation of the 
utility of skin and saliva sampling alongside the current forerunner in non-invasive sampling, 
breath analysis. 
In these early stage pilot studies healthy participants were recruited and subject to stress 
interventions to act as a surrogate for disease state, rather than using unproven 
methodologies with precious samples from un-well individuals. These studies may also provide 
useful insight into the potential confounding factors due to psychological and physical stress in 
patients.  
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4 THE EFFECT OF INDUCED PSYCHOLOGICAL STRESS ON VOC OF 
YOUNG ADULTS: A PILOT STUDY 
4.1. INTRODUCTION 
This chapter presents the first application of the Skin Patch methodology to non-targeted 
metabolomic profiling following the workflows established in Chapter 3.  The intent was to 
critically evaluate the potential of the Skin Patch approach as a non-invasive sampler for in-vivo 
human VOC measurements. To do this the relative merits of skin and breath sampling were 
explored with parallel samples taken from participants subject to a controlled intervention 
designed to induce psychological stress. Candidate markers for stress identified from skin VOC 
profiles were compared against those from breath samples.  
 
4.2. STRESS 
‘Stress’, as it is understood in modern biology, was first discussed by Hans Seyle who 
described it as the failure of an organism to respond appropriately to perceived threats, 
whether emotional or physical [161]. Seyle proposed 3 stages of coping that the body 
undertakes to confront this threat; alarm, adaptation and finally exhaustion.  Alarm is the initial 
response to the identified stress causing the hypothalamus to activate the pituitary gland, 
which in turn activates the adrenal glands to release adrenaline, nor-adrenaline and cortisol. 
The autonomic nervous system is also activated which leads to a number of physiological 
responses including increased heart rate and blood pressure, faster and shallower breathing 
and sweating. The liver responds by releasing sugars, cholesterol and fatty acids into the blood 
to supply energy to the muscles for the ‘fight or flight’ response. Muscles tense for action and 
the blood clotting ability increases to prepare for potential injury [162]. 
Adaptation follows in which a resistance to the stressor is built and the body remains mobilised 
to fight. Finally if the stress is prolonged, exhaustion occurs at which stage the bodies 
resources are depleted making it more vulnerable to stress related conditions [162]. 
These physiological responses indicate an alteration in metabolic state. Significant research 
effort has focused on calibrating these responses to be indicators of stress [163]. A study 
investigating the incidence of anxiety and depression in patients suffering from chronic 
obstructive pulmonary disease (COPD) suggests that comorbid psychological problems 
increase the functional disability of the patient, reducing quality of life. The authors propose 
psychological characteristics to be important variables that interact with physical symptoms 
and recommend that psychosocial variables are taken into consideration when treating 
patients suffering from COPD [164]. The observations in this study focused on the metabolic 
changes associated with stress and addressed the question:  
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are there stress sensitive compounds detectable in VOC profiles, and if so what implication 
does this have for putatative biomarker discovery? 
 
The effect of stress on VOC profiles associated with breath and skin have yet to be established, 
and there may prove to be significant confounding factors in the disease marker discovery 
process. Conversely if biomarkers for stress exist in such samples the following question 
arises: 
 
is it possible to objectively monitor stress, or distress, in those unable to communicate 
effectively to relatives and medical staff? 
 
Significant research is currently focused on non-invasively identifying markers for chronic 
diseases, including COPD, in exhaled breath, skin, urine and saliva [34] [57] [121] [165]. The 
apparent higher prevalence of ‘stress’ in patients suffering from such diseases compared to 
healthy controls may contribute significant confounding factors and generate a false suite of 
candidate markers from such studies. This study therefore induced a stress response in young 
adults by employing a PASAT intervention and then evaluated changes in the skin VOC profile 
associated with the stress event.  
Results from the concurrent breath study, published by Turner et. al., reported 6 stress breath 
marker candidates. Levels of indole and 2-methylpentadecane were observed to increase with 
stress, whilst benzaldehyde, 2-hydroxy-1-phenylethanone, 2 ethylhexan-1-ol and an as yet 
unidentified terpene compound were shown to decrease with stress [62].    
 
4.3. SAMPLING CAMPAIGN 
20 healthy non-smoking adults (10 male and 10 female) were recruited from Loughborough 
University staff, students and social networks in the age range 19-26. The study followed a 
randomised cross-over design with participants attending two sampling sessions. In one they 
were asked to sit comfortably and listen to classical music, this was denoted as the ‘neutral’ 
intervention. In the other session, participants were asked to undertake a mental arithmetic 
test known as the Paced Auditory Serial Addition Task (PASAT), the ‘stress’ intervention.  
The data presented in this chapter forms part of a wider study devised by the author in 
collaboration with Pareen Patel, Matthew Turner and Aditya Malkar. The PASAT test was 
provided by Dr Stephan Bandelow and Dr Louisa Edwards and administered by Toni McKay and 
Elliot Poole, all of the School of Sport, Health and Exercise Sciences at Loughborough 
University (SSHES).  
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4.3.1. Physiological measurements 
Heart-rate (HR) and blood-pressure (BP) measurements were recorded using a Datex Ohmeda 
S/5 patient monitoring system. Heart rate was monitored via a finger clip attached to the index 
finger of the participants’ left hand, a Critikon 22-33 cm Dura-Cuf blood pressure cuff was 
applied to the upper left arm. At each time point heart rate, systolic blood-pressure, diastolic 
blood-pressure and mean arterial pressure were recorded. Upon arrival 3 replicate 
measurements of the participants’ blood pressure and heart rate were taken at 2 minute 
intervals to provide a baseline level, a further 12 readings were taken over the course of each 
experimental session at 12, 16, 19, 23, 30, 42, 45, 48, 49, 57, 60, 65 and 71 min.  
 
4.3.2. Paced Auditory Serial Addition Task (PASAT) 
The PASAT was first developed by Gronwall in 1977 to monitor the recovery of patients who 
had sustained mild head injuries [166].   The test involves single digits presented to the 
participant via an audio feed. The participant is required to verbally add each newly presented 
digit to the one immediately preceding it. Since its development to monitor recovery, the PASAT 
has found application as a psychological stressor in several studies. [166] [167].    
In this study the PASAT was used to induce psychological stress. The protocol follows that 
described above with incorrect answers, and pre-defined correct answers, highlighted with the 
use of a loud horn to disorient and further stress the participant.  
The participants were subjected to the neutral condition on their other study visit, this involved 
sitting in a quiet room listening to a collection of classical music provided by SSHES comprising 
four instrumental pieces; Truman Sleeps by Burkhard Dallwitz, Guitar Flute & String by Moby, 
Gabriel’s Oboe by Ennio Morricone and Suite Bergamasque: Clair De Lune. The participant’s 
received no input from the researchers during this time. Both interventions were 11 min in 
duration and the participants’ blood pressure and heart rate was recorded at 4 time points 
during each. 
 
4.3.3. Skin sampling 
4.3.3.1. Selection of sampling site 
The skin is a large complex organ adapted to perform a range of functions across different 
locations of the body and as a result the levels and classes of compounds emanating from the 
skin are likely to vary with body site. Careful consideration of sampling area was required to 
ensure any effects on the skin VOC profile due to the stress response were captured.  
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Although the main function of sweating in humans is thermal regulation, sweating from the 
palms often occurs when an individual is subject to emotional stimuli such as fear or mental 
strain [168].  Apocrine sweat glands are stimulated by emotional stress and open into hair 
follicles in body areas such as the axillae, eyelids and forehead. Eccrine glands on the palms of 
the hands and soles of the feet also respond to emotional stimuli [169] [170].   
Emotional sweating has been evaluated in several studies as a measure of mental strain; 
measurements are usually based on electrodermal activity, employing techniques such as skin 
conductivity, which measures the resistance of skin to the passage of an electric current, 
known as the galvanic skin response [171][172].  One such study measured the electrodermal 
activity across the palm during three activities; arithmetic calculation to induce mental strain, a 
hand-grip exercise to induce physical strain and a deep breathing exercise to induce relaxation. 
All subjects showed a marked increase in palmar sweating during oral explanation of all three 
tasks, which returned to baseline before beginning the exercise. Subjects also showed an 
increase at the beginning of each exercise, whatever the stimulus, highlighting the importance 
of allowing time for equilibration to such interventions and the nervous response simply 
associated with being presented with such a task in a research environment. The palmar 
sweating response returned to baseline very quickly after beginning the deep inspiration 
exercise,  but showed a continued elevation above baseline with the physical stimulus and 
gave an unstable high response to the mental strain exercise, indicating its applicability to 
assessment of mental strain [171].  It is also important to observe from this study that sweating 
responses to the mental arithmetic tasks reduced with repetition, indicating learned behaviour 
and reduced effectiveness of the task over time. 
Kamei et al described sweating as a good indicator for surprise and emotional stress in their 
study on physical and emotional stress induced sweat secretions in the human palm and 
forehead [169].  By measuring the rates of sweating on the palm and forehead during a set of 
interventions the authors were able to conclude that the secretion of sweat is dependent on 
the way the individual absorbs stress, and propose the palm or forehead as locations for 
monitoring the human body under stress [169].   
Investigations into the emotional sweating responses of medical students during a practical 
examination were conducted to determine whether forehead sweating could be applied, as a 
substitute for palmar sweating, for the measurement of mental strain when both hands were 
required for the task [173].  The majority of students monitored showed bursts of sweating 
during particularly difficult sections of the task and students who failed the first attempt 
showed elevated sweating during the second. Careful attention was paid to the ambient 
temperature and humidity during the experiment leading to the conclusion that increases in 
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forehead sweating were directly related to the emotional stress experienced by the participant 
[173].   
A review of the literature has established that emotional stress is accompanied by a sweating 
response in certain areas of the human body. Based on this it can be proposed that the VOC 
profile associated with the skin in these regions will change during emotional stress. Several 
studies have indicated the potential for the forehead as a location for monitoring emotional 
sweating due to mental strain [171-173].  As the palms and axillae were inaccessible due to other 
sampling constraints in this study the forehead was chosen for sampling of skin VOCs.  
4.3.3.2. Skin sample collection and analysis 
Skin VOC profiles were recovered using the PDMS Skin Patch as described in Section 3.2, the 
Skin Patch was located centrally on the participant’s forehead with a sampling time of 30 min. 
Sampled Skin Patches were then sealed into empty, inert coated stainless steel 3.5” x ¼” 
thermal desorption tubes and stored at -80 ºC until analysis. The analytical instrument 
parameters employed in this study are detailed in Tables 3.6 and 3.7, GC programme 2 was 
used in the analysis of both skin and breath samples.  
As participants were asked to fast on the morning of each study visit and each visit was of 
approximately 1.5 hr duration only two study visits were scheduled per day. The first visit 
commenced at 9 am and the second at 11 am so the sampling campaign would span a 
minimum of 20 working days and in fact was a total of 6 weeks in duration. As discussed in 
Section 3.2.3 a skin sample can be confidently stored at -80 ºC for a maximum of 21 days with 
the current protocols and so the sampling and analysis campaigns were run concurrently.  
 
4.4. RESULTS AND DISCUSSION 
4.4.1. Blood pressure and heart rate 
Average observations from collated heart rate and systolic and diastolic blood pressures clearly 
show responses to the PASAT and neutral interventions, shown in Figure 4.1. An autonomic 
nervous system response to the PASAT intervention is evident when observing both BP and HR 
whereas no discernible change was observed for the neutral intervention, providing compelling 
evidence for the applied stressor eliciting the predicted physiological responses.  
 
4.4.2. Physiological response score 
The participants’ physiological responses to the PASAT (PSRP) and neutral interventions (PSRN) 
were scored on the basis of observed changes in their systolic blood pressure and heart rate. 
This scoring system was devised by Turner et. al and is reproduced here with  his permission. 
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The method used to compute the scores summarised in Table 4.1 and Figure 4.1 [63] can be 
found in Appendix 3. 
 
 
Figure 4.1 Heart rate and blood pressure data depicting evidence of a physiological response to 
induced psychological stress. Left, Average responses for systolic blood pressure (top) 
and heart rate (bottom) over the 70 minute PASAT (solid line) and relaxing music 
(dashed line) interventions. 0-23 min pre intervention baseline, 24-48 min intervention, 
49-72 min post intervention recovery period. The error bars designate the 95% 
confidence limit on the mean. Right, box-whisker summaries of the physiological stress 
response (PSR) scores classified by male stressed and neutral interventions (MS and 
MN) and female stressed and neutral (FS and FN) and the total group stressed and 
neutral results (TS and TN). Figure reproduced from reference 62 with the author’s 
permission. 
The PSR sought to emphasise the cardiovascular responses to the intervention and relate 
them to the baseline measurements.  The scores were framed to give a higher score to 
participants exhibiting the largest changes in systolic blood pressure and heart rate during the 
intervention. The PSR scores are summarized in Table 4.1 where PSRP is the score for the 
PASAT intervention and PSRN the score for the neutral intervention. PSR is the neutral score 
subtracted from the PASAT score and for 14 out of the 15 participants PSR is positive. This 
indicates a greater physiological response to the PASAT than the neutral intervention for these 
participants, consistent with the individuals experiencing stress during the PASAT intervention 
period.  
 
Pre-intervention
baseline
Post-intervention
recovery
Intervention
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Table 4.1 Physiological response scores to the PASAT (PSRp) neutral (PSRN)interventions, 
computed based on cardiovascular responses and reproduced from reference 63.  
ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
PSR P 0.9 30.3 12.9 56.7 26.1 74.2 87.6 84.5 19.7 149 34 233 40.8 27.5 72.6 
PSRN 5.3 1.6 7.4 1.9 2 3.2 15.5 5 4.2 18.6 7.7 2.7 1.2 4.5 1.4 
ΔPSR -4.4  28.7 5.5 54.8 24.1 15.5 72.1 79.5 71 130 26.3 230 39.6 23 71.2 
 
4.4.3. Chromatographic data 
Gas chromatographic-mass spectrometric (GC-MS) data was processed following the workflow 
described in Section 3.5 to produce a data-matrix. A total of 5 samples were lost due to a 
combination of failures in instrumentation or storage and, due to the randomized cross-over 
study design, this led to the exclusion of the other intervention for those participants. The final 
data set contained the data from 15 participants. VOCs were excluded from the matrix if they 
were found to be present in field blanks or were found in less than 30% of observations. This 
resulted in a skin VOC matrix of 30 observations (15 participants) and 40 variables (VOCs). 
Figure 4.2 shows example chromatographic data for a single participant that has been aligned 
by retention index and undergone dynamic background compensation.  
 
Initially partial least squares discriminant analysis (PLS-DA) was applied to the pareto scaled 
matrix and an S-plot generated. This S-plot, shown in Figure 4.3, indicated 4 candidate 
variables with significant contributions to differences between the profiles from the two 
interventions. Subsequent unsupervised principle component analysis (PCA) of these four 
variables enabled evaluation of the separation between the two interventions based on those 4 
variables. The principle components identified exhibited 57% (PC1) and 27% (PC2) of the total 
explained variance of the data set. It was not possible at this stage to comment on the 
sensitivity and selectivity of the PCA as there seems to be some ambiguity over the clustering 
as shown in Figure 4.4; 87% of relaxed observations appear to sit within one cluster, whilst 
87% of stressed observations sit in another. 3 observations, 2 relaxed and 2 stressed are 
located in a central region and it is unclear whether they belong to either of the existing 
clusters or form their own (Figure 4.4). This will be explored in more detail later in this Chapter. 
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Figure 4.2 Example dynamic background compensated, retention  index aligned skin TIC chromatograms from a female participant after the neutral 
intervention (top) and the PASAT (inverted), and a field blank (offset, grey).  
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Figure 4.3 The loadings S-plot generated from the PLS-DA model for the metabolomic comparison 
between the PASAT and the neutral intervention skin VOC samples. The four variables 
highlighted (solid dots) at the extremes of the S-plot indicate potential markers sensitive 
to the PASAT intervention.  
 
 
Figure 4.4 Unsupervised principle component analysis (PCA) of four potentially stress sensitive 
compounds identified from PLS-DA of skin VOC samples from PASAT and neutral 
interventions. Red markers denote the stressed condition and green the relaxed, 87% of 
stressed observations lie in one cluster, 87% of relaxed in another, 4 observations are 
unassigned. 
Box-whisker plots were constructed from peak area responses for σ1 – σ4 in the stressed and 
relaxed states. The up-regulation of σ1 and σ2 in the stressed state and σ3 and σ4 in the 
relaxed state is clearly demonstrated in Figure 4.5.  
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Figure 4.5 Box and whisker plots for the 4 stress sensitive skin VOC’s identified by PLS-DA; the 
annotation _R denotes responses during the relaxed state and _S the stressed. Peak 
areas have been normalised so that the median of the relaxed phase is equal to 1, 
outliers are represented by the solid circles. 
Receiver-operator characteristic (ROC) curves were constructed for the four candidate stress 
sensitive VOCs to determine the accuracy with which their responses predict the stressed 
state. Area under the curve (AUC) values were calculated from the ROC curves shown in Figure 
4.6.  AUC for σ1 and σ2 for predicting a stressed state were 0.813 and 0.852 respectively 
indicating that the level of these compounds is a good test for stress, AUC values for σ3 and σ4 
for predicting a stressed state were 0.102 and 0.071 respectively indicating that these would 
be worthless for predicting a stressed state. For the prediction of an unstressed state σ3 and 
σ4 gave AUC values of 0.898 and 0.929 respectively again indicating a good test for the 
unstressed state.   
114 
 
 
Figure 4.6 Receiver – operator characteristic curves for 4 candidate PASAT sensitive skin VOCs. A 
and B show curves for up-regulated compounds α1 (A) and α2 (B) predicting a stressed 
state. C and D show curves for down-regulated α3 (C) and α4 predicting an un-stressed 
state. 
The candidate markers were tentatively identified based on spectral matching between their 
deconvolved mass spectra and the NIST mass spectral database (NIST 11) and a satisfactory 
match between the experimentally determined and published theoretical Kováts retention 
index. The criteria for these matches are detailed in Section 3.5.4.  
Table 4.2 lists the library entry for each candidate marker, as described in Section 3.5.4 and 
the tentative identification. The deconvolved mass spectrum for each peak is listed as follows:  
 
m/z of the base peak (Intensity normalized to 999), m/z of second most intense spectral peak 
(Intensity normalized relative to the base peak of 999),….. 
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The quality of the spectral match with the NIST mass spectral database is generated by NIST 
11 as two scores: a forward (F) and a reverse (R) match. The ‘forward’ match score is the 
match factor for a direct comparison between the unknown spectrum and the library spectrum. 
The ‘reverse’ match score is the match factor for the unknown and the library spectrum 
ignoring and peaks in the unknown spectrum that are not present in the library spectrum. Both 
scores are calculated based on a modified cosine of the angle between the spectra [174], a 
perfect match returns a maximum score of 999, a result with no peaks in common returns a 
score of 0. Generally a score of >900 is an excellent match, 800 – 900 a good match and 700 
– 800 a fair match.  
Computation of the observed retention index value (O) is described in detail in Section 3.5.3, in 
Table 4.2 the expected retention index value (E) is the estimated Kováts retention index for the 
library match generated by NIST.  
As yet it has not been possible to confirm these assignments by comparison of retention index 
and mass spectra with pure standards.   
Table 4.2 Tentative identification of PASAT sensitive skin compound σ1-σ4, including deconvolved 
mass spectra of the unknowns, forward (F) and reverse (R) NIST spectral match factor 
and observed (O) and expected (E) retention indices for the unknown and library match 
respectively. 
Ref Name / Library Entry Deconvolved Mass Spectra NIST 
Match 
(F/R) 
Retention 
Index 
(O/E) 
σ1 Benzoic Acid 
Sk-1262-105-122-77-51 
105 (999), 122 (857), 77 (700), 51 (357) 866 / 924 1262 / 
1271 
σ2 n Decanoic Acid 
Sk-1380-60-73-41-43 
60 (999), 73 (920), 41 (508), 43 (480) 764 / 782 1380 / 
1385 
σ3 p Xylene 
Sk-862-91-106-105-77 
91 (999), 106 (600), 105 (260), 77 (125) 914 / 914 862 / 872 
σ4 3 – Carene 
Sk-995-93-91-77-79 
93 (999), 91 (560), 77 (320), 79 (298) 872 / 879 995/ 1010 
 
Example responses for these four compounds from a female participant (participant 4) are 
shown in Figure 4.7.  
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Figure 4.7 Base peak extracted ion chromatograms (EIC) from a single participant for the candidate 
stress sensitive skin VOC σ1 (m/z 105),  σ2 (m/z 60), σ3 (m/z 91) and σ4 (m/z 93) . EIC 
from the PASAT session (solid line) are overlaid with those from the neutral session 
(dashed line) for each candidate.  
The scores plot produced from unsupervised principle component analysis showed some 
ambiguity in the clustering with 4 observations lying between the two distinct clusters, two from 
the stressed and two from the relaxed states. In an effort to better classify these observations 
as belonging to one group or the other a dendrogram was constructed. Distances between 
clusters were calculated by Ward’s method which joins groups so that the smallest possible 
change in a given measure of heterogeneity is achieved. In this way the most similar clusters 
are joined minimising the within cluster variance with each linkage [153]. 
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Figure 4.8 A dendrogram constructed from unsupervised PCA of 4 candidate stress sensitive skin VOCs to determine the degree of similarity between 
stressed and unstressed states. Left: Dendrogram constructed from scores and loading from unsupervised PCA showing good clustering for 
the relaxed and stressed states. The solid green bars indicate relaxed observations and the dashed red stressed; the length of the vertical 
bars indicates similarity with longer bars denoting a reduction in similarity. Two relaxed observations exhibit more similarity with the stressed 
than the other relaxed states and can be found to the right of the dendrogram. Right: unsupervised PCA from Figure 4.4 redrawn to show the 
4 previously unassigned observations now associated with the ‘stressed’ cluster based on information from the dendrogram.  
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The dendrogram constructed from PCA of the four candidate markers from this study shows 
good clustering for the neutral and stressed states, with two participants from the neutral 
condition sitting within the stressed cluster (Figure 4.8). As observed in Figure 4.4, the scores 
plot shows two stressed observations, participants 3 and 5, and two relaxed observations, 
participants 3 and 6, that are not clearly associated with one cluster or the other. The 
hierarchical clustering depicted in the dendrogram indicates that these 4 observations should 
be included in the ‘stressed’ cluster, the implication being that participants 3 and 5 were not 
relaxed during the neutral intervention.  
 
4.4.4. Comparison with breath 
An in-depth discussion of the results from the breath samples [62] does not form part of this 
thesis. Conceptually the prospect of injury-free, non-invasive breath sampling for metabolic 
investigation is attractive. However isolation of the low-concentration endogenous VOCs in 
exhaled air requires representative sampling of the alveolar, or end-tidal, portion of exhaled 
breath and the challenges associated with this were discussed in Section 1.1.3. The principle 
challenge with collecting breath samples when compared with skin samples is the additional 
level of complexity in the sampling procedure, and the necessity for specialised equipment to 
ensure a reproducible and representative end-tidal breath fraction is sampled. In this study an 
adaptive breath sampler, described in detail elsewhere [63] was used to achieve this. 
The adaptive breath sampler is specialist instrumentation requiring accompanying utilities such 
as power and a supply of clean compressed air. The operator needs to be a trained scientist, 
and as such despite many advantages over blood and urine based approaches, does not 
completely fulfill the criteria for the ideal non-invasive sampler, Section 1.1.3. Breath sampling 
is technically difficult and the sampling itself requires trained personnel and is not self-
administrable. 
The Skin Patch was well received by participants and no adverse effects were reported. It is 
unobtrusive, simple to use, self administrable depending on sampling site, does not restrict the 
participant to one location during sampling, requires no external power or other utilities and is 
easily transported and stored allowing for batch sampling in–field and off-line analysis. In many 
regards the Skin Patch fulfils the criteria for the ideal non-invasive diagnostic tool. The question 
remains as to whether any biologically significant information can be recovered from skin VOC 
profiles. 
Visual inspection of skin and breath chromatograms from the same participant in this study 
reveals approximately 100-150 more compounds to have been recovered from the skin; this 
becomes particularly apparent for higher molecular weight compounds which are less likely to 
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be found in exhaled breath than on the skin surface. Figure 4.9 shows example skin and 
breath samples from one participant in this study which have been aligned by retention index, 
it is important to note that these samples were analysed on different analytical systems and so 
a comparison of absolute response is not possible. 
 
Figure 4.9 Example skin and breath VOC TIC chromatograms from a single participant. (Top) 
Example breath VOC profile shown at 50 fold magnification and (Bottom) example skin 
VOC profile from the same participant shown at 10 fold magnification, both 
chromatograms are shown with a maximum intensity of 200 M Counts. The shape of the 
profiles demonstrates the affinity of the PDMS Skin Patch for higher molecular weight 
semi-volatile compounds whilst the breath profile is most rich towards the more volatile 
end of the chromatogram.  
A suite of candidate stress-sensitive biomarkers was generated from the breath study following 
an analogous work flow to that described above for the skin data. This facilitated easy 
interrogation of the skin VOC profiles to determine whether the breath markers were present in 
the emanations from the skin and, if so, did they exhibit any changes associated with the 
stress intervention? Tables 4.3 and 4.4 detail the proposed stress sensitive markers and their 
retention index values in both skin and breath sample compared to the theoretical value (NIST 
11).  
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Table 4.3  Proposed stress sensitive breath markers, from reference 62, and their experimentally 
determined retention index values in skin and breath samples compared with 
theoretical retention indices from NIST.  
Breath Marker BRI SkRI NIST RI 
Indole 1286 Not Found 1276 
2-hydroxy – 1 - phenylethanone 1063 1075 1272 
2-methylpentadecane 1527 1483 1548 
Unknown terpene 951 995* N/A 
Benzaldehyde 976 955 982 
2-ethylhexan-1-ol 1019 993 995 
 * Gives good spectral match with σ4, proposed 3-Carene Figure 4.10 
Table 4.4 Proposed stress sensitive skin markers and their experimentally determined retention 
index values in skin and breath samples compared with theoretical retention indices 
from NIST.  
Skin Marker BRI SkRI NIST RI 
Benzoic Acid 1195 1262 1271 
n-Decanoic Acid Not Found 1380 1371 
p-Xylene 903 862 872 
3-Carene 951 995 1010 
 
 
None of the compounds identified as changing in response to the PASAT in the skin study were 
found to change in the breath data. Two PASAT sensitive breath compounds, 2-ethylhexan-1-ol  
and the unknown terpene, Figure 4.10, now tentatively identified as 3-carene, were also found 
to change in the skin samples.  
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Figure 4.10 Mass spectra of an unidentified terpene compound found to be down-regulated in both 
breath and skin VOC samples after the PASAT intervention. Top: mass spectrum for the 
unidetntified terpene with a etention index of 951 from the breath study [62]. Inverted: σ4 
with RI 995, tentatively identified as 3-carene, from the skin study. 
The breath samples from this study were analysed using a different TD-GC-MS instrument fitted 
with a 30 m column, of the same stationary phase, film thickness and internal diameter, as 
opposed to the 60 m column used in the skin analysis. Using the workflow described in Section 
3.5 it was possible to compare data generated from these studies using retention index 
alignment where a maximum drift in retention index between compounds on the two systems 
was 67 RI units. The overall duration for this study, for analysis of skin and breath samples, 
was 19 weeks during which instrument maintenance was necessary on several occasions and 
the retention indexing protocol described in Section 3.5.3 was needed to correct for changes in 
retention time. 
The biological origin of the candidate stress sensitive VOCs observed from skin and breath 
samples is not well defined and their presence in the VOC profiles may result from a 
combination of endogenous and exogenous origins. It is not possible to postulate metabolic 
pathways and roles for these compounds as part of a stress sensitive response in the human 
body. 
It is interesting to note that only two VOCs were observed as potentially stress sensitive in both 
skin and breath. 2-ethyl-hexan-1-ol has been reported as a potential marker for lung cancer in 
human breath and was found to decrease in response to psychological stress in breath [62] [175] 
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, whilst in skin profiles it was found to increase, whether this phenomenon is due to an 
increase in blood flow under the skin surface with the increase in cardiovascular activity 
accompanying stress leading to faster clearance from the blood, or a change in metabolic 
processes as a part of the ‘fight or flight’ response or due to something else entirely is unclear 
and not the focus of this study. The unidentified terpene from the breath study shows good 
spectral matching with σ4 from the skin study and the retention index values are only 17 units 
outside the tolerance set in this study, giving a suggestion that these may be the same 
compound; however without analysing a pure standard it is not possible to confirm this 
suspicion. What is evident, however, is that for both compartments a volatile terpene 
compound was shown to be down–regulated as a response to the stress intervention. The 
origin of terpenes in breath and skin profiles is not well defined and may not be endogenous. 
Terpenes occur naturally in foodstuffs [176], yet the data from this pilot study would indicate that 
they are perhaps involved in the metabolic processes associated with the body’s response to 
psychological stress.   
Benzoic acid has been reported as a metabolite of both benzaldehyde and toluene and studies 
evaluating the safety of benzaldehyde use in cosmetic products list benzoic acid as its primary 
metabolite [177]. Boehlein et al reported the oxidation of benzyl alcohol to benzoic acid in skin 
by alcohol dehydrogenase with benzaldehye as the presumed intermediate [178] while Turner et 
al reported a down regulation of benzaldehye in breath with the PASAT stress intervention [62], 
suggesting that oxidative metabolic pathways may be increasing in activity with stress. 
Occurring commonly in food stuffs, benzaldehyde is readily absorbed through the skin and 
lungs and, along with its metabolites, distributes to all well-perfused organs and does not 
bioaccumulate in any one tissue type. Its primary metabolite is benzoic acid, which conjugates 
with glycine or glucaronic acid and is excreted in urine. Oxidation of benzyl alcohol and 
benzaldehyde appear to be the most commonly documented source of benzoic acid in urine, 
blood and on skin [177-179]. Benzoic acid has also been reported as a biomarker for asthma and 
lung cancer in exhaled breath [180] [181]. 
A wide range of short (C2-C5) and medium (C6-C11) chain volatile fatty acids are frequently 
reported in apocrine sweat as a source of malodour. These were commonly understood to 
carried to the skin surface as glutamine conjugates and released by bacterial action [182]. A 
major route to short and medium chain volatile fatty acids in axillary secretions was shown to 
be partial catabolism of methyl branched longer chain fatty acids by the Corynebacterium 
bacteria; resident at highest levels in the axilla and on the forehead [183] [184].  Structurally 
unusual fatty acids such as these methyl branched analogues are reported to originate from 
triacylgylcerol component of sebum, and from apocrine sweat, and are released by bacterial 
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lipases. Up-regulation of medium chain fatty acids such as n-decancoic acid reported in this 
study may be the result of an increase in apocrine sweat, elevated bacterial action with 
increased skin temperature or as the end product of a longer metabolic change increasing the 
secretion of methyl branched fatty acids precursors to the skin surface [182] [183]. Methylated 
hydrocarbons have been reported as markers for oxidative stress and numerous compounds in 
this class have been proposed as biomarkers for cancers [65] [185]. There is no evidence linking 
these to the up-regulation of skin surface volatile fatty acids, in particular decanoic acid, 
observed in this study. This once again indicates that links between psychological stress and a 
potential increase in oxidative metabolic pathways warrants more in-depth investigation.  
The source of xylene on skin is likely to be at least partly exogenous; exposure is generally via 
household cleaning products, vehicle exhausts and cigarette smoke [186]. Xylenes are highly 
lipophillic so are absorbed readily through the skin and distribute quickly throughout the body 
[187], p-xylene has also been reported as a biomarker for lung cancer in exhaled breath [181].  
 
4.5. CONCLUSIONS 
This pilot study set out to evaluate the use of the Skin Patch sampler for metabolomic studies. 
Observations during sampling showed the Skin Patch to be comfortable for participants and 
simple to use. The Skin Patch was also easy to combine with other sampling techniques and 
allowed for short term storage and off-line analysis of skin samples.  
This pilot study has shown that the VOCs recoverable from human skin are wide ranging both in 
the class and concentration of compounds. Ubiquitous siloxane compounds may be exploited 
as internal standards for retention indexing, facilitating successful alignment of 
chromatograms analysed over several months, while strict control of the analytical instrument 
performance with regular external quality control standards could enable semi-quantitative 
comparisons between peak area responses. Evaluation of the retention indexing strategy 
revealed greater errors in retention index accuracy for those compounds eluting during the 
retention time periods when the GC oven temperature ramp rate (GC programme 2) was 
changing; this was observed both between skin and breath samples on the two analytical 
systems and between skin samples run on the same instrument. As a result subsequent 
studies employed a linear temperature programme to improve accuracy in retention index 
alignment with no loss in chromatographic quality (GC programme 3). 
While a small number of samples were excluded due to failures in storage or instrumentation, 
another set were excluded based on visual inspection of the chromatograms; significant drops 
in baseline intensity or skewing of mass spectra, so that the response of higher m/z values was 
significantly reduced, was observed after particularly high concentration samples and 
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attributed to ‘dirtying’ of the ion source. If this was observed a QC standard was analysed and 
the decision taken whether to proceed or pause analysis to perform maintenance based on the 
responses across the QC range, this inevitably caused the suspect sample data to be excluded 
from data processing. The desirability of introducing an internal standard to reduce the 
subjective nature of this screening process became apparent during this study and will be 
explored in Chapter 6.  
Stress changes in the VOC profile recovered from the skin of healthy volunteers were observed 
in this pilot study. Four compounds, present in >30% of observations, were found to contribute 
significantly to these changes and a tentative correlation with physiological response to 
induced stress was observed.  
Two compounds were found to increase with stress and these have been tentatively identified 
as benzoic acid and n-decancoic acid. The biological origin of benzoic acid has yet to be 
completely described. Literature evidence suggests its presence on skin to be primarily due to 
oxidation of benyl alcohol and benzaldhyde. The biological origin of the two down-regulated 
VOCs, tentatively idenitifed as p-xylene and 3-Carene, is as yet unclear.  
Comparison of these results with breath samples generated from the same study but analysed 
on a different TD-GC-MS system has allowed evaluation of the workflow described in Chapter 3 
and demonstrated the ease with which data from different studies, systems or even 
laboratories can be compared when this protocol is adhered to. This study has also highlighted 
the weaknesses with the retention index alignment approach for GC temperature programmes 
with more than one ramp rate and this was addressed for subsequent studies.  
Whilst the majority of the most stress sensitive skin compounds were present in breath, and 
vice versa, only two compounds were found to change significantly with stress in both 
compartments. The implications of this observation could be wide-ranging and varied and it is 
not the focus of this study to compare the chemistries associated with the two sample types. It 
is perhaps a good point to highlight that, whilst the compounds identified as changing in 
response to stress were shown to be the most statistically significant in these studies, it does 
not necessarily follow that they are the most biologically significant and there may be a sub-set 
of data showing better correlations between breath and skin.  
The Skin Patch has been demonstrated to perform reliably in a pilot metabolomic study and 
generate data allowing classification of skin profiles from stressed and relaxed individuals. The 
ease of use, transport and storage of the Skin Patch has distinct advantages over breath 
sampling for larger or more remote studies and it fulfils more of the criteria described in 
Section 1.1.3 for the ideal non-invasive sampler. The potential for confounding factors with the 
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skin sampling will always be much higher than with breath samples, when such samples 
include only the end-tidal portion of an exhaled breath.   
The possible correlations observed with down-regulation of benzaldehyde in breath and up-
regulation of its well known oxidation product benzoic acid in skin, as well as the down-
regulation of terpene compounds in both compartments, raise interesting questions about the 
transport of biological VOCs into and out of skin and breath. These merit further 
characterisation studies of their own. At this stage it may be advantageous to operate with the 
working hypothesis that skin and breath profiles are complementary, with the possibility that 
markers identified from breath may undergo biotransformations before reaching the skin 
surface that could be applied to clinical screening scenarios in a more targeted approach – 
enabling all the advantages of the Skin Patch to be employed in the larger scale studies.  
The continuation of this work into a larger panel study and investigation of other stressors will 
build on the initial observations made here and improve understanding of skin VOC profiling as 
a potentially useful, non-invasive measurement of human function.  
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5 THE EFFECT OF INDUCED PHYSIOLOGICAL STRESS ON VOC 
PROFILES OF YOUNG ADULTS: COMPARING SKIN AND SALIVA 
SAMPLING IN A PILOT STUDY 
5.1. INTRODUCTION 
Extending the application of a ‘stressor’ as a surrogate for disease state, this study employed a 
physical stress task which enabled a different set of physical and biochemical processes to be 
evaluated, and for the first time to include the saliva sampling protocol developed in Section 3 
in a pilot metabolomic study. The primary research questions were: 
 Was it possible to observe a measurable change in skin and saliva VOC profiles 
attributable to physical stress?  
 Which of the two approaches might yield the “best” approach to physical stress 
measurements and, by implication, other perturbations of metabolism?    
 Would it be possible to discern any metabolic links between the two profiles? 
 Would there be any benefit in combining the data sets? 
 
 
5.2. SAMPLING AND ANALYSIS CAMPAIGN 
This study was devised and carried out in collaboration with Matthew Turner, Pareen Patel and 
Aditya Malkar. The workflow incorporated exhaled breath for VOC analysis, drooled saliva, 
whole blood and urine for elemental and metabolite analysis as well as skin and saliva for VOC 
analysis. A detailed study timeline may be found in Appendix 4. The results of the studies 
based on the additional sample sets are discussed elsewhere [46], and are beyond the scope of 
this thesis. The study was carried out in collaboration with Prof. Ronald Maughan and Dr Phillip 
Watson  of the School of Sport, Health and Exercise Sciences at Loughborough University.  
The sampling campaign ran over 5 consecutive days in an environmentally controlled chamber, 
in the School of Sport Health and Exercise Science at Loughborough University. Ten healthy 
non-smoking adult males aged 18-35 volunteered to participate and attend a single 2 hr long 
study visit. The study session was run over four consecutive phases, each 30 minutes in 
duration:  
 Phase A – Baseline measurements, pre-exercise phase. (0 – 30 min) 
 Phase B – Exercise on cyclometer with a workload of 2 W/kg. (30 – 60 min) 
 Phase C – Recovery phase 1, post exercise rest phase. (60 – 90 min) 
 Phase D – Recovery phase 2, post exercise rest phase. (90 – 120 min) 
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Baseline measurements and samples were taken at the start of the session (Phase A) before 
physical stress was induced by peddling on a cyclometer at a workload of 2 watts/kg of body 
mass for 30 min (Phase B). At the end of the 30 min exercise intervention sampling and 
monitoring took place over two consecutive 30 min recovery phases, during which the 
participants rested as their metabolism returned to their pre-intervention baseline physical 
state (Phases C and D). 
VOC samples were obtained following the protocols described in Sections 3.2 and 3.3; skin 
VOC samples were taken during all four phases and saliva during phases A, C and D. Each 
participant’s heart rate was monitored throughout the study visit and recorded at 10 minute 
intervals during rest phases and 5 minute intervals during the exercise phase.  
Saliva VOC samples were stored at 4 ºC and analysed within 24 hours of sampling while skin-
patches were stored at -80 ºC for a maximum of 21 days before analysis. The analytical 
protocol is described in Section 3.4, GC programme 3 was employed for this study.  
 
5.3. RESULTS AND DISCUSSION 
The skin and saliva sampling protocols were easy to implement and work into a complicated 
study timeline and well tolerated by volunteers. The simplicity of these sampling techniques 
was highlighted when deployed in the field alongside the others sample collection techniques; 
breath sampling required transportation of an air compressor, blood sampling required a 
trained technician to be available and further processing before storage. Urine and drooled 
saliva samples also required immediate processing prior to storage and transport. One 
researcher was therefore dedicated to processing blood, urine and drooled saliva samples 
throughout each study visit totaling 20 hours work in a 10 participant pilot study. Skin & saliva 
VOC samples, however, simply required immediate transfer to thermal desorption tubes and 
temporary storage on dry ice until return to the laboratory within 6 hours.  
5 biological compartments were sampled in this study and, despite the heavy sampling burden, 
a rigorously controlled study timeline enabled a unique set of samples to be obtained. 
Metabolomic analysis of the profiles from these samples will provide insight into the effect of 
physical stress on elements, VOCs, SVOCs and non-volatiles in skin, saliva, breath, urine and 
blood.  The results from these will be combined to give a description of the metabolic changes 
associated with physical stress. The stitching and global analysis of the full sample suite is 
beyond the scope of this thesis. This chapter will focus on VOCs and SVOCs from skin and 
saliva samples.  
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5.3.1. The effect of induced physiological stress on VOC profiles from human skin 
Upon visual inspection of the skin VOC profiles across the four phases the effect of the exercise 
intervention on the dominant features is evident. Figure 5.1 shows the raw TIC chromatograms 
from one participant for skin samples from Phases A – D. An increase in concentration of 
compounds eluting between 30 and 40 minutes is clearly visible from Phase A, the baseline 
phase, to Phase B, the exercise intervention. There is evidently a large amount of information 
obscured in the unresolved chromatography in this region and this will be discussed further in 
Chapter 6.  
 
Figure 5.1 Unprocessed TIC chromatograms of skin samples from a single participant subject to a 
physical stress intervention. Phase A (bottom) is the pre-exercise baseline 
measurement, Phase B (offset at 60 M Counts) was sampled during exercise, Phase C 
(offset at 190 M Counts) is the first 30 minute recovery period after exercise and Phase 
D (offset at 290 M Counts) is the second 30 minute recovery period immediately 
following Phase C.  
 
A pareto-scaled data matrix of 107 variables and 20 observations, derived using the workflow 
described in Section 3.5, populated with peak area responses from the 10 Phase A and 10 
Phase B observations was subject to PLS-DA and the resultant S-Plot is shown in Figure 5.2. 
Eight variables from the extremes of the S-Plot were selected as candidates differentiating 
between participants in a baseline and a physically stressed state.  
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Figure 5.2 The loadings S-plot generated from the PLS-DA model for the metabolomic comparison 
between pre-exercise (Phase A) and during excerice (Phase B)  skin VOC samples. The 
variables highlighted (solid dots) at the extremes of the S-plot indicate potential markers 
sensitive to the exercise intervention. 
 
The candidate markers highlighted in Figure 5.2 were tentatively identified based on spectral 
matching between their deconvolved mass spectra and the NIST mass spectral database (NIST 
11) and a satisfactory match between the experimentally determined and published theoretical 
Kováts retention index. The criteria for these matches are detailed in Section 3.5.4. Table 5.1 
lists the library entry for each candidate marker, as described in Section 4.3.3 and the 
tentative identification. 
Table 5.1 Tentative identification of exercise sensitive skin compounds α1-8, including 
deconvolved mass spectra of the unknowns, forward (F) and reverse (R) NIST spectral 
match factor and observed (O) and expected (E) retention indices for unknown and 
library match respectively. 
Ref Name / Library Entry Deconvolved Mass Spectra N (F/R) RI (O/E) 
α1 9-Octadecanal 
Sk-2009-55-69-67-54 
55 (999), 69 (400), 67 (380), 54 (307) 770 / 823 2009 / 
2007 
α2 E-2-Nonen-1-ol 
Sk-1121-57-41-43-68 
57 (999), 41 (669), 43 (550), 68 (230) 854 / 849 1121 / 
1120 
α3 2-Butanoylfuran 
Sk-1057-95-110-138-123 
95 (999), 110 (560), 138 (100), 123 (45) 820 / 799 1057 / 
1077 
α4 Tridecanoic Acid 
Sk-1659-73-60-43-55 
93 (999), 91 (560), 77 (320), 79 (298) 872 / 879 1659 / 
1670 
α5 n-Decanoic Acid 
Sk-1402-60-73-55-129 
60 (999), 73 (900), 55 (400), 129 (350) 786 / 787 1402 / 
1385 
α6 Palmitoleic Acid 
Sk-1929-55-69-83-97 
55 (999), 69 (810), 83 (620), 97 (480) 903 / 897 1929/ 
1936 
α7 2, 3-Dichlorobenzoic Acid 
Sk-1521-173-190-175-192 
173 (999), 190 (810), 175 (635), 192 (500) 935 / 941 1521 / 
1510 
α8 Octanoic Acid 
Sk-1220-60-73-55-101 
60 (999), 73 (630), 55 (375), 101 (240) 907 / 913 1220 / 
1197 
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Unsupervised PCA was applied to a secondary matrix constructed of peak area responses for 
the eight variables (candidate compounds) in all four experimental phases (40 observations) 
the scatter plot generated is shown in Figure 5.3 and shows that these compounds 
differentiate between the skin VOC profiles recovered across the 4 experimental phases.  
 
 
Figure 5.3 Unsupervised principle component analysis (PCA) of eight candidate exercise sensitive 
VOC selected from PLS-DA of skin VOC samples. Blue dots show the pre-exercise 
baseline measurements (Phase A), red triangles show the exercise phase (Phase B), 
black squares show the first recovery stage (Phase C) and inverted green triangles show 
the second recovery phase following on from Phase C (Phase D).  
 
Principle components 1 and 2 identified here exhibit 38 and 28% respectively of the total 
explained variance of the data set across all 4 experimental phases. The perturbation of the 
skin VOC profile with physiological stress is evident as is the subsequent relaxation towards the 
baseline state with each recovery phase. Closer inspection of the raw peak area responses for 
each of the candidates reveals two behaviour types; one sub-set of candidates (subset A) 
exhibits a change with physical stress that tends to relax towards the baseline level by Phase D 
shown in Figure 5.4. The remaining candidates (subset B) also exhibit a change with stress, 
although they do not return to the resting state in the timeframe monitored in this study, shown 
in Figure 5.5.  
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Figure 5.4 Box and whisker plots of peak areas for 4 of the execrise sensitive skin VOCs that relax 
towards the baseline response during the monitored recovery phases, C and D. Peak 
areas have been normalised so that the median of the baseline phase is equal to 1. 
 
Figure 5.5 Box and whisker plots of peak areas for 4 of the exercise sensitive skin VOCs for whom 
baseline state is not recovered during recovery Phases C and D. Peak areas have been 
normalised so that the median of the baseline phase is equal to 1. 
Exploration of the set of candidates that relax towards the baseline state indicates these may 
be sensitive to short term, rapid physiological changes associated with exercise, elevated heart 
rate for example. Figure 5.6 explores the correlation between two such compounds; α1 up-
regulated with exercise and α6 down-regulated, and change in heart rate. 
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Figure 5.6 The relationship between percentage change in peak area response and percentage 
change in heart rate for candidate exercise sensitive compounds α1 and α6.  Up-
regulated 1 (black) and down-regulated α6 (red) relationship with HR, dashed lines 
represent upper 95% confidence limit on baseline responses. 
 
Figure 5.6 shows the correlation between global averages of percentage change in peak area 
and percentage change in heart rate over the 4 study phases. Excluding the exercise phase R2 
values for ΔHR (%) against ΔPA (%) ranged from 0.9726 to 0.9899 for subset a, indicating a 
degree of correlation, when phase B is included these graphs appears to plateau. The 
implications of these observations may be that these compounds are up- or down- regulated 
during exercise as the result of a faster heart rate; a combination of vasodilation and higher 
velocity blood flows under the skin surface serve to shorten the pathlength and increase 
concentration gradients between compounds in circulating blood and on the skin surface.  
Not all of the compounds identified as changing between the rest and exercise phases can be 
explained by a higher heart rate and greater volume of blood passing under the skin surface; 
α3, 7 and 8 do not return towards the baseline level during the recovery phases monitored 
while α4 peaks during exercise then drops below the baseline level and remains there for the 
duration of the recovery phases. An equivalent plot to Figure 5.6 for these candidates shows no 
correlation between ΔPA and ΔHR. These changes may be indicative of a longer metabolic 
chain associated with the physical stress that takes longer than the hour monitored post 
exercise to recover; heart rate is not the only factor contributing to changes in skin VOC profile 
with exercise.  
A stress response scoring system was devised by P. Patel which was based on that of Turner et. 
al., Section 4.4.3, and is reproduced here with his permission. A participant’s response to the 
stressor was scored on the basis of body mass index (BMI) and change in heart rate. The 
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equation was designed to normalise responses against baseline heart rate measurements so 
that only change in physiological response influences the score, rather than baseline physical 
fitness.  
 
                                   
   
     
     
Equation 5.1 
 
 
 
Table 5.2 Physical stress response scores (SRS) for each participant. 
ID 1 2 3 4 5 6 7 8 9 10 
SSR 2274 2664 1390 2310 2498 917 2089 2654 3323 3272 
 
 
 
 
To assess the ability of the candidate compound suite to predict the degree of physical stress 
the proportional response (PR) of the up-regulated compounds at each experimental phase 
was calculated as shown in equation 5.2. The PR is computed so that an increase in up-
regulated compounds and / or a decrease in down regulated compounds will give a larger PR 
value.  
 
   
                              
                     
 
∑[    ]
∑[    ]
  
Equation 5.2 
 
Figure 5.7 shows the stress response score (SRS) plotted against the proportional response 
(PR) for each participant during each of the four experimental phases, A – D.  
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Figure 5.7 Stress response score (SRS) plotted against the proportional response of up-regulated 
compounds (PR) at each experimental phase.  A (blue dots), B (red triangles), C (black 
squares) and D (green triangles). A trend line plotted for phase B indicates a weak 
positive correlation between the proportion of up-regulated candidates and stress 
response score.  
Figure 5.7 shows that there is no relationship between the levels of candidate compounds and 
stress response in phases A or D. Phase B is clearly separated from the other phases while 
phase C exhibits a mix of behaviors. A weak positive correlation between PR and SRS is evident 
in phase B and implies that the PR may offer a measure of physical stress.  
The stress response score derived in this study is based only on changes in heart rate and so it 
is, of course, entirely possible that Figure 5.7 simply describes the ability of the candidate 
compounds to predict an elevated heart rate.  
 
5.3.2. The effect of physiological stress on VOC profiles from human saliva 
Saliva VOC samples were obtained following the protocol described in Section 3.3. The saliva 
sampling protocol requires the participant to hold the sampler in their mouths for the duration 
of the sampling period, see Section 3.3, the risk to the participant was deemed too high to 
perform this sampling during the exercise phase, Phase B.  
The exercise phase was excluded from the saliva study, reducing the number of observations 
to 3 per participant: baseline, A, and recovery phases C and D. It is interesting to note here that 
drooled saliva samples from participants post-exercise took up to 3 times longer (>10 minutes) 
to collect and for 2 volunteers it was not possible to obtain sufficient drooled saliva for 
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elements and non-volatile compound analysis in all phases. Whilst the ability to standardise 
sampling times and collect a full sample with the in-situ sampler offers unique advantages over 
passive drool the level of oral hydration is perhaps a factor that should be considered with this 
sampler – is there a point at which only the surfaces of the oral cavity are being sampled and if 
so, to what degree will this alter the physical chemical processes governing sampling? 
 A malfunction of the filament in the ion source of the mass spectrometer during the analysis of 
a sample from participant CZ03 necessitated the removal of data from this participant from 
multivariate analysis. A pareto-scaled data matrix of 144 variables and 18 observations, 
derived using the workflow described in Section 3.5, populated with peak area responses from 
the 9 Phase A and 9 Phase C observations was subject to PLS-DA. The resultant S-Plot is 
shown in Figure 5.8. Seven variables from the extremes of the S-Plot were selected as 
candidates differentiating between participants in the baseline state, and those recovering 
from a physically stressed state.  
 
Figure 5.8 The loadings S-plot generated from the PLS-DA model for the metabolomic comparison 
between pre-exercise (Phase A) and post exercise (Phase C)  saliva VOC samples. The 
variables highlighted (solid dots) at the extremes of the S-plot indicate potential markers 
sensitive to the exercise intervention. 
The candidates were tentatively identified based on spectral matching between their 
deconvolved mass spectra and the NIST mass spectral database (NIST 11) and a satisfactory 
match between the experimentally determined and published theoretical Kováts retention 
index (NIST 11). The criteria for these matches are detailed in Section 3.5.4.  
Table 5.3 lists the library entry for each candidate marker, as described in Section 4.3.3, and 
the tentative identification. 
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Table 5.3 Tentative identification of exercise sensitive saliva compounds β1-7, including 
deconvolved mass spectra of the unknowns, forward (F) and reverse (R) NIST spectral 
match factor and observed (O) and expected (E) retention indices for unknown and 
library match respectively. 
Ref Name / Library Entry Deconvolved Mass Spectra N (F/R) RI(O/E) 
β1 Undecane* 
Sa-1110-57-43-71-85 
57 (999), 43 (900), 71 (500), 85 (293) 840 / 833 1110 / 
1100 
β2 Butyl Carbitol Acetate 
Sk-1405-87-57-43-101 
87 (999), 57 (999), 43 (950), 101 (200) 890 / 865 1405 / 
1408 
β3 2, 3 – dimethyl pyrazine 
Sk-904-67-108-52-66 
67 (999), 108 (999), 52 (105), 66 (100) 893 / 888 904 / 911 
β4 Methyl-pyrazine 
Sk-802-94-67-53 
94 (999), 67 (500), 53 (150) 955 / 907 802 / 807 
β5 Undecanal 
Sk-1346-57--43-55-82 
57 (999), 43 (950), 55 (700), 82 (500) 930 / 932 1346 / 
1305 
β6 (E) – 2 – Tridecen-1-ol 
Sk-1550-57-82-55-67 
57 (999), 55 (530), 82 (400), 67 (350) 855 / 863 1550 / 
1564 
β7 3, 4-dimethyl -2-hexanone 
Sk-836-43-72-57-85 
43 (999), 73 (430), 57 (150), 85 (50) 729 / 805 836 / 824 
* Assignment confirmed with standard. 
Unsupervised PCA was applied to a secondary matrix constructed of peak area responses for 
the seven variables (candidate compounds) in the three experimental phases (27 
observations) the scatter plot generated is shown in Figure 5.9 and shows that these 
compounds differentiate between the saliva VOC profiles recovered across the experimental 
phases.  
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Figure 5.9 Unsupervised principle component analysis (PCA) of seven candidate exercise sensitive 
VOC selected from PLS-DA of saliva VOC samples. Blue dots show the pre-exercise 
baseline measurements (Phase A), black squares show the first recovery stage (Phase 
C) and inverted green triangles show the second recovery phase following on from 
Phase C (Phase D).  
 
Principle components 1 and 2 identified here exhibit 51% and 20% respectively of the total 
explained variance of the data set across all 3 experimental phases. The perturbation of the 
saliva VOC profile with physiological stress is evident in the first recovery phase, C, and in D. 
The scores plot for skin VOC profiles from phases A and D showed no separation whereas for 
saliva there is distinct clustering between baseline and second recovery phase.  
Two observations lie outside the 95% confidence limits for the PCA model as defined by a 
Hotelling’s T2 ellipse in both the baseline and the first recovery phase, these correspond to the 
same two participants in both phases; identified as CZ06 and CZ08. Interrogation of each 
variable reveals these participants to have levels of β5 greater than 3 standard deviations from 
the mean in baseline measurements and β1 the same in recovery 1; this can be clearly seen in 
the variable plots shown in Figure 5.10. At this time there does not appear to be a link between 
these levels and any meta data collected during the study visit. It is interesting to note 
however,  that β1 has been confirmed as undecane whilst β5 has been tentatively identified as 
undecanal; it is not the focus of this study to determine the biological origin or metabolic 
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pathways associated with the candidate physical stress sensitive compounds, however it would 
be interesting to explore any correlations between these compounds in other samples from this 
study. 
 
Figure 5.10 Plots of peak area against observation identity (where the letter denotes experimental 
phase and the number participant ID) for outlier exercise sensitive saliva VOCs β1 and 
β5 identified in Figure 5.9.  The horizontal lines represent limit values with green; the 
mean peak area, black; 2 standard deviations and the red; 3 standard deviations. Whilst 
the population shift between the phases can clearly be seen there are two outlying 
observations for each variable corresponding to participants 6 and 8.  
The two trends observed with skin VOC samples: perturbation followed by relaxation to 
baseline within 60 minutes post exercise and perturbation without relaxation to baseline are 
also evident for saliva VOC profiles, although without a sample for Phase B it is difficult to 
directly compare the kinetics.  
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Figure 5.11 Box and whisker plots of peak areas for the 7 exercise sensitive saliva VOCs identified by PLS-DA. Peak areas have been normalised so that 
the median of the baseline phase is equal to 1. Compounds β1 – β4 are up-regulated in the first recovery phase with respect to the baseline 
and β5 – β7 are down-regulated. 
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Up-regulated β1 and β2 increase post – exercise and return to baseline levels in the second 
recovery phase, β3 and β4 continue to increase across the monitored recovery periods. In 
contrast to observations in skin profiles none of the down-regulated compounds β5, 6 and 7 
shows any indication of returning to the initial baseline levels. Calculated as described in 
Section 5.3.1 plots of SRS against PR for phases A, C and D show no correlation between the 
levels of saliva candidates and the degree of physical stress as described by the stress 
response score.  
 
Figure 5.12 Stress response score (SRS) plotted against the proportional response of up-regulated 
compounds (PR) at each experimental phase.  A (blue dots), C (black squares) and D 
(green triangles).  
The lack of correlation between saliva candidates and the stress response score could lead to 
one of two conclusions; these compounds do not indicate physical stress or the stress 
response score, being based primarily on ΔHR, in fact only gives an indication of increased 
heart rate. Without saliva samples from the exercise phase to compare with to explore this any 
further would be speculation. 
 
5.3.3. Comparison of skin and saliva VOC profiling for tracking metabolic changes 
associated with physical stress 
Skin and saliva VOC profiles appear to change as a result of physiological stress, with two types 
of change observed. The first change type appeared to be related to the change in heart rate. 
Compounds tentatively identified as 9-octadecanal and E-2-nonenal in skin and undecane and 
butyl carbitol acetate in saliva increased, (Figure 5.4 and 5.11) during the exercise phase 
(Phase B) and then reduced during the recovery phases towards the starting conditions. 
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Conversely n-decanoic acid and palmitoleic acid in skin reduced during exercise and then 
increased towards the starting conditions Figure 5.4, no such behaviour was observed for the 
saliva candidates.   
The second type of behaviour was not correlated to heart rate and the changes in candidate 
marker levels developed beyond the duration of the exercise phase and did not return to the 
starting conditions during the duration of the test. For instance 2-butyanoyl furan in skin and  
2, 3 dimethyl pyrazine and methyl pyrazine in saliva increased , and 2, 3-dichlorobenzoic acid 
and octanoic acid in skin and undecanal, E-2-tridecen-1-ol and 2, 4 dimethyl hexanone in saliva 
decreased relative to the starting conditions (Figure 5.5 and 5.11).  
Different candidate stress sensitive compounds were identified in skin and saliva VOC profiles, 
the following sections explore the relative merits of the two approaches and the potential 
implications of the differences in candidate marker panels.  
 
5.3.3.1. Implementation of sampling and analysis protocols 
Both approaches were well tolerated by the participants in this study, neither caused any pain 
or discomfort and researchers found them straightforward and easy to implement. 
Both sampling techniques offer the same advantages in that the sampling methodology is 
inherently simple, and skilled researchers or clinical staff are not required for sampling. The 
sample medium is re-usable, samples require no particular treatment before storage and are 
easy to transport.  
While sampling from the skin surface is straightforward it may be difficult to standardise the 
skin type/condition for every participant.  Skin is not necessarily the same in character at the 
same location in all the individuals in a cohort. The effect of freckles, moles, scars or other skin 
lesions on the VOC profile collected from the skin has yet to be described. Candidate sites for 
sampling that appear to be consistent between individuals need to be tested and verified, from 
the observations in this, and other as yet unpublished studies. The suggested sampling sites 
are the forehead, abdomen and inner forearm. Whether the most consistent sampling sites 
also provide the most relevant information also requires further characterisation.   
The oral cavity is a more well-defined area in terms of reproducibility in sampling site between 
participants and subject to less exogenous interference and in these studies participants were 
excluded if they presented with any oral hygiene problems. Clearly the utility of studying the 
VOC profiles associated with oral lesions, and periodontic disease as well as poor personal 
hygiene is a logical development of this study. One that might yield useful diagnostic markers 
as well as identify the potential confounding VOCs associated with such conditions.  
142 
 
The skin sampling protocol followed in this study requires a sampling duration 6 times as long 
as the saliva sampling. Although this may ultimately be optimised for more targeted studies 
following the current methodologies saliva sampling offers greater time resolution than skin 
sampling. Conversely as the Skin Patch can be comfortably and securely worn, out of sight if 
necessary, participants are able to be sampled whilst carrying out specific tasks in the study 
protocol, such as the exercise intervention described here, or simply continuing with their 
normal daily tasks with minimal interruption which cannot realistically be performed while 
saliva sampling is in progress.  
The nature of the skin sampling allows duplicate or even multiple samples to be obtained 
simultaneously from one participant, whether this is at a range of body sites or to provide 
replicate measurements, it is difficult to comfortably obtain duplicate saliva samples 
simultaneously using the current sampler design.  
In use neither sampling approach has a decisive advantage over the other, and, if the VOC 
profiles are complementary then using both techniques simultaneously with the same 
participant is not a burden. The non-invasive, injury/trauma-free, embarrassment-free nature of 
both sampling techniques combined with the low equipment/consumable overheads and 
straightforward sample storage conditions offer distinct advantages over breath, blood, urine 
and faeces for large scale, remote investigative or diagnostic studies.  
 
5.3.3.2. Which technique generated the highest quality data? 
Visual inspection of skin and saliva VOC profiles reveals information-rich chromatograms, with 
the skin VOC profile being the more complex with wider range of peak intensities. Figure 5.13 
compares the skin and saliva profiles and it is immediately apparent that the Skin Patch yields 
several orders of magnitude in peak intensity. It is necessary to magnify the saliva profile ten 
times before a similar level of complexity is discerned, which makes the levels of artefacts from 
the PDMS samplers of greater concern. The higher recoveries from the Skin Patch may be 
attributed to: the larger volume of PDMS and therefore increased phase ratio relative to the 
saliva sampler; the larger surface area in contact with the sample; the nature of the Skin Patch 
sampling mechanism from the lipid layer on the skin surface providing enhanced pre-
concentration; or the wider range of VOCs on the skin and the high concentrations that arise 
from topically deposited materials; or a combination of some or all of these factors. 
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Figure 5.13 Example skin and saliva VOC TIC chromatograms from a single participant. (Top) 
Example skin VOC profile and (inverted) example saliva VOC profile from the same 
participant shown at 10 fold magnification.. 
When comparing the two techniques the implications of the higher recovery with the skin 
sampler should be explored; higher recoveries and concentration ranges have been observed 
with the Skin Patch – does this mean, therefore, that the skin profile offers a more efficient 
solution to non-invasive sampling?   
It is evident from the skin profile shown in Figure 5.13 that a number of peaks are 
chromatographically overloaded and as a result may not give an accurate representation of the 
levels sampled by the Skin Patch, this can be easily overcome by introducing a split into the 
thermal desorption method. This comes with the sacrifice of the lower intensity, but not 
necessarily less significant, compounds. Re-collection of the split flow onto a tube packed with 
an appropriate sorbent is an elegant solution to the problem of samples within which a large 
concentration range is spanned. The initial sample is run at a ‘high’ split so as not to overload 
the high level compounds, the split flow is collected onto a sorbent tube which can then be 
analysed with a ‘low’ split for maximum sensitivity.  
Recollection of the split portion of a skin sample would allow retention of the maximum amount 
of useful information from these complex samples. Preliminary observations in developing such 
a method using Skin Patch samples has shown the high inter-sample variability with respect to 
the presence and levels of compounds in the profile to present significant difficulties when 
choosing these ‘high’ and ‘low’ split ratios as the optimum tends to be somewhat sample 
specific. Further, introducing additional desorption steps may introduce selectivity and losses 
of the more active component and will double the sample analysis time for the study.  
While the saliva samples have been shown to deliver lower levels of compounds than the skin, 
the necessity to run each skin sample twice, once with a high and once with a low split, 
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significantly increases the work load associated with analysis and data processing for the skin 
compounds if the full range of VOCs detected was to be available for quantitative analysis, 
somewhat negating this advantage of the skin sample over the saliva.  
It is particularly interesting to note that whilst each skin profile on average yields 3-400 
resolved and un-resolved VOCs and each saliva sample typically yields in the order of 200 the 
resultant matrices from this study include 107 variables from the skin and 144 from the saliva 
samples. The criteria for inclusion to the matrix in this study was that a compound was 
required to be present in a minimum of 30% of all observations, the implication of this then is 
that whilst the skin profiles are comparatively rich in information the inter-sample variability is 
so great that less compounds pass the criteria for inclusion into the matrix for subsequent 
consideration as candidate markers than from the saliva. When the relative biological functions 
of skin and saliva are considered this is not a surprising observation. As a barrier the skin is 
subject to a range of exogenous influences from the environment, clothing and personal care 
products – the story of a person’s day may very well be written in the VOC profile on their skin. 
While this provides a highly personalised and interesting set of compounds in this class of 
sample, potentially highly valuable in forensic – type applications, these exogenous inputs add 
a level of confounding factors when prospecting for markers of a metabolic state that do not 
need to be considered to the same extent with a saliva sample. There will still be exogenous 
inputs and confounding factors in a saliva sample, however saliva is replenished more often 
and it is generally easier to control the exogenous factors with a participant’s saliva by inducing 
fasting and restricting oral hygiene and personal care products.  
5.3.3.3. The best measure of physical stress? 
This study was designed to perturb the metabolism of healthy young adults and assesses the 
relative merits of the skin and saliva VOC sampling approaches in tracking such a change. In 
this case both approaches have presented candidate compounds that differentiate between 
baseline measurements and measurements during exercise and the following recovery. When 
the biological pathways and physical chemical processes involved in creating the endogenous 
portion of skin and saliva VOC profiles are considered, discussed in detail in Sections 1.3.2 and 
1.4.1, it is not surprising that different suites of compounds were found to differentiate 
between the stress states.  
This raises the question; does one provide a better indication of physical stress than the other, 
and if so, is this likely to extend to the measurement of other metabolic or disease states?  
Using the PR value, the relative response of up-regulated compounds described in Section 
5.3.1, receiver operator characteristic (ROC) curves were constructed to determine how well 
the stressed state can be predicted during each experimental phase. Table 5.4 summarises 
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the area under the curve (AUC) values for each sample at each phase. A perfect ROC curve, i.e. 
a good prediction of the stressed state, has an AUC of 1, a ‘useless’ curve AUC ≤0.5 [188].  
Table 5.4  Summary of area under the curve (AUC) values for ROC curves predicting stress in each 
experimental phase with standard error (Estd) and upper and lower bound confidence 
intervals (ConfU / ConfL) 
 AUC (EStd, ConfU, ConfL) 
Phase Skin Saliva 
B 1.00 (0.00, 1.00, 1.00) N/A 
C 0.97 (0.32, 1.00, 0.97) 0.95 (0.53, 0.85, 1.00) 
D 0.75 (0.11, 0.97, 0.53) 0.99 (0.2, 0.95, 1.00) 
 
The relative levels of up and down regulated candidate markers for both skin and saliva 
provide good prediction of physical stress when compared to the pre-exercise baseline state. 
Skin VOC profiles appear to provide a less accurate prediction of physical stress with each 
recovery phase, while stress prediction with candidate saliva markers appears to remain 
accurate up to one hour after exercise had finished. This observation is supported by the 
accompanying non-volatile and elemental saliva studies which also showed measurable profile 
differences in saliva samples from Phases A and D [46].  
There are several implications that may be considered from this; Skin VOC profiles are more 
susceptible to short term physiological changes than saliva. Metabolic perturbations affecting 
saliva VOC profiles take longer to recover than skin. Large changes in compounds correlating 
with a change in heart rate are dominating the skin VOC profiles and masking contributions 
from markers that may show the same behaviour as those found in saliva [46]. 
Both approaches offer a solution enabling VOC profiles from unstressed, stressed and 
recovering individuals to be distinguished, but it is not clear whether one provides a superior 
measure of physical stress. The data presented here indicates that saliva profiles may react 
more slowly to an intervention and that such changes take longer to return to baseline levels; 
an advantage perhaps for biomarker discovery but also an additional source of confounding 
factors that will need to be considered going forward with this technique. 
 
5.4. CONCLUSIONS: A DIAGNOSTIC OF PHYSICAL STRESS? 
5.4.1. Complementary data sets 
Skin and saliva VOC profiling in a combined pilot metabolomic study has revealed measurable 
changes due to an exercise intervention. Furthermore the advantages of the sampling 
techniques over those for blood, breath, urine and drooled saliva have been highlighted; the 
sampling methodologies are inherently simple and skilled researchers or clinical staff are not 
required for sampling. Furthermore the sample media are re-usable and samples require no 
particular treatment before storage and are easy to transport. 
146 
 
The overriding trend in the skin response to physiological stress was a maximum perturbation 
during exercise and a relaxation back to baseline state at the end of a 1 hr recovery period 
while the saliva response did not relax to baseline in this timeframe. It is clear that different 
underlying metabolic and physiological responses contribute to the VOC profile for each sample 
and while different compounds were found to differentiate between adult males who were 
stressed and those who were not for the two sample types, a candidate diagnostic for physical 
stress was obtained from them both. 
A correlation between global averages for peak area response and change in heart rate for skin 
VOC profiling, which was not observed in saliva profiles, indicates that physical responses may 
have a dominant effect on the profiles obtained.  
There is no clear indication that one sample type offers distinct advantages over the other in 
implementation, data quality or diagnostic potential. Simultaneous sampling from a single 
participant is straightforward and efficient, therefore at this stage the logical conclusion is to 
consider these sampling methods as complementary in future studies.  
Overall this study has shown the Skin Patch and saliva sampler and the workflow for VOC 
profiling in metabolomic studies to perform well and distinguish between surrogate disease 
states: stressed and relaxed.  
 
5.4.2. Next steps 
The potential future directions in evaluating and exploring skin and saliva VOC profiling for in-
field and in-clinic screening techniques are virtually limitless and will be discussed in detail in 
Chapter 6.  
The next steps for this particular intervention involve further collaboration with experts in both 
exercise physiology and chemometrics. Physical stress, as the average person may understand 
it, seems to be a subjective concept and a baseline level of fitness will have a marked effect on 
how ‘stressed’ an individual becomes. In repeating this study on a larger scale consultation 
with exercise physiologists on selecting a more homogenous cohort in terms of baseline fitness 
and body mass index and in devising an objective measure of physical stress would reduce the 
subjectivity and perhaps enable a degree of stratification in the data sets: can the degree of 
physical stress be predicted using skin and saliva profiling? 
Larger, as well as more homogenous, cohorts will enable more powerful statistical analysis and 
collaboration with chemometricians is the next step in handling such complex data sets on a 
larger scale. Further investigation of the two types of behaviour observed with stress; relaxation 
to baseline or not, and the potential correlation between change in heart rate and some skin 
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VOCs are both important next steps in understanding the relationship between skin and saliva 
VOC profiles.     
Finally, incorporation of skin and saliva samples into a combined data set in the first instance, 
followed by inclusion of blood, breath and urine VOC profiles as well as elemental and small 
molecule data will provide invaluable insight into the relationship between the sample types 
and a step towards linking the metabolic profiles associated with each.  
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
6.1. THESIS REVIEW 
Successful development of skin and, or, saliva sampling and the accompanying analysis and 
data-modeling have the potential to lead to non-invasive in-vivo methods for biomarker 
discovery and clinical screening, hence the underlying thesis of this research: 
There is diagnostic information in volatile emanations from the skin, and or saliva, of 
individuals in differing states of health and well-being.  Furthermore this information may be 
captured and exploited in the measurement of human function towards developing the next 
generation of non-invasive clinical screening techniques.  
This research sought to develop, implement and refine sampling protocols and analytical 
workflows for the non-invasive measurement of human function.  
To this end non-invasive samplers have been developed and characterised for skin and saliva 
samples and tested and evaluated in pilot metabolomic studies. Three principle research 
objectives were outlined:  
 
Objective 1: Develop and characterise PDMS-based non-invasive sampling techniques for 
human skin and saliva. 
Objective 2: Critically evaluate and optimise existing workflows for pilot volatile metabolomic 
studies for the application to skin and saliva sampling. 
Objective 3: Evaluate the performance of the samplers and workflows in pilot metabolomic 
studies with healthy young adults subject to stress interventions. 
 
6.2. CONCLUSIONS 
6.2.1. Objective 1: Develop and characterise PDMS-based non-invasive sampling 
techniques for human skin and saliva 
6.2.1.1. Skin sampling 
The PDMS Skin Patch has been characterised previously and demonstrated in some small, 
target led studies [34] [111] ]135]. This research has developed robust workflows for sampler 
preparation and sampling and 2 areas of control have been highlighted as essential to the 
reliability of this approach: 
 PDMS conditioning 
  Sample storage. 
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A poorly conditioned Skin Patch has the potential to introduce hundreds of nanograms into the 
analytical system, and this would not only confound the analysis of endogenous VOCs but it 
could contaminate instrumentation. The conditioning protocol that was developed comprised 
sonication in methanol, drying at 190 ºC under vacuum, 1 > mbar, and conditioning at 185 ºC 
in 100 ml min-1 of clean helium carrier gas. This protocol gave reproducible blank GC-MS 
profiles that contained a series of PDMS derived siloxanes and were otherwise contamination 
free; the siloxanes were present in all blanks albeit at different levels between Skin Patches.  
As well as careful conditioning and preparation of the Skin Patches the cotton pads used to 
secure the Skin Patch to the skin surface also needed to be conditioned. Failure to do this 
would also result in unacceptable levels of exogenous contamination in the subsequent 
analysis for un-targeted studies, and a step was introduced into the sampler preparation work 
flow to include vacuum conditioning of the cotton pads at 70 ºC for 4 hr.  
Stabilised samples mean that they can be stored long enough to enable efficient and cost 
effective analytical campaigns to be planned. Previously published work indicated a loss in 
sample integrity above 24 hours storage at 4 ºC, up to 300 fold increases in response to a sub-
set of monitored VOCs were observed and attributed to bacterial metabolism [101]. Lower 
storage temperatures were tested and it was demonstrated that VOC profiles skin samples to 
be stable up to 21 days at -80 ºC.  
With these changes a Skin Patch PDMS based sampling workflow was described that was 
suitable for use in pilot untargeted VOC profiling studies of skin.  
6.2.1.2. Saliva sampling 
The complexity and instability of saliva as a sample medium has been remarked upon 
extensively in the literature, and many of the previously published work flows, methods and 
protocols do not address the physical chemical attributes of VOCs [47].  A new in-situ VOC 
sampler for salivary VOCs, sampling directly from the oral cavity, using a polydimethylsiloxane 
(PDMS) based sampler has been developed and demonstrated with in-vitro and in-vivo 
characterisation studies [47]. Further, comparison with passive drool saliva collection revealed 
that this approach delivered substantial improvement in the recovery and reduced variability of 
VOCs from saliva. As with the Skin Patch careful conditioning of the PDMS samplers at 185 ºC 
in 100 ml min-1 helium produced blanks in which the only detectable features were siloxane 
artefacts from the PDMS. An extended storage study was not conducted for saliva samples and 
will be an essential next step in further development of this methodology.  
This approach to in-situ saliva VOC sampling appears to have significant analytical utility for the 
study of volatile signatures in human saliva, and this was demonstrated in a pilot metabolomic 
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study where a dataset, complementary to accompanying skin samples, provided a 
differentiator between stressed and un-stressed individuals.  
 
6.2.2. Objective 2: Critically evaluate and optimise existing workflows for pilot 
metabolomic studies for application to skin and saliva VOC profiling. 
Recently a work flow has been proposed to address the variability in exhaled breath analysis 
and the lack of standardisation and unified methods for such studies [70]. The authors claimed 
that such work flow based approaches enabled straightforward inter-laboratory and inter-study 
comparison and data consolidation. Such a development was seen to be beneficial in the 
acceleration of the application of exhaled breath analysis in discovering and validating VOC 
markers of disease.  The current study has translated this approach to skin and saliva VOC 
analysis and has expanded the benefits of standardised sample processing, data acquisition 
processing and modelling to enable the construction of complementary data matrices from 
different sample types; providing a platform for integration of data from different sample types, 
studies and laboratories into a single statistical analysis in the future. Indexing of VOCs by 
study, sample matrix, retention index and deconvolved mass spectrum facilitates the 
consolidation of data and learning across the studies in this, and future, research to produce 
the first version of a database for biological VOCs and move this research one step closer to 
the description of a human volatalome. 
Skin and saliva samples are more complicated than breath samples; typically breath 
compounds span 2 – 3 orders of magnitude while skin profiles in this thesis have exhibited up 
to 4 orders of magnitude between responses in a single profile. By simply observing the shape 
of skin and saliva profiles in Figures 4.9 and 5.12 the higher recovery of less volatile 
compounds from skin and saliva compared to breath is evident. Skin, and to a lesser extent 
saliva, profiles on visual inspection are dominated by features characteristic of polar species, 
in particular volatile fatty acids, suggesting that the range of chemical functionality recovered 
from these profiles is more extensive than breath. The additional complexity of such samples 
makes development of a unified analysis and data processing method challenging and a 
number of factors within this workflow were addressed to accommodate this. Optimisation of 
the workflow was required to enable its application to skin and saliva as well as breath which 
currently requires a significant degree of manual intervention. This has demonstrated the 
impact of automated data processing on the quality of data output and the necessity for 
rigorous control of all stages in a study work flow.  
Optimisation of dynamic background compensation to prevent truncation of broad peaks, 
development of two deconvolution methods to accommodate Gaussian and non-Gaussian 
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peak shapes, application of PDMS-derived siloxanes as internal retention index markers to 
avoid the complication of internal standard addition and optimisation of existing breath VOC 
profiling GC methods to improve the accuracy of retention indexing between instruments were 
all required to incorporate skin and saliva VOC profiling into a workflow with exhaled breath 
analysis.  
The ability to compare data from different sample types has been demonstrated. The 
exploitation of this will lead to greater understanding of the volatile metabolome and the 
potential translation of breath derived markers to corresponding skin or saliva markers. This 
would facilitate simple, self-administrable and wide spread sampling campaigns which are 
currently difficult with breath sampling.  
 
6.2.3. Objective 3: Evaluate the performance of samplers and workflows in pilot 
metabolomic studies with healthy young adults subject to stress 
interventions 
The pilot studies in this thesis were designed to invoke a perturbation in the metabolism of 
healthy young adults and employ the samplers and workflows developed in Chapter 3 to track 
the emanating VOCs resulting from such a change. Using induced short term stress as a 
surrogate for disease states the performance of the samplers and workflows could be 
evaluated and optimised in an iterative process without wasting precious samples from 
genuinely un-well participants in early stage sampler development.  
The skin and saliva sampling protocols and associated work flows were used to study changes 
in the respective VOC profiles following psychological-stress and physiological-stress 
interventions. Both types of VOC profiles were observed to change as a result of the 
intervention, and further new and previously unreported candidates for VOC markers of stress 
in humans have been tentatively identified; the validation and confirmation of these markers is 
beyond the scope of the current study.  
Both the Skin Patch and the saliva samplers were well-tolerated by participants and were found 
to be safe and comfortable non-invasive samplers. Strict control of all aspects from ethical 
clearance through to multivariate statistics enabled the potential of these samplers to provide 
complementary information to breath samples to be demonstrated. The potential benefits of 
further larger follow-up studies have also been argued. 
 
6.3. FUTURE DIRECTIONS 
The research presented in this thesis has developed, tested and optimised sampling and 
analytical protocols for prospecting for volatile biomarkers of human function using non-
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invasive methodologies. The testing, evaluation and subsequent enhancement of the 
workflows is an iterative process and the work in this thesis represents the first step towards a 
robust workflow for metabolomic studies using skin and saliva sampling, facilitating 
straightforward comparison between sample types, individual studies and even laboratories. 
Future collaboration with experts in chemometrics will allow complementary data sets 
generated using these workflows to be integrated for combined analysis.  
The next steps for this work can be split into two categories; further improvements to the 
analytical workflow and its application to more extended metabolomic studies. These directions 
will be discussed independently of one another.  
 
6.3.1. On-going workflow development 
Recently a study of human body malodour by Unilever PLC employed the Skin Patch and the 
workflows detailed here to sample the axillae of a panel of female participants selected by 
genotype [189]. The preparation of sampling materials took place in Loughborough, UK, and 
these were then shipped to a research centre in Manila, Philippines, where skin VOC samples 
were taken and malodour assessed. These samples were then shipped back to three different 
laboratories in Europe for analysis. The results from the sample set sent to Loughborough, and 
analysed by Helen Martin, demonstrate the application of the protocols developed in this thesis 
to remote, in-field sampling of human skin in a targeted study of malodour and demonstrates 
the classification of the malodour phenotypes based on skin VOCs [190].  
The workflow presented in this thesis has been adapted from a breath VOC specific protocol to 
accommodate the additional complexity from skin and saliva. The workflow appears to 
generate complementary data sets from these sample types and enable straightforward inter-
sample comparison that should translate easily to inter-study and inter-laboratory sharing of 
the biological VOC data. This should facilitate the development of volatile metabolome 
databases and help accelerate and direct research efforts in the identification and validation 
of biomarkers and move non-invasive screening towards in-field and in-clinic application.  
The workflow presented here is by no means prescriptive or definitive, it will be the work of 
many future studies to identify other challenges that arise from more widespread application in 
larger cohorts and current work has highlighted gaps in storage stability, internal standard 
addition, automated data processing and sampling bias that should be addressed before the 
next cycle of pilot studies.  
6.3.1.1. Storage stability 
Long-term sample storage is an on-going concern, in metabolomic studies it may be desirable 
to collect samples over a period of months, or even years, then analyse them in one batch to 
153 
 
minimise variations in performance of the analytical instrumentation. The minimum storage 
requirement for a sample should allow for transportation from the field when necessary, 
sufficient time to analyse all samples in a randomised order and allow for a predictable degree 
of instrument failure and maintenance. Studies in this thesis have shown VOC samples from 
human skin to be stable for up to 21 days when stored at -80ºC, whereas to date no such 
studies of saliva VOC samples have been undertaken.  
It is clear that more extended storage studies for both sample types at -80ºC will be required 
before they can be applied to larger scale studies. In Section 3.1.3 it was demonstrated that 
storage at -20ºC was insufficient to halt the apparent sample degradation causing an increase 
in levels of 6-methyl-5-hept-2-one beyond 11 days storage and raised the concern that 
bacterial activity on the PDMS may not be completely halted by low temperature storage and 
other approaches to sterilise the sample should be investigated.  
Potential solutions for storage of such samples focus around creating an environment that 
does not support bacterial life; Riazanskaia et.al proposed irradiating Skin Patch samples with 
ultra-violet light prior to storage [111], while this may achieve the desired result it will be 
important to assess the potential for UV-induced reactions by absorbed VOCs.  Re-trapping the 
VOCs onto an adsorbent material presents itself as an elegant solution; the PDMS sampler 
which plays host to bacterial life is desorbed with high temperature and an inert gas flow, in the 
same way as during sample analysis, the flow is redirected so that it passes onto an adsorbent 
tube instead of a secondary focussing trap or the GC column. Provided that the sorbent(s) 
selected are able to quantitatively trap and release the range of VOCs under study and that the 
breakthrough volume of the sorbent is not exceeded complete transfer of VOCs from the 
sampler to the tube can be achieved at the same time as sterilisation with high temperatures 
and oxygen starvation. Multiple bed adsorbent tubes can be stored at 4ºC for a number of 
weeks [62] [70] and as indicated in as yet unpublished studies on the storage of breath VOC 
samples; at -80ºC for up to one year. 
This approach offers the advantage that no additional instrumentation is required; however it 
will be necessary to purchase additional sorbent tubes and conduct a storage study with them. 
6.3.1.2. Internal standard addition 
The addition of an internal standard to liquid samples has become an accepted stage in 
automated GC procedures [125] and can be used in targeted studies for quantitation, or in non-
targeted studies for normalisation in which the peak area for each compound in the 
chromatogram is divided by the internal standard peak allowing for correction in instrument 
performance between samples.  
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The workflow described in this thesis aims to provide a framework that will allow 
straightforward integration of data sets from different samples, instruments and laboratories. 
The addition of an internal standard to allow normalisation across data sets, as opposed to 
external standards currently employed, would be a highly desirable step. 
The challenges associated with reproducibly adding a standard to solid adsorbents has been 
addressed for adsorbent tube samples by directing a flow of a gas standard onto the sampling 
end of an adsorbent tube. The gas standard could be commercially available or produced from 
a permeation source as described by Huxham et.al [191]. This can be incorporated into the 
workflow either pre- or post- sampling, or even both with different standards, providing a 
standard to validate sampling, storage and analysis.  
Adding internal standards to absorbent materials such as PDMS is not a trivial task. Absorption 
is an equilibrium process so the addition of gas phase standards after sampling is unlikely to 
yield 100% and reproducible capture of standard compounds in a vapour stream and some 
desorption of absorbed analytes should also be expected. 
Soini et. al. embedded standards into the PDMS phase of their ‘rolling stir bar’ skin sampler 
prior to sampling [110] by stirring the samplers in an aqueous solution of the standards. The stir 
bars were then rolled across human skin in-vivo to sample VOCs from the skin surface. The 
authors do not discuss recovery of the internal standards but have shown moderate 
reproducibility with 14.7 %RSD for C13-benzyl alcohol and 14.3% for 7-tridecanone. The authors 
state that by embedding the standards inside the polymer sorption material human skin 
exposure to the standards is minimised, yet no evidence is presented to support this. Internal 
standards should be chosen to closely match the physical and chemical properties of the 
compounds under study whilst not being present in samples or ambient air. By this definition 
the concentration of standard at the skin surface must be zero at the start of sampling, as 
protocols in this thesis sample skin and saliva for 30 and 5 min, respectively, the sample 
medium is likely to act as an absorbent to extract the standards from the sampler. The 
potential for losses of internal standard during sampling renders this approach not viable both 
ethically and as a means of normalisation between samples.  
For untargeted global VOC profiling internal standard addition will offer the benefit of 
facilitating normalisation, but not quantitation. This raises the question – at what stage of the 
workflow is it necessary to add an internal standard? 
To normalise for instrument performance it is simply necessary to add the standard prior to 
analysis, a simple method for achieving this would be to add a bed of adsorbent material to the 
sample tube containing the Skin Patch. A liquid phase standard injected onto the sorbent 
would be desorbed along with the sample. Adding the standard(s) to the sorbent bed before 
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storing the sample in the tube would provide an internal standard to asses storage, however 
losses from the sorbent bed may not reflect losses from the PDMS and diffusion between the 
two phases must be well characterised.  
A second PDMS coupon impregnated with standards added to the thermal desorption tube 
with the sample would provide an internal standard for the storage and transport process. If 
this was used alongside the sorbent bed approach different internal standards could then be 
used to validate sample storage and transport as well as instrument performance moving 
towards robust, intrinsically valid sampling and analysis protocols for metabolomic studies.   
6.3.1.3. Sampling bias 
The advantages of using PDMS for non-invasive in-vivo sampling were described in detail in 
Section 2.2 and while it has been demonstrated to perform well for in-vivo sampling in this 
thesis the hydrophobic nature of PDMS affords a bias against very polar species such a salts 
and sugars found in skin and saliva. Moderately polar species, fatty acids and alcohols, are 
often reported in such samples. This is due to their proportional partitioning into the PDMS 
giving a quantitative, representative profile. It is possible to predict the maximum proportional 
uptake of a compound into PDMS using its Ko/w values from equation 6.1 [134]  
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Equation 6. 1 
If we assume a sample volume of 1 ml and Skin Patch with a PDMS volume of 34 µl the 
equilibrium percentage recovery into the Skin Patch can be calculated. Examples for some 
compounds reported in skin / saliva samples are included in Table 6.1. 
 
Table 6.1 Example maximum recovery values for PDMS sampling of biological VOCs with differing 
log Ko/w values. 
VOC log Ko/w Max Recovery (%) 
Octane 5.15 99.98 
Hexanal 1.78 67.20 
1-Nonanol 4.02 99.72 
Propanoic Acid 0.33 6.78 
 
The implications of this are not that PDMS cannot be used for polar species, quantitative 
results have been demonstrated, and only that equivalent sensitivity will not be achieved for 
polar and non-polar species using PDMS alone [196]. 
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Further work on untargeted global profiling of VOCs from skin and saliva would benefit from a 
more in-depth evaluation of the sampling phase to enhance the coverage and reduce bias in 
the sampling step. Polyacrylate and ethylene glycol phases have been compared to PDMS for 
the extraction of whisky and fruit juices and both showed higher affinities for polar species 
such as phenols and acids while the ethylene glycol phase, which has a dimethylsiloxane base, 
gave better extraction efficiency for non-polar compounds than the polyacrylate phase. The 
authors found that by using the ethylene glycol and the PDMS phase sequentially they were 
able to achieve an overall analyte profile of polar and non-polar analytes [192]. Silica monolith 
technology, which allows hybrid sorbents to be formed incorporating octadecyl silica, 
graphitised carbon or PDMS, has been recently applied to solid phase extraction applications. 
The high porosity of the monolith provides a naturally high surface area and adsorption and 
absorption processes can be utilised in one sampling device, extending the range of 
compounds that are extracted efficiently [193] [194]. 
While these technologies have been applied to liquid samples so far, the potential to develop a 
combined sampler employing more than one extraction phase is an exciting and important next 
step for non-invasive global untargeted VOC profiling by direct contact methods.  
6.3.1.4. Analytical instrumentation 
The difficulty in finding a single GC column that provides efficient separation and acceptable 
peak shapes for the wide range of volatility and polarity found in skin and saliva VOC profiles 
presents a significant challenge in untargeted global profiling. Careful application of 
deconvolution algorithms with mass spectral data compensates for a significant degree of co-
elution. The range of peak shapes and widths from skin VOC were shown in Section 3.5 to 
present significant challenges for such automated data processing.  
One solution for the wide range of functionalities present in these sample types would be to 
move from a single column to a two-dimensional gas chromatography system (GCxGC) in which 
two capillary columns with different stationary phases are coupled and the sample directed 
onto each by backflushing, heart-cutting or thermal or flow modulation. For skin and saliva 
VOCs the use of a mid to non-polar stationary phase, such as a DB-1 or the DB-5 used here, 
with a polar phase such as a DB-Wax column may provide improved resolving power and 
Gaussian peak shapes for all compounds. Automated data processing with GCxGC data may 
require specialist software and the costs, both for initial instrument purchase and overheads 
such as liquid cryogen for thermal modulation, may make this approach more applicable for 
biomarker discovery leading to a simpler targeted approach on a single column system for 
screening applications. 
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6.3.2. We don’t need your blood: future direction for non-invasive biomarkers 
prospecting using skin and saliva VOC profiling 
The application of the samplers and workflows to metabolomic studies is the logical next step 
to this research. This will not only improve the understanding of these profile types and the 
links between them but provide further insight into the development of the techniques 
themselves. The scope for such studies is virtually unlimited and this section prioritises two of 
the many potential study types as the next phase for this research. 
The first set of studies focuses on characterising and understanding the volatile metabolome. 
Selection of sampling site for skin VOC studies generally seems to be based on other study 
constraints and a better understanding of the implications of sample site on the skin profile is 
essential before this kind of sample can be usefully employed in studies of systemic 
conditions. Simultaneous sampling of a range of body sites is easy to achieve with the Skin 
Patch and a ‘body mapping’ study, perhaps incorporating saliva and breath samples, will be a 
valuable and highly informative next stage in this research.  
Further to this a study, tracking the fate of an isotopically labelled substrate, such as a topically 
applied ointment or the C13 labelled breakfast cereal [195] used by Jonderko et. al, across skin, 
saliva, breath, urine, blood and faecal samples over a defined time period would give an insight 
into the relationships between the profiles associated with each sample type and be a first step 
towards finding metabolic links between the profiles.  
The second set of studies moves the biomarker discovery aspect of this research onto more 
real world clinical studies. While ultimately a diagnostic for systemic diseases using such non-
invasive samplers would be desirable, the logical first step is to examine the profiles 
associated with conditions of the skin and oral cavity. Studies of skin cancers, lesions, grafts, 
ulcers, burns, scars and infections would all benefit from a pain free monitoring technique, 
while oral cancer, lesions and periodontal diseases are a logical development of salivary 
profiling. Such studies may also yield useful information on VOCs associated with such 
conditions that may confound biomarker discovery for other systemic diseases.  
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6.4. SUMMARY 
Mamas et. al. present three fundamental questions to critically appraise the contribution of 
biomarkers identified in metabolomic studies towards clinically useful diagnosis [196]; 
 
Can the clinician measure it? 
Does it add new information? 
Does it help the clinician to manage patients? 
 
If a biomarker does not, or will not, reach these benchmarks then does it really add any value? 
This philosophy can be extended to non-invasive sampler development; while it is relatively 
easy to bring a cohort of participants to a laboratory and use a bespoke sampler or a real-time 
analysis technique to be ‘non-invasive’, how relevant will this information be in developing a 
real world clinical diagnostic technique? 
The current status of this research is a long way from dip-stick type technology that can be 
employed in a doctor’s office or a remote location to provide an instant diagnostic. The 
samplers described here are non-invasive, pain-free, simple, self-administrable, portable and 
clean representing a significant step towards fieldable non-invasive samplers for real world 
applications.  
‘We don’t need your blood’: The outcome of this research is the description of new methods 
and workflows, the result of continuous evaluation and modification throughout the studies 
that represent a significant step towards more robust methods for non-invasive marker 
discovery and diagnostic techniques.  
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7 APPENDICES 
APPENDIX 1: Example application for ethical approval 
Appendix 1.a: Generic protocol application 
This document and the accompanying supporting documents show examples of those 
submitted to the ethical advisory committee to apply for generic approval for the sampling 
technique, study specific checklists were also submitted where sampling required an 
intervention. 
GENERIC PROTOCOL APPROVAL FORM FOR  
HUMAN BIOLOGICAL/PSYCHOLOGICAL/SOCIOLOGICAL* INVESTIGATIONS 
* delete as appropriate 
This application form should be completed for generic protocols NOT individual research 
proposals.  It applies to procedures/techniques that will be performed on a regular basis 
and form all or part of subsequent research projects.  This form should not be used for one-
off research projects. 
This application form should be completed after reading the University Code of Practice on 
Investigations on Human Participants (found at 
http://www.lboro.ac.uk/admin/committees/ethical/ind-cophp.htm).   
 
 
1. Title of Procedure/ Technique 
Chemical Profiling of Human Skin. 
 
2. Brief lay summary of the procedure/ technique for the benefit of non-expert members of 
the Committee 
This project seeks to develop advanced sampling and measurement methodologies 
for measuring human chemical profiles in-vivo. In order to develop sensitive and 
specific assays to recover key bio markers from the skin surface a novel non-
invasive device called “Skin Patch” was developed. The silicon Skin Patch is a thin 
inert membrane that is placed on the skin surface in order to adsorb all volatile and 
non-volatile material from the skin.  
The Skin Patch was awarded a favourable ethical opinion on the 26th September 
2006 by Oldham Local Research Ethics Committee, Reference number: 
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06/Q1405/34 (Annex 1). The Committee designated this study as exempt from 
site-specific assessment and this document is designed to update local ethics 
committees for continuation of this work.   
 
3. Details of responsible investigator (supervisor in case of student projects) 
Title:  Prof   Forename: Paul  Surname: Thomas 
Department: Chemistry 
Email Address: C.L.P.Thomas@lboro.ac.uk 
Personal experience of and/or training in proposed procedure/technique, 
Prof Thomas and his research group designed and tested the sampling patch for use on the 
skin surface at Manchester Uni. It has proven very successful in sampling volatile organic 
compounds from skin and is currently being used in prospecting studies for skin cancer, 
profiling of chronic wounds and human odour profiles.   
 
4. Names, experience, department and email addresses of additional investigators (if known) 
Please notify the Committee Secretary when additional investigators are trained in the 
procedure/technique. 
 Helen Martin, PhD student/researcher, H.J.Martin@lboro.ac.uk 
Trained at Loughborough awaiting ethics approval to practice, Chemistry 
 Matthew Turner, PhD student/researcher, M.A.Turner@lboro.ac.uk 
Trained at Loughborough awaiting ethics approval to practice, Chemistry 
 Aditya Malkar, PhD student/researcher, A.Malkar@lboro.ac.uk 
Trained at Loughborough awaiting ethics approval to practice, Chemistry 
 Pareen Patel, PhD student/researcher, P.Patel@lboro.ac.uk 
Trained at Loughborough awaiting ethics approval to practice, Chemistry 
 Corrine Burns, Post Doctoral Research Assistant, C.Burns@lboro.ac.uk 
Trained at Loughborough awaiting ethics approval to practice, Chemistry 
 
5. Location(s) if known 
Currently Analytical Research F2.07/F2.08 Chemistry 
 
6. Will any of the participants be from one of the following vulnerable groups? 
Children under 18 years of age       Yes   No  
People over 65 of age        Yes   No  
People with mental illness       Yes   No  
Prisoners/other detained persons       Yes   No  
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Pregnant women        Yes   No  
Other vulnerable groups        Yes   No  
 
7. Will the procedure/technique involve any of the following? 
Testing new equipment/drugs       Yes   No  
Administering drugs (including caffeine)       Yes   No  
Use of radiation (eg x-rays)       Yes   No  
Assisting/altering the process of conception in any way    Yes   No  
Methods of contraception       Yes   No  
Genetic engineering        Yes   No  
Will be conducted outside of the UK      Yes   No  
If yes, please submit a full research proposal to the Ethical Advisory Committee.  Generic 
Protocols cannot be used to cover these activities. 
 
8. Description/outline of procedure/ technique including reasons for performing the 
procedure/technique  
Please refer to Appendix 1b 
 
9. Do any investigators stand to gain from a particular conclusion of the 
procedure/technique? 
No 
10. Methodogy (detailed description) 
Please refer to Appendix 1b 
 
11. Detail of measurements to be taken 
Please refer to Appendix 1b 
 
12. Please indicate whether the proposed procedure/technique: 
Involves taking bodily samples        Yes   No  
Involves procedures which are physically invasive     Yes   No  
Is designed to be challenging (physically or psychologically in any way)   Yes   No  
Involves dietary manipulation or supplementation     Yes   No  
Prescribes intake of compounds additional to daily diet    Yes   No  
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Involves procedures which may cause embarrassment to participants  Yes   No  
Involves collection of personal and/or potentially sensitive data   Yes   No  
 
If Yes - please give details of the arrangements to deal with adverse effects. 
No adverse effects foreseen 
13. Participant information 
Details of participants (gender, age, special interests etc) 
Participants are likely to be recruited from cohorts of people who are phenotypically 
matched and have well characterised disease, metabolitic or environmental factors 
associated with them for which metabolitic markers on their skin are sought.  
Preliminary studies will focus on establishing the boundaries of normal 
homeostaisis correlated to indicators of vitality. These will recruit from healthy 
young (18 yr to 35 yr) adults of both sexes. 
Future studies may require additonal approval as the research methods are 
adopted and adapted to serve the needs of other studies within the Loughborough 
University Research Network. 
Please outline inclusion/exclusion criteria to be used in selecting participants for this 
procedure/ technique. 
Inclusion and exclusion criteria are specific to individual studies.  
Such studies will be the subject of further ethical approval if indicated by Loughborough 
University Ethical Clearance Checklist. 
Where appropriate please indicate where participants will be recruited from. 
Loughborough University Staff and students and their associated social networks. 
 
14. Procedures for chaperoning and supervision of participants during the procedure / 
technique 
1. Briefing and consent. 
Volunteers are briefed in private in an annex to F 2.07 with windows in the doors. The 
researcher explains the process, and answers questions about the procedure during the 
briefing. Informed consent is taken and an appointment is made for the samples to be taken. 
2. Participants questionnaire 
The questionnaire is completed in private in an annex to F2.07 with windows in the doors. 
3. Skin sampling 
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This takes place in a screened and designated area in our laboratory F 2.07.  Normally one 
researcher will work with the participant while co-workers will be aware of and observant of the 
procedure. (They will not necessarily be involved in the sampling procedure but will be briefed 
and ready to assist if required.) There are always more than two researchers present in the 
laboratory and lone working is forbidden. 
4. Escorting and supervision. 
Participants are accompanied at all times while they are in our laboratory. 
Participants will be offered a same sex chaperone. 
 
15. Possible risks, discomforts and/or distress to participants 
1. Possible Risks 
The procedure takes place in a sampling station which is screened and designated 
area within F2.07. Within this facility the normal hazards associated with our 
laboratory operations (Mainly accidental splashes and high pressure gas 
installations) are mitigated. Walking to the sampling station exposes the participant 
to the normal risks associated with our laboratory operations and personal 
protective equipment (Safety glasses and laboratory coat) will be issued to them. 
It may be possible for a participant to be allergic to the silicone sampling device. 
Allergic reactions to silicone are rare and, as it is used in cookware, baby bottles, 
numerous medical applications and even personal care products, it is highly 
unlikely that a participant would be unaware of this allergy.  Participants are 
informed of the risks and asked to fill in a health questionnaire in which they are 
asked to detail any allergies, with these precautions the risk of allergic reaction is 
minimal.(Reference - Medical Device and Diagnostic Magazine. Nov 1999. Charles 
Heide. 'Silicone Rubber for Medical Applications'.) 
2. Discomfort 
The sampling patch itself is a small, malleable membrane that we can foresee no 
discomfort associated with. 
3. Distress 
A stranger working very close to you may be unsettling. 
During sampling, care is exercised to ensure that the participant is comfortable and 
aware of what is happening. Every action is described and explained before it is 
undertaken and during the procedure. For example: 
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"Is it OK for you me place the patch on your skin and cover it with this dressing?"  
"Is that comfortable, are you OK to continue with the experiment?” 
 
16. Details of any payments to be made to the participants 
No payments are made to participants 
17. Will written consent be obtained from participants for the procedure/technique? 
          Yes   No  
If Yes, please attach a SAMPLE (generic wording to cover this procedure/technique to be 
included in main consent form) of the consent form to be used. 
If No, please justify. 
Please see Appendix 1.d. 
 
18. How will participants be informed of their right to withdraw from, or stop, the 
procedure? 
This is explained during the briefing and in the participant’s information sheet  
(Appednix 1.c). 
Before each stage of the procedure the researcher seeks permission from the 
participant to proceed, typically as part of the explanation and discourse provided 
about the procedure. For example: 
"Could I remove the patch and dressing from your skin?", "Was that OK, would you 
be OK to give another sample in the same way?” 
Finally, as the participant is in control of the device, they are able to remove the 
device quickly and easily at any time during the process. A reminder of their right to 
withdraw whenever they wish with no ill consequences is given to the participant 
immediately before sampling 
19. Will the procedure / technique include the use of any of the following? 
Audio/video recording         Yes   No  
Observation of participants       Yes   No  
If yes to either, please provide detail of how the recording will be stored, when the recordings 
will be destroyed and how confidentiality of data will be ensured. 
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20. What steps will be taken to safeguard anonymity of participant . confidentiality of 
personal data? 
All data are anonomised. Participant questionnaires do not contain personal 
details. A record of the participants attendance is maintained separately and held 
securely. 
 
21. Will collection and storage of data comply with the data protection act? 
Yes. All personal information and details will only be entered onto written consent 
forms which will be kept in a locked drawer in the chemistry department. All 
experimental data, questionnaires and outputs will refer to participants only by 
identification numbers. Only information relevant to the specific study will be 
recorded and data will only be used in conjunction with the specific study.   
22. Insurance cover 
It is the responsibility of investigators to ensure that there is appropriate insurance cover for 
the procedure/technique. 
The University maintains in force a Public Liability Policy, which indemnifies it 
against its legal liability for accidental injury to persons (other than its employees) 
and for accidental damage to the property of others. Any unavoidable injury or 
damage therefore falls outside the scope of the policy. 
Will the procedure / technique result in unavoidable injury or damage to participants or 
property? 
         Yes   No  
If yes, please detail the alternative insurance cover arrangements and attach supporting 
documentation.  
The university insurance related to claims arising out of all normal activities or the university, 
but insurers require to be notified of anything of an unusual natures.  
Is the procedure / technique classified as normal activity? 
  Yes   No  
If NO, please check with the university insurers that the policy will cover the activity. If the 
activity falls outside the scope of the policy, please detail alternative insurance cover 
arrangements and attach supporting documentation.  
23. Declaration 
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I have read the University's Code of Practice on Investigations on Human Participants and 
completed this application. 
I agree to provide the Ethical Advisory Committee with appropriate feedback should I need 
to make any changes to this protocol in light of experience. 
Signature of applicant:  ....................................................................  
Signature of Head of Department:  ....................................................................  
Date  ....................................................................  
 
 
For all applications: 
Please ensure that you have attached sample copies of the following documents to your 
submission 
 Participant Information Sheet 
 Informed Consent Form 
 
In addition, please attach sample copies of the following documents if applicable.  
 Willingness to Participate Forms 
 Health Screen Questionnaire 
 Questionnaires and Example Interview Questions 
 Advertisement/Recruitment material 
 Evidence of consent from other Committees 
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Appendix 1.b: Sampling protocol 
Detection of Volatile Organic Compounds on human skin 
 
 Helen Martin,  Research Student, Loughborough University 
 Professor Paul Thomas, Professor of Analytical Science Loughborough University 
 Professor Colin Creaser, Professor Analytical Chemistry, Loughborough University 
   
Background 
It is ten years since the publication of Phillips’ landmark review of volatile organic compounds 
(VOC) as markers of disease1, since then the continuous development of instrumentation, 
sampling and information processing techniques has revealed the existence of a dynamic 
individualised and highly complicated VOC profile associated with every aspect of human life. 
Our research group has developed expertise in extracting this VOC profile from exhaled breath 
and from the skin surface and much of our work focuses on creating next generation devices 
for non-invasive in-vivo VOC sampling. This study aims to take one such device that has proven 
successful on skin2,3 in other locations and extend it to further studies at Loughborough 
University. 
The current study seeks to discover if relationships between VOC profiles and well-being exist; 
where well-being may be represented by a variety of non-specific indicators such as induced 
stress, cardio vascular function, body mass index and respiratory function for instance. 
This study will use modern, state-of-the-art chemical detection systems to pinpoint potential 
biomarkers within the VOC profile and identify them. Identification of such chemical signatures 
may ultimately provide an objective method for monitoring human vitality.  
Hypothesis and aims. 
Our research hypothesis is that there is a detectable difference between the chemical 
compounds present on the skin of participants who enjoy different levels of health and well-
being and who engage in different lifestyles. Such chemical differences could be identified as 
potential biomarkers for varying degrees of vitality.  
This generic protocol will collect samples of VOC from the skin surface and chemically analyse 
them. Using advanced statistical approaches the intent is to establish if it is possible to 
distinguish between the skin of participants with differing states of well-being. Further the 
intention is to determine the chemical identity of any candidate markers that are discovered in 
such studies.. 
Methods 
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Setting 
A laboratory F 2.07 in the Department of Chemistry equipped with a comfortable seat for the 
volunteer participants and a table for skin sampling equipments. 
Volunteer participants 
This generic ethical approval will enable volunteers to be recruited from individuals who are 
clearly differentiated in their lifestyle or levels of health from the general population. Specific 
studies will be subject to ethical approval based on individual research proposals. 
Prospective participants will be provided with written information about this study and where 
they are able and willing, informed consent to participate in the study will be obtained.  
Participants will normally have at least 24 hours to decide whether to participate in the study. 
Any information relating to personal information about participants will be made available to 
the researchers by sample codes only, no names or addresses will be used. 
Inclusion criteria 
 These will be study specific and subject to ethical approval obtained for individual 
project proposals.  
 Age normally ≥ 18yrs. Should participants from vulnerable groups be sought additional 
safeguards will be implemented that will be described in individual project proposals. 
Exclusion criteria 
 These will be study specific and subject to ethical approval for individual project 
proposals.  
Sample collection 
VOC sampling from skin will employ an inert silicone patch placed on the skin surface, normally 
on the forearm, forehead or upper back. The sampling patch will be held under a non-adhesive 
dressing which in turn is held in place by hypoallergenic micro porous tape. The patch will 
remain on the skin for up to 30min at any one time and multiple patches may be applied in 
parallel. Once sampling is complete the researcher will remove the patch from the participant  
and transfer the silicone patch to an empty thermal desorption tube using tweezers. The ends 
of the tube will be sealed with swagelock caps and samples will be stored at 4ºC until analysis. 
Factors that may affect results may be controlled by asking participants to fast or refrain from 
smoking for a specified period of time prior to sampling. Any medications that may affect the 
results will be specified in the exclusion criteria. 
Sample processing 
The samples will be analysed using a combination of thermal desorption, chromatographic, 
mass spectrometric and ion mobility techniques. The basic operation of this system is to allow 
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us to detect all the different chemicals in a breath sample. The ion mobility systems generate 
three-dimensional surfaces that can be used like a fingerprint for a specific phenotypic state.  
 The mass spectrometer allows us to identify single components and look for differences in 
peoples’ saliva VOC profiles. It is an extremely powerful tool that will aid us in identifying 
potential biomarkers. The data it generates is displayed in two forms; a chromatogram and a 
mass spectrum. An example chromatogram is displayed below in Figure 1. 
 
 
 
The chromatogram above, in Figure 1, allows the relative concentrations of the different 
components of the VOC profile to be estimated. Each point on the chromatogram is built up 
from integrated mass spectra, which may be used to identify the compound.  
A range of standard compounds built up into a ladder across the chromatogram can be used to 
generate a library. Components in the sample VOC profiles can then be referenced against the 
standards to give a value known as the retention index; this provides another reference point 
for identification of markers and comparison between samples. 
Data analysis 
All data will be treated as confidential and rendered anonymous at the point of sampling.  
The data flow that we shall use for the analysis of the VOC profiles is detailed in Figure 2. 
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 Visual inspection of the data will be performed to ensure that no loss in sensitivity has 
occurred and no contaminant artefacts are present. 
 Deconvolution of mass spectral data will be performed using state-of-the-art software to 
generate VOC peak lists for each profile. 
 Components will be incorporated into a library set up for the study based on their 
retention index and where possible identified by comparison to mass spectral 
databases. 
 Target component analysis may be performed to compare specific data sets. 
 Individual datapoints from the chromatogram will be compared between groups using 
ANOVA and ROC analysis, to identify potentially discriminating compounds 
 
Summary 
A sampling approach used on skin has been shown in previous work to be robust and reliable 
for VOC profiles from all but the most delicate structures of human skin. The analytical utility of 
this technique and its compatibility with existing instrumentation has been demonstrated on 
skin and this study aims to extend this simple methodology to further studies.  
Our non-invasive methodology aims to provide next generation in-vivo VOC sampling 
techniques for the discovery of endogenous VOC chemistry. If successful this sampling 
approach will then be applied to phenotypically distinct groups of people in prospecting for 
chemical markers of health and vitality.  
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Analysis is performed using thermal desorption gas chromatography mass spectrometry (TD-
GC-MS) yielding complex profiles that present a significant data processing challenge. A 
retention index based on Kováts system is employed to generate component libraries and 
facilitate sample comparison, combining this with mass spectral deconvolution provides part of 
a comprehensive data processing strategy for identification of biomarkers and yet unidentified 
components in VOC profiles.  
References. 
1. Phillips, M., Gleeson, K., Hughes, JMB., Greenberg, J., Cataneo, RN., Baker and McVay, WP. 
Volatile Organic Compounds in Breath as Markers of Lung Cancer: A Cross-sectional Study. 
Lancet 1999; 353:1930-1933. 
2. Riazanskaia, S., Blackburn, G., Harker M., Taylor D., and Thomas, C.L.P. The analytical utility 
of thermally desorbed polydimethylsilicone membranes for in-vivo sampling of volatile 
organic compounds in and on human skin. Analyst, 2008, 133, 1020–1027. 
3. Alexis N. Thomas, Svetlana Riazanskaia, William Cheung, Yun Xu,  
Royston Goodacre, C. L. Paul Thomas, Mohamed S. Baguneid, Ardeshir Bayat.  
Novel noninvasive identification of biomarkers by analytical profiling of chronic wounds 
using volatile organic compounds. 
Wound Rep Reg 2010 18 391–400. 
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 Appendix 1.c: Participant information sheet 
Skin Analysis in <Study Title>> 
Part 1 
Invitation to participate 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take time 
to read the following information carefully. Talk to others about the study if you wish. This part 
(Part 1) tells you the purpose of this study and what will happen to you if you take part. Part 2 
gives you more detailed information about the conduct of the study.  
Please ask us if there is anything that is not clear, or if you would like more information. Please 
take time to decide whether or not you wish to take part.  
What is the purpose of this study? 
We are testing a new way of detecting changes in the human body by monitoring tiny amounts 
of chemical substances on skin.  These substances arise from all the processes and reactions 
that occur in the body and we think that analysis of these compounds may be able to give us 
information about health and well-being of individuals. 
Why have I been invited? 
You will have been invited because you have << specific inclusion criteria goes here>> and this 
makes you part of the group of people we are particularly interested in seeing.  
Do I have to take part? 
It is up to you to decide.  
We will describe the study and go through this information sheet, which we will then give to 
you. You will have the opportunity to ask questions of the researchers and be given time to 
consider whether you wish to participate. We will then ask you to sign a consent form to show 
you have agreed to take part. You are free to withdraw at any time, and you do not have to give 
us a reason.  
What will happen to me if I take part? 
If you agree to take part we will arrange for you to visit our laboratory for a single visit lasting 
about an hour. During this visit we will first ask you a series of questions relating to factors that 
can influence the chemical substances on your skin.  These will include questions about food, 
drink, medications recently consumed, and smoking habits. We will also ask you some 
questions about personal care including toiletries, perfumes and personal care products. We 
will also ask you for information about diet and digestion, and  finally we will ask for  some 
information about <Inclusion criteria specified here>.   
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If you would like a chaperone of the same sex to be available during your study visit this will be 
arranged for you. 
For the same reasons, you may be asked to refrain from eating, drinking (other than 
unflavoured water) and smoking for an agreed time period prior to the study visit.   
After we have collected this information, we will then begin by taking a single sample.   This 
involves placing a small section of an inert membrane on the surface of your skin. The 
membrane will be held by a generic dressing usually used for first aid. You will be asked to sit 
comfortably while compounds from the surface of your skin absorb onto the membrane, each 
sample will take up to a maximum of 30 minutes and we will ask for up to 5 samples, however 
samples are often taken simultaneously. You are under no obligation to complete the full 30 
minutes or give more than one sample and you can stop that study at any time with no 
consequences.   
What will I have to do? 
We need you to not smoke, eat or drink (although you are permitted to drink unflavoured water) 
for an agreed time period prior to the study visit.   
We also ask you not to use perfumed products (which include not only perfume, but also 
deodorants, after-shaves), any facial products (such as make-up or creams (scented or un-
scented)), for an agreed time period (usually a few hours) prior to your visit. 
What are the possible disadvantages and risks of taking part? 
We do not anticipate any risk from taking part in this study. There is the possibility of allergic 
reaction to the silicone sampling device however this is very rare and as silicone is used in 
cookware, baby’s bottles and many medical devices including incubators, catheters and 
dressings we think it highly unlikely that you will experience any adverse effects.  We will always 
be with you during this process and you will be in complete control of the sampling and be able 
to stop it quickly and easily whenever you chose.  
What are the possible benefits of taking part? 
There will be no direct benefits to you from taking part in this research. The aim is to develop a 
new test that may be able to provide objective information about state of health and well-being. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. You may withdraw from the study at any time; either before 
or during the study. The detailed information on this is given in Part 2. 
Will my taking part in the study be kept confidential? 
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Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
Part 2 
What will happen if I don’t want to carry on with the study? 
You are under no obligation to participate in this study and you may withdraw from the whole 
study, or contribute only to a part of the study (for example you may not wish to give a sample, 
or answer the questionnaire, or vice versa), in which case we will use only the sample(s) and 
answers you agreed to provide. 
We will ensure that you are able to stop the sampling procedure at any time quickly and easily 
should you want to.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number 0150 922 2549). 
You may ask a researcher to clarify anything about the study at any time, both before and 
during sampling. If you remain unhappy and wish to complain formally, you can do this through 
Loughborough University Complaints Procedure. Details can be obtained from the University. 
In the event that something does go wrong and you are harmed during the research due to 
someone’s negligence then you may have grounds for a legal action for compensation against 
Loughborough University but you may have to pay your legal costs.  
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the Laboratory will have your 
name and address removed so that you cannot be recognised. 
What will happen to the samples I give? 
The samples are collected on the patches of membrane that are placed on your skin, these are 
then removed and placed in small tubes that are sealed and will be processed at Department 
of Chemistry at Loughborough University.  Your name will be removed, and the samples 
identified only with a code. No genetic testing will be performed on any of your samples. 
What will happen to the results of the research study? 
It is intended to publish the results of this study in a scientific journal. Data generated will be 
kept at the Department of Chemistry at Loughborough University. Your name and address will 
not be kept with the data although a record of your participation will be maintained by the 
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principle investigator. The measurement data will only be made available to people who are 
directly involved with the study. 
Who is organising and funding the research? 
This study is a collaboration between Loughborough University and Unilever PLC.  
Who has reviewed the study? 
This study has been reviewed and been given a favourable opinion by Loughborough University 
Ethics Committee to protect your safety, rights, wellbeing and dignity. 
Who should I contact for further information? 
 
Prof. C. L. Paul Thomas 
Professor of Analytical Science 
Department of Chemistry 
Loughborough University 
LE11 3TU 
Tel: 0150 922 2549 
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Appendix 1.d 
CONSENT FORM for Skin analysis in <Study Title>> . 
Mr/Mrs/Miss/Ms/Dr.............................................  
Name.............................................................. 
Age........................................................................  
Contact details...................................................................... 
 
Trial Supervisor 
Prof. Paul Thomas, Professor Analytical Science, Department of Chemistry, Loughborough 
University, LE11 3TU 
Tel.  No. 0150 922 2549 
Before participating in our study we request that you complete this consent form.   
Please circle the appropriate response. 
I have been given a copy of the information sheet Skin Analysis in <Study Title>> Yes No 
I understand that my participation in this study is voluntary and that I am under no 
obligation to take part. 
Yes No 
I have read and understood the information sheet 
 
Yes No 
I have had the opportunity to ask questions and I understand the answers I have been 
given. 
Yes No 
I understand that I may withdraw from the study at any time 
 
Yes No 
I have been shown how to stop the sampling procedure if I want to. 
 
Yes No 
I consent to participate in this study Yes No 
PLEASE SIGN HERE 
 
Date 
Many thanks for your help. 
 
Researcher use 
Participant identifier:  
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Appendix 1.e:  
Health screen questionnaire 
Female Health Screen Questionnaire For skin analysis in <Study Title>> . 
Participant Identifier.................................................. 
 
Trial Supervisor 
Prof. Paul Thomas, Professor Analytical Science, Department of Chemistry, Loughborough 
University, LE11 3TU 
Tel.  No. 0150 922 2549 
Before participating in our study we would like you to complete this health screen 
questionnaire, you are not obligated to answer any of the questions if you feel uncomfortable 
about doing so. 
 
Please circle the appropriate response.  
Do you have any allergies that you are aware of? Yes No 
Do you have any specific dietary preferences? (eg, vegan, vegetarian) Yes No 
Are you taking or using any medicines, pills, tablets, ointments, injections or 
any other drug, either from your doctor or on your own accord? 
Yes No 
Have you experienced nausea, sickness or dizziness in the last week? Yes No 
Do you have sensitive skin? Yes No 
Is there anything else concerning your health, you think we should know 
about? 
Yes No 
 
If you answered ‘Yes’ to any of the above could you please provide further information here: 
................................................................................................................................................................
................................................................................................................................................................
.................................................................................... 
Please inform us of any changes in the above before the study starts. 
For Female Participants only 
Are your periods normal/regular? Yes No 
Are you on the contraceptive ‘Pill’? Yes No 
Do you use any other form of contraception that may affect your menstrual 
cycle? (Implants, injections, IUD etc) 
Yes No 
Could you be pregnant? Yes No 
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To the best of my knowledge this information is correct.  I confirm that I have read and understood 
the information sheet for the above study and have had the opportunity to ask questions.  
 
PLEASE SIGN HERE........................................................................................................ 
Date........................................... 
Many thanks for your help. 
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APPENDIX 2: THE ORIGINAL DESIGN OF THE SALIVA SAMPLER 
The original design for the saliva sampler in Figure 3.4, reproduced here with the permission of Peter Carroll, Unilever PLC.  
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APPENDIX 3: COMPUTATION OF PHYSIOLOGICAL STRESS RESPONSE SCORES 
This excerpt is taken from M. A. Turner et. al. ‘The effect of a Paced Auditory Serial Addition Task 
(PASAT) intervention on the profile of volatile organic compounds in human breath: A Pilot Study’ 
[63] J. Breath Res. 7 (2013) 017102 
PASAT response score 
The participants’ individual cardiovascular responses to the PASAT and neutral interventions were 
scored on the basis of observed changes in their systolic blood pressure and heart rate. The 
average of the three initial baseline observations were used to give BP and HR start values (Pstart S 
and HRstart). The maximum observed values of the four readings taken during the intervention 
periods (Pmax S and HRmax) were assigned the 
points of maximum ‘stress’. A PASAT response score (PSR) may be derived for the PASAT (PSRS) 
and neutral interventions (PSRN) by: 
    
   
  
        
   
       
      
 
Where     
      
       
     
 
 
and 
                   
 
The PSR sought to emphasize the relative change in systolic blood pressure that occurred during 
the intervention (ΔPS) compared to baseline observations (  
      .  Heart rate was also included in 
the same manner providing a ratio between the overall change (_HR) and the baseline values. The 
PSR score was framed to give higher score for those individuals showing the largest cardiovascular 
responses under the interventions. One male participant did not exhibit a stress response (PSRS = 
0.9, PSRN = 5.3). The average response for the remaining 21 participants was a PSRS of 64.5 
compared to PSRN score of 4.5. The median PSR score during the neutral intervention was 3.5 
compared to 42.8 for the PASAT intervention. Male and female responses were not statistically 
different; female PSR scores showed a greater range of responses during the PASAT intervention 
(PSR = 12 to 233), while it was the male participants who had the greatest variability (PSR = 0.1 
to 18.6) in the neutral state. Overall, the cardiovascular responses summarized in figure 1 and by 
the PSR scores are consistent with the participants experiencing psychological stress from the 
PASAT intervention. 
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